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Summary
Atomic resolution models of proteins are crucial for understanding their biological
mechanisms and provide insights into the relationship between protein sequence and
structure. Many protein structures incorporate metal ions, exploiting their unique
chemistry as reaction centres or for structural stability. This thesis describes the
progress made towards solving the structures of three such metal-binding proteins by
means of X-ray crystallography.
Complement component C1 is a large protein complex that initiates the first
line of immune defence and requires calcium for structural stability. Fragments of C1
have already been solved at high resolution, but there are no accurate models of the
assembled complex. In this work, a new method for purifying intact C1 from human
serum was developed and the purified complex was characterised by various methods.
Finally, attempts were made to crystallise native human C1 with a view to obtaining
high-resolution structures of the entire complex.
Serum amyloid P is another serum protein, also thought to be involved in the
immune response. It is often found associated with amyloid deposits, although SAP
binds a variety of ligands in a calcium-dependent manner. While the structure of SAP
has been determined, its physiological function is still not fully understood. SAP was
purified using established methods and its ligand-binding properties were investigated
under various conditions using dynamic light scattering, in an attempt to gather more
information about the possible function of this molecule. 
Finally, ZiCo is a small peptide that was designed to switch between a
multimeric coiled coil and a monomeric zinc finger fold on binding zinc. The system has
been characterised extensively in solution, but high-resolution structures are required to
validate the design. ZiCo was crystallised and diﬀraction data were collected. The
structure of the peptide was partially solved, indicating that the multimeric form of the
ZiCo peptide is indeed a trimeric coiled coil.
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Chapter 1
Introduction
1.1  Overview
This introductory chapter will set out the context of the present thesis. I will begin by
introducing proteins and the importance of determining high-resolution models of their
structures, focusing on the roles that both metals and metal-binding proteins play in
the cause and treatment of disease. I will then describe the three diﬀerent
metal‑binding proteins that are the topic of this thesis, in terms of both their structural
features and our current understanding of their respective functions. I will underline the
importance of unravelling the structures of these metal-binding proteins so as to deepen
our understanding of fundamental biological processes — both for the sake of furthering
basic scientific knowledge and because it oﬀers the potential of modulating protein
structures to treat disease. The background to my work will also be explored, and I will
critically review the literature, as well as demonstrate how I hope to complement
previous work on the three proteins under study. The chapter will conclude with a
statement of the aims of my investigations into the structures of the serum proteins
complement component C1, serum amyloid P component, and the designed switch
peptide ZiCo.
2
1.2  Proteins
With the new millennium, we have entered the era of genomics. A rapidly growing
number of genomes have been sequenced from a diverse set of organisms, and the
information they contain is ready to be exploited. Aside from what genes can tell us
about evolution and genetics, the power of genes lies in the proteins they encode. The
word protein comes from the ancient Greek prōtos, meaning first; proteins are so called
because they are a primary material of plants and animals (OED Online, 2008).
Proteins have structural and mechanical, as well as catalytic functions. Fibrous keratins
are the major component of the hair, scales, shells, silk and feathers that oﬀer external
protection to almost every species. Even viruses use protective protein coats to conceal
their genetic material. The enzymes that catalyse the myriad of reactions inside cells
are also almost exclusively proteins.
The key to the manifold functions of proteins lies in their three-dimensional
structure, which is encoded by the sequence of amino acids that constitutes a protein.
Precisely how proteins fold into their native state based on the information contained
within their primary structure remains one of the great unanswered questions of
biochemistry today. However, by using modern techniques to probe the molecular
structure of proteins we can gain insights into their mechanisms to help further our
understanding of biological processes and what happens when they go awry. Moreover,
the design approach to drug discovery relies heavily upon high-resolution structures of
disease-related protein targets and is becoming increasingly successful, with more and
more designed drugs coming onto the market.
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1.3  Metal-binding proteins
Metals are ubiquitous in biological systems and are essential for life. A variety of metals
are employed as charge carriers, electron transporters, and catalysts in cellular
processes throughout the plant and animal kingdoms. Photosynthesis, the process of
converting light into chemical energy, is one of the most fundamental biological
reactions. It requires a magnesium ion to be co-ordinated to the centre of a chlorophyll
molecule, which absorbs and channels solar energy to drive the production of ATP, the
‘energy currency’ of the cell. Furthermore, ATP itself requires magnesium ions in order
to be biologically active.
However, by far the most diverse role that metals play in biological systems is
when they are found incorporated into proteins. This arrangement combines the
function of the protein with the unique chemistry of the metal ion. For example, the
alkali metals sodium and potassium carry charges across biological membranes,
facilitated by protein pumps and channels, thereby regulating osmotic pressure and
depolarisation. The alkaline earth metals calcium and magnesium both play major
roles: calcium in stabilising protein structures, and magnesium in signal transduction
pathways and catalysis. The transition metals, on the other hand, are exploited for
their variable oxidation states and catalytic properties, which enable them to
participate in a range of fundamental biological reactions.
Given their prevalence in biological systems and the vital role they play, it is
not surprising that metals have long been used for medicinal purposes. The
antibacterial properties of metals such as copper and mercury were well known to the
ancient Greeks and Egyptians. In Ayurvedic medicine, which has its roots in the Indus
valley, metals are central to the preparation of treatments for an assortment
of ailments. Yet despite their widespread use in traditional medicine, metals as
therapeutic tools in western medicine did not come of age until the early part of the
twentieth century, when Paul Ehrlich used an arsenical drug for the specific treatment
of syphilis.
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Some decades later, Rosenberg et al., 1967, discovered that certain platinum
compounds inhibited cell division. This led to the development of the revolutionary
chemotherapeutic drug cisplatin, which is still widely used to treat a number of cancers
by virtue of its ability to cross-link DNA and induce apoptosis of cancerous cells.
Nowadays metals have become firmly established as therapeutic agents in modern
medicine and their involvement in fundamental life processes is incontrovertible. Given
their prevalence and the diversity of their functions, metal-binding proteins are of
considerable interest to the medical and scientific community.
In order to understand proteins — and the metals they contain —
at a molecular level, atomic resolution structural models are required. These are
commonly obtained by nuclear magnetic resonance spectroscopy (NMR), which is
confined to the study of small proteins up to around 30kDa, and X-ray crystallography,
which is primarily limited by the availability of protein crystals. For the purpose of this
thesis, only crystallography will be discussed in detail.
Briefly, NMR exploits the magnetic properties of certain atomic nuclei to gain
information about the chemical environment surrounding the nucleus. When placed in a
magnetic field, nuclei that have spin — stable isotopes like 1H with an odd number of
protons and/or neutrons — absorb at characteristic frequencies. Variations in this
resonant absorption arise depending on the local environment experienced by the
nucleus (e.g. diﬀerent functional groups), and are known as chemical shifts. These must
be assigned to each atom in the NMR spectrum, and can be combined with restraints
on distances and angles between atoms to give information about the structure and
dynamics of an aqueous protein sample. For a comprehensive review of using NMR in
structural genomics see Yee et al., 2006.
X-ray crystallography, on the other hand, uses the diﬀraction of monochromatic
radiation by the electrons within a crystal lattice to deduce a map of the electron
density contained within the unit cell of a protein crystal. A detailed overview of the
technique is given in section 2.5, p. 91. By studying the detailed models that these two
techniques provide and combining them with other methods to examine the solution
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behaviour of proteins, we can hope to gain a more precise understanding of the
molecular basis of biochemical processes. This would not only increase our knowledge
base, but could also be exploited to develop targeted therapeutics.
The usefulness of metals in a biological context is not limited to naturally
occurring metal-protein interactions. Figure 1.1 illustrates the range of metals that are
naturally found in biological systems, as well as those that are used as specific tools in
a biological context.
Li Be
Na Mg Al
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Fr Ra Ac
Figure 1.1: Common metals in biological systems. Biologically important metals are highlighted and
boldfaced. Metals commonly used as therapeutic or biochemical tools are shown in white. Alkaline
metals are coloured magenta; alkaline earth metals are yellow; transition metals are blue;
lanthanide and actinides are not shown but are indicated in green and orange, respectively; and all
other metals are shown as dark grey.
Biologically occurring metals are found clustered together in the periodic table where
elements share common characteristics. The prevalence of these metals in life largely
reflects their natural abundance and availability. Sodium and potassium form small,
singly charged positive ions that are highly abundant in all living cells. They play
important roles in maintaining osmotic pressure and regulating the electric potentials
that drive such diverse processes as nerve impulses or stomatal opening. Similarly, the
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small alkaline earth metals (calcium, magnesium) have roles in signal transduction and
regulation, and many enzymes require these metals as cofactors. The transition metals
are defined as elements whose atoms or cations have an incomplete d sub-shell. As a
result of their partially filled d shells, transition metals possess a number of exclusive
properties. They have the ability to adopt multiple oxidation states thanks to the
relatively low reactivity of unpaired d electrons, which makes them ideal reactive
centres in many enzymes. Transition metals often form coloured compounds, so the iron
found in haemoglobin is responsible for the red colour of human blood while the blue
colour of lobster blood is due to the copper-containing haemocyanin. Zinc is an
essential biological trace element that is typically found as a divalent ion. It is relatively
abundant and plays ubiquitous roles in the biochemistry of life, including a purely
structural role in certain proteins (notably zinc-finger-containing transcription factors).
Metals can be used as drugs (platinum, for example, is used to therapeutic
eﬀect as described on page 5), but they can also be used as biochemical tools to study
protein structures. A particular impasse in the undertaking of solving a protein
structure by X-ray crystallography is the availability of phase information for the
molecule being studied. This is required in order to transform the recorded diﬀraction
data into a map of the electron density within the protein crystal. Phase information
cannot be recorded directly; instead it must be derived using approaches such as
molecular replacement, multi-wavelength anomalous diﬀraction and multiple
isomorphous replacement. While molecular replacement simply borrows the phase
information from a known homologous structure, the other two phasing methods rely
on the properties of heavy metals to provide phases for the unknown structure directly.
Because of their increased number of electrons, heavy metals such as platinum,
gold or mercury, scatter X-rays much more strongly than the lighter elements that
constitute the bulk of macromolecular structures. If the contribution to the overall
scattering is significant, the phases of the scattered X-rays will be similar to those
which would be observed for the heavy atoms alone. The problem of solving protein
phases is thus reduced to the problem of finding a few heavy atom positions in the unit
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cell, which can be achieved using methods developed for small-molecule crystallography.
Two common techniques for introducing heavy atoms into protein structures are to
soak heavy metal compounds into protein crystals or to incorporate selenomethionine in
the place of methionine by expressing proteins using specialised growth media for the
host organism.
In summary, metals and metal-binding proteins are ubiquitous in biological
systems and play an essential role in life as it is found on earth. The link between
metals and disease has been established and the usefulness of metals as therapeutic
agents has been explored. Finally, an outline has been given of the role of metals as
tools in the study of protein structure. The next three sections of this chapter will
describe three widely diﬀering metal-binding proteins in terms of our current
understanding of their respective structures and functions, with an emphasis on the
importance of studying these proteins in order to deepen our understanding of both the
fundamental biological processes they are involved in, and the role these proteins play
in human health and disease.
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1.4  Complement component C1
This next section will introduce a calcium-binding protein complex, complement
component C1, which is a key player in the immune response. The complement system
is an evolutionarily ancient branch of the immune system, in which C1 plays a decisive
role. The state of our current understanding of the structure and function of the
complex will be described, going on to discuss further the role that complement, and
C1 in particular, plays in innate and adaptive immunity. This section will conclude by
outlining the role of complement component C1 in disease and therapy.
1.4.1  The complement system and C1
The complement system is a subcomponent of the immune system, found in various
forms throughout vertebrate and invertebrate species (Zarkadis et al., 2001). In
humans, it comprises a host of serum proteins and receptors organised into a highly
regulated and complex network. The system is primed for a cascade of activation,
which produces a multitude of eﬀectors that contribute to host immunity
(Molina, 2004). Complement plays a crucial role in defending against infection and
maintaining the integrity of an organism by targeting invading pathogens or aberrant
cells. The nature of the complement system makes it a potent weapon in the defence
against pathogens and other harmful entities. However, deregulation of this powerful
system can have grave consequences for the host organism. Inappropriate activation of
complement is thought to contribute to the development of various inflammatory
diseases, and complement deficiencies are pathological too (Sjoholm et al., 2006). The
role of complement in disease states is covered more fully in section 1.4.4, p. 19.
Complement activity was first described in 1988, but the term ‘complement’
itself was only coined at the turn of the century by Paul Ehrlich, to describe a heat
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labile bactericidal substance present in normal serum that complemented the
antibacterial action of antibodies in haemolytic systems (Skarnes and Watson, 1957).
Today some thirty proteins that make up the biochemical cascade of complement have
been identified and the role of complement in health and disease (as well as its
therapeutic potential) are becoming increasingly clear (Wagner and Frank, 2010).
Nonetheless, despite the increasingly large body of evidence that has been accumulated
with a view to understanding the complement system, the precise details of its diverse
pathways and functions are still largely speculative.
1.4.1.1  Complement activation pathways
Our present understanding is that there are three distinct mechanisms that result in
complement activation, which converge towards the later stages of the reaction cascade.
The most thoroughly investigated of these mechanisms is undoubtedly the classical
pathway. The two other major pathways that activate complement are the mannan-
binding lectin (MBL) pathway and the alternative pathway. An overview of the various
pathways of complement activation is shown in Figure 1.2, p. 13.
The first component of the classical pathway is C1, a large protein complex that
circulates in serum as a proenzyme. On recognising and binding to activators, it
undergoes a conformational change, resulting in the activation of its serine protease
subcomponents. Activated C1 subsequently cleaves the next protein in the complement
cascade, C4. This cleavage generates a fragments that associates with C2 to form the
catalytic subunit of C3 convertase. The C3 convertase in turn cleaves C3 to produce
C3b, which binds to the surface on which complement was initiated. This process also
generates C3a, which triggers a local inflammatory response. Cleavage of C3
precipitates the terminal events in the complement cascade: inflammation and
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phagocyte recruitment; opsonisation of pathogens; and the assembly of the terminal
complement components into the membrane attack complex (MAC), which ultimately
results in the destruction of the target cell (Rother et al., 1998).
In addition to binding to pathogen surfaces, C3b also associates with the C3
convertase to give C5 convertase. Again, this complex cleaves the next protein in the
cascade into C5a and C5b. The final reactions of the complement cascade involve the
proteins C6 through C9, which associate with C5b. These reactions result in the
formation of MACs on the surface of the target cell: pores in the cell membrane that
disrupt cellular homeostasis and lead to destruction of the target cell.
While much research is currently being done on these pathways, the classical
pathway remains the most studied to date. It has been connected with a number of
diseases and is the most relevant to the present study. For this reason, the alternative
and MBL pathways will not be discussed further here, but for comprehensive reviews of
complement activation and its consequences see Duncan et al., 2008 and Sakamoto et
al., 1998. Although C3 is clearly a key target for research into modulating the eﬀects of
complement, complement component C1 is interesting because it specifically controls
activation by the classical pathway.
Furthermore, C1 shares significant structural and functional similarity with the
activating molecule of the MBL pathway. MBL is analogous to C1q, while the mannose-
associated serine proteases it joins with are analogous to the serine protease
subcomponents C1r and C1s. In particular, MASP2 is very similar to the C1s molecule
of the classical complement pathway and they are thought to have a common
evolutionary ancestor (Stover et al., 2001). When the carbohydrate-recognising heads of
MBL bind to specifically arranged mannose residues on the phospholipid bilayer of a
pathogen, MASP2 is activated to cleave complement components C4 and C2 into C4a,
C4b, C2a, and C2b. The structural and functional similarity between C1 and the
MBL/MASP complex suggests
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1.4.1.2  C1-inhibitor
C1-inhibitor (C1–INH) is a member of the serpin family of proteins, the archetypal
serine protease inhibitors. Unlike most serpins, C1-INH possesses — in addition to its
serpin domain — a unique N-terminal domain whose structure and function are as yet
unknown (Wagenaar-Bos and Hack, 2006). Serpins share a common fold, which
typically features three β-sheets and eight or nine α-helices as well as an exposed loop
region known as the reactive centre loop (RCL). The RCL protrudes from the central
β-sheet region and presents a pseudosubstrate to target proteases.
Serine proteases cleave proteins in a reaction that involves the formation of an
ester bond between the enzyme and its substrate, giving rise to an acyl-enzyme
intermediate. Subsequent hydrolysis of this ester bond usually regenerates the active
site and releases the cleaved substrate. On cleaving the RCL of a serpin however, a
rapid conformational change takes place — prior to hydrolysis of the acyl
intermediate –in which the RCL inserts into a β-sheet at the distal end of the molecule,
forming an additional β-strand. Since the protease is attached via an ester bond, this
results in a loss of structural integrity and disruption of the active site, thereby
stabilising the acyl intermediate and forming a covalent complex between the two
proteins (Huntington et al., 2000).
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Figure 1.2: Overview of the activation pathways of the complement system. The most common
activators are indicated for each pathway. The classical and lectin pathways are homologous, both
generating the C4b2a complex (C3 convertase). The alternative pathway generates the C3bBb
complex, a diﬀerent C3 convertase. All three pathways converge at the level of C3 hydrolysis. The
C3b fragment associates with either C3 convertase, transforming it into a C5 convertase. This
cleaves C5, which precipitates the terminal events in the complex cascade, leading to formation of
the MAC.
13
1.4.2  Structure and function of C1
Complement component C1 is an 800kDa complex composed of two functional
subcomponents: a recognition element, C1q, and a catalytic core comprising two
molecules each of the modular serine proteases C1r and C1s. The C1q subcomponent is
itself composed of 18 homologous chains of approximately 25kDa — designated A, B
and C — each possessing an N-terminal collagen-like domain and a C-terminal globular
domain. In the absence of an activating signal, C1 exists as a proenzyme. Upon
encountering a target molecule, C1q binds the ligand via the globular domains and
relays the activation signal to the catalytic core via structural changes. These result
first in the auto-activation of C1r, which subsequently cleaves C1s to yield the catalytic
complex.
The first model for C1q was proposed by Reid and Porter, 1976, and this still
forms the basis for our current understanding of the structure of C1q. The structure
has six-fold symmetry and is commonly described as a bouquet of flowers: the collagen
domains being the ‘stalks’ and the globular domains the ‘heads’. The individual chains
are linked in the N-terminal region of their collagen-like domain by disulphide bonds to
give three C-C dimers and six A-B dimers. The dimers then associate by forming a
collagen-like triple helix to give three ABC-CBA structural units, which associate via
strong non-covalent bonds to give C1q (Kishore and Reid, 2000). Furthermore, the C1q
stalks are not straight, but splay outwards from the central fibrous portion. The
collagen-like domains of the C1q chains contain a flexible hinge, resulting from a break
in the continuity of the Gly-X-Y repeat sequence, which allows the ‘arms’ to diverge
from the central stalk region (Schumaker et al., 1981). The accepted C1q structure just
described is illustrated in Figure 1.3.
14
A B C C
B.
ABC-CBA
C.
N C
stalk arm
head
collagen-like globular
A.
Figure 1.3: The domain structure of C1q and association of subcomponents. A. The domain
structure of C1q showing the N-terminal collagen-like domain, which mediates subcomponent
assembly; and the C-terminal globular domain, which is responsible for ligand binding. B. The
association of A-B and C-C dimers via disulphide bonds in the N-terminal region. C. Two A-B
dimers assemble with a C-C dimer in a triple helical collagen-like structure to give the ABC-CBA
structural unit.
The catalytic core of C1 is a tetramer of the subunits C1r and C1s, which are
homologous modular proteins. The C-terminal complement control protein modules
(CCP1 and CCP2) mediate the activity of the serine protease (SP) domain, while the
N-terminal CUB1 and EGF modules eﬀect the assembly of the C1s-C1r-C1r-C1s
tetramer (Villiers et al., 1985). This tetramer can be isolated independently of the
C1 complex (Arlaud et al., 1980), and is thought to act as a scaﬀold for the attachment
of C1q — and thus the assembly of the entire molecule — via the C1r moieties.
Assembly of the core is dependent on the presence of calcium ions, which are bound
with high aﬃnity to C1r and C1s. In the accepted model of the tetramer, the catalytic
domains of C1r are located at the centre and those of C1s at the ends of the assembly.
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Within the C1 complex, the tetramer folds into a figure eight conformation around the
arms of C1q. This brings the catalytic domains of C1r and C1s into contact, which is
necessary for C1s activation by C1r (Arlaud et al., 2002). An illustration of the
proposed structure for the assembled C1 complex is given in Figure 1.4.
Figure 1.4: The proposed structure of the assembled C1 complex. The figure shows a schematic
diagram based on the model derived by Gaboriaud et al., 2004, which builds on previously proposed
theoretical models by incorporating high-resolution structural data from X-ray and NMR studies on
fragments of the complex. The structure is shown as viewed from the side (left) and below (right).
C1q is shown in grey, while the two C1r chains are shown in magenta and green. For C1s, the N-
terminal serine protease domain is shown in yellow, while the C-terminal control domain is shown in
blue. The figure shows how the C1q arms splay outwards from a central collagen-like stalk, while
the serine protease subcomponents wrap around them, exposing the activated serine protease C1s.
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1.4.3  Role in innate and adaptive immunity
Complement is established as a crucial player in innate immunity, the ancient branch of
the immune system that provides an initial and non-specific barrier to infection. The
innate immune system is phylogenetically much older than adaptive immunity. It is
found in some form in all multicellular organisms, while the adaptive immune system is
exclusive to all vertebrates except jawless fish. In lower vertebrates, complement is
activated by the alternative and MBL pathways and its primary function is to promote
the opsonisation of foreign material, while in higher vertebrates complement plays an
important role as an eﬀector and regulator of both types of immune response and is
activated by all three pathways (Zarkadis et al., 2001). This suggests that the classical
pathway of complement activation is a crucial component of the complex immune
response specific to higher vertebrates and therefore particularly worthy of investigation
in terms of human health and disease.
1.4.3.1  Innate immunity and complement
The human immune system can be viewed as being composed of distinct sequential
reactions towards pathogens or aberrant cells. The complement system acts as an
immediate barrier to infection, closely followed by the cell-mediated immune response,
which involves the release of various cytokines and the action of phagocytes, natural
killer cells and other leukocytes to rid the host of the oﬀending antigen. Finally, after
several days the adaptive immune response begins to exert its eﬀects, mediated by T-
and B-lymphocytes that act in response to antigen specific T-cell receptors and
immunoglobulins or antibodies (Zipfel, 2009). This layered response caters for the short
term need to neutralise the threat and at the same time oﬀers the long term advantage
of priming the immune system to recognise and remember previously encountered
pathogens, generating immunity.
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The role of the complement system in innate immunity has been reviewed fully
elsewhere (Gasque, 2004), but the specific part that C1 and the classical pathway play
in the crucial first stages of the immune response will be briefly outlined. As already
mentioned, C1q binds to immune complexes (Cooper, 1985), toxic debris such as
amyloid (Tacnet-Delorme et al., 2001), and epitopes on apoptotic cells (Paidassi et al.,
2008). In addition to activating the complement cascade via its interaction with C1r
and C1s, C1q independently stimulates myeloid cells via the C cell surface receptor
CR1 and promotes phagocytosis of the foreign or toxic matter (Nicholson-Weller and
Klickstein, 1999). The fact that individual complement components can elicit a variety
of responses means that C1 exerts a level of control over a whole range of potential
outcomes. Eﬀectively, C1 triggers a self-contained system capable of destroying and
removing pathogens, as well as serving to stimulate further immune responses in
cellular immunity and the adaptive immune system.
1.4.3.2  Adaptive immunity and complement
While early experiments revealed a tentative link, it was the work of Mark Pepys that
provided the first direct evidence linking complement to acquired immunity (Pepys,
1974). Complement is also now generally accepted to interact with the adaptive
immune system, the lymphocyte-mediated defence system that confers long-term
immunity against specific pathogens. The notion is now emerging that complement is
not confined to particular roles in either innate or adaptive immunity, but acts as a
bridge between both systems (Morgan et al., 2005).
Complement clearly plays an important role in defending an organism against
attack by pathogens, but it is also important in maintaining homeostasis, for example
by regulating tolerance to certain self-antigens (Prodeus et al., 1998) and promoting
clearance of apoptotic cells (Ogden and Elkon, 2006). Given this dual role it is hardly
surprising that complement has been linked with numerous diseases that are either the
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result of inappropriate or excessive complement activation or caused by the absence of
certain elements of an otherwise functional complement system. As a key activator of
complement, C1 is uniquely placed in the wider context of the immune system, and
certainly a protein worth further investigation in this respect.
1.4.4  Role in disease and therapy
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can be
debilitating or even fatal. While it can be treated (mainly with steroids and
immunosuppressant drugs) it remains incurable. Deficiencies of any of the proteins
involved in the classical pathway, particularly in the early stages of complement
activation, are associated with a predisposition to SLE, and complement itself is
implicated in the characteristic inflammatory autoimmune response (Walport, 2002). 
Complement activation has been implicated in pulmonary disorders such as
asthma (Regal, 1997), as well as cardiac disorders such as atherosclerosis (Niculescu
and Rus, 1999) and tissue injury following myocardial infarction (de Zwaan et al.,
2003). Atherosclerotic heart disease is a leading cause of death in western countries and
is thus of considerable interest to the research and medical community. The current
consensus is that the disease is a consequence of chronic inflammation of the coronary
arteries. Over time, the normally protective inflammatory response becomes part of the
disease process itself (Ross, 1999). Complement activation in atherosclerosis is thought
to occur via both the alternative and classical activation pathways (Niculescu and Rus,
1999). The function and regulation of the complement system in cardiovascular disease
is broad and complex, and will not be discussed further here. However, the reader is
directed towards a recent review of the subject for further information (Oksjoki et al.,
2007).
Perhaps unsurprisingly, given its role in clearing foreign bodies and damaged
cells, complement is also involved in other types of tissue damage, for example
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traumatic brain injury (Stahel et al., 1998) and rejection of transplanted tissues and
organs (Sacks et al., 2003). Indeed, complement activation via the classical pathway is
thought to contribute to pathogenesis in conditions as diverse as Alzheimer’s disease
(D’Andrea, 2005) and HIV infection (Stoiber et al., 2003). For a comprehensive review
of the therapeutic applications of the complement system, see Wagner and Frank, 2010.
Complement component C1 thus constitutes a very attractive target for developing
drugs to inhibit undesired activation of the system. Aside from the benefits these could
bring to patients, successful treatment with a complement inhibitor is the only
conclusive way to prove a link between complement activation and a given disease,
since the presence of elevated levels of complement components does not necessarily
constitute a causative eﬀect.
There are several approaches to inhibiting complement. The first is to block the
pathway at the central stages with the aim of extending the inhibitory action as widely
as possible. The problem with this approach is that it does not take into account either
the diverse mechanisms of complement activation and their contributions to
pathophysiology, or their protective eﬀects (Mollnes and Kirschfink, 2006). A far more
eﬀective approach would be to target specifically those proteins involved in the initial
stages of the various activation pathways, since this would allow the development of
precise therapeutic tools with which to treat and investigate complement-related
diseases.
Naturally, the development of inhibitory compounds for clinical applications is
generally greatly aided by the availability of detailed structural information about
target molecules and an understanding of the processes they are involved in. It follows
that C1, as the first component of the classical pathway and thus a key player in
numerous diseases, represents a particularly attractive subject for further investigation.
In fact, the naturally occurring C1-inhibitor has been used in a clinical setting to treat
angioedema, sepsis and myocardial infarction (Clemenza et al., 2003).
Widespread therapeutical application of C1-inhibitor is nonetheless hampered
by diﬃculties in producing large quantities of C1-INH: isolating the protein form
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donated blood is expensive and risky, while recombinant C1-INH does not possess the
same glycosylation as the natural human form (Koles et al., 2004). A full understanding
of the structure and action of complement component C1 would thus appear to be of
great interest, both from a therapeutic perspective as well as for the sake of basic
science.
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1.5  Serum amyloid P component
This section will introduce serum amyloid P component (SAP), another protein
involved in immunity and associated in particular with Alzheimer’s disease. SAP is a
member of the pentraxin family of proteins, and this group of immune modulators will
be described with a particular focus on the structure and function of SAP. I will then
outline our current understanding of the role of SAP in disease, and describe the
potential applications of my work in the wider scope of the life sciences.
1.5.1  SAP and the pentraxins
SAP is a glycoprotein found in normal plasma. It is a member of the pentraxin family,
which also includes the acute phase protein, C-reactive protein (CRP). The pentraxins
are a highly conserved family, characterised by their calcium-dependent ability to bind
a variety of ligands. Functionally entwined with the complement proteins described in
the previous section, pentraxins are also involved in the innate immune response
(Bottazzi et al., 2006).
Pentraxin monomers exhibit an overall β -jelly roll topology, similar to the
legume lectins, but their name derives from their distinctive ultra-structure. Five
identical subunits associate non-covalently to form a ring with five-fold symmetry,
approximately 10 nm in diameter. Members of the pentraxin family have been found to
be highly conserved among vertebrates and even show homology to proteins from the
distantly related horseshoe crab, Limulus polyphemus. This suggests that they provide a
distinct evolutionary advantage, implying that they play an important physiological
role (Gewurz et al., 1995).
As components of humoral immunity, the pentraxins can be grouped with
members of the complement cascade, collectins and ficolins under the heading of soluble
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pattern recognition receptors. These molecules are key eﬀectors and modulators of
immunity, and represent the functional ancestors of antibodies (Mantovani et al., 2008).
The family can be split into two distinct groups, based on sequence characteristics. The
short pentraxins are typified by CRP and SAP, which are produced in the liver, while
the classic long pentraxin is PTX3, which is secreted by a variety of diﬀerent cell types.
The short pentraxins exert their eﬀects at a systemic level, while the eﬀects of PTX3
are locally targeted.
CRP was the first pentraxin to be identified, as a serum component which
precipitated the C-polysaccharide produced by streptococcus pneumoniae during acute
infection (Tillett and Francis, 1930). Since its discovery, much work has been done to
elucidate the structure and function of CRP, and it is now used a routine diagnostic aid
in the treatment of heart disease. As an acute phase protein, levels of CRP rise
dramatically during the inflammatory response, making it a useful marker for
inflammation. Serum levels can be easily measured using ELISA for example, and can
be used to chart the progress of a disease or the eﬀectiveness of treatments.
However, despite its widespread clinical use, the biological function of CRP has
not been unequivocally defined. This is in part due to the considerable diﬀerences
between species in terms of sequence, and above all in the regulation of CRP. For
example, while CRP is the classical human acute phase protein, it is not an acute phase
protein in the mouse. Conversely, a major acute phase reactant in mouse is SAP, which
demonstrates no comparable function in man. This has limited the use of traditional
genetic approaches to unravelling the physiological role of both CRP and SAP. In
contrast, studies of the long pentraxin PTX3 using genetically modified mice have
clearly defined the role of this molecule at the crossroads of innate immunity, matrix
assembly, and female fertility (Bottazzi et al., 2006).
23
1.5.2  Structure and function of SAP
The major known physiological function of SAP is its binding to various substances
in vivo, including DNA, apoptotic cells and — of course — amyloid (Pepys and Butler,
1987; Bijl et al., 2003; Pepys et al., 1979). Trimers of human SAP have been shown to
activate classical complement by binding strongly to C1q (Ying et al., 1993), and both
SAP and CRP opsonise apoptotic cells for phagocytosis by interacting with Fcγ
receptors (Mold et al., 2002). The contribution of SAP to maintaining immunological
tolerance to self is demonstrated by the observation that SAP knockout mice, in which
the gene encoding the protein has been deleted, spontaneously develop an autoimmune
disease similar to human SLE (Bickerstaﬀ et al., 1999). However, targeted depletion of
the protein by a competitive inhibitor of amyloid binding, which causes the SAP
molecules become cross-linked dimers, was developed as an approach to treating
diseases such as systemic amyloidosis, Alzheimer’s disease and type 2 diabetes (Pepys
et al., 2002). SAP inhibition by this method shows no negative eﬀects in toxicological
studies.
In normal human serum, SAP exists as a pentamer of identical 25 kDa subunits
that form a non-covalent glycosylated protein complex (Hutchinson et al., 2000). The
pentameric structure of SAP was solved over a decade ago (Emsley et al., 1994), closely
followed by the structure of CRP bound to phosphocholine (Thompson et al., 1999).
These seminal studies have furthered our understanding of the structure and function
of the pentraxins. A crystal structure of SAP in complex with the cyclic pyruvate
acetal of galactose has since been described by Thompson et al., 2002, shedding yet
more light on some of the ligand-binding properties of SAP.
Although SAP exists as a pentamer in vivo, in the absence of calcium it forms
stable decamers composed of two pentamer rings interacting face to face (Pepys et al.,
1997). In contrast, in the presence of calcium, isolated human SAP auto‐aggregates and
precipitates from solution. This calcium-dependent aggregation is inhibited by all
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known SAP ligands that require calcium for recognition, by physiological concentrations
of albumin, and by elevated salt concentrations. The molecular basis for this behaviour
can be explained in terms of the crystal structure of SAP (Thompson et al., 2002).
The native pentameric SAP assembly is shaped like a donut, approximately
100 Å in diameter and 35Å̊ deep. It possesses C5 symmetry, with the subunits arranged
like the petals of a flower around the rotational symmetry axis (see Figure 1.5). Each
subunit contains two calcium binding sites. Calcium I is co-ordinated by two ligands on
Asp-58, and single ligands on Asn-59, Glu-136, Gln-137 and Asp-138. An additional
seventh ligand is provided by a buﬀer ion. Calcium II is more loosely bound to the
protein and is co-ordinated by the side-chains of Glu-136, Asp-138, Gln-148 and two
water molecules (see Figure 1.6).
Crystals of SAP can be grown at pH5.5 in the presence of high calcium and
acetate ion concentrations, conditions that circumvent the tendency towards excessive
aggregation in the presence of calcium ions at near neutral pH. Interestingly, it has
been shown that the calcium-dependent and -independent binding of SAP to
glycosaminoglycans and amyloid is slightly enhanced at acidic pH (Danielsen et al.,
1997). This has relevance in a biological context, since the pH is typically lowered at
sites of infection or inflammation, lending weight to the validity of SAP structures from
crystals obtained under these conditions.
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Figure 1.5: The pentameric structure of SAP. The top view (left) shows the five-fold symmetry of
the assembly, with the subunits arranged in a ring around the symmetry axis. The calcium ions are
shown in blue. The side view (right) shows the calcium ions bound to one face of the pentamer,
with each of the subunits a diﬀerent colour.
Figure 1.6: The calcium binding site of SAP. The calcium I ion (right) is singly co-ordinated by
Asp-59, Glu-136, Gln-137 and Asp-138, and doubly co-ordinated by Asp-58. An additional ligand is
provided by a buﬀer molecule (not shown). The calcium II ion (left) is more loosely bound to SAP,
and is co-ordinated by Glu-136, Asp-138, Gln-148 and two water molecules.
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1.5.3  Role in disease
The precise physiological function of SAP is still unclear and experimental evidence
with regard to the role of SAP in disease has yielded little in the way of firm answers.
SAP is known to bind a variety of ligands — most notably amyloid — and this is likely
to be the key to its biological role. Like its homologue CRP, it is able to activate the
classical pathway of complement (Hicks et al., 1992), although others have speculated
that SAP is primarily involved in regulating complement activation (Garcia de Frutos
and Dahlback, 1994). The interplay between the complement system and SAP places it
squarely in the context of numerous diseases that have an inflammatory component. 
Alzheimer’s disease is perhaps the most widely known of the diseases involving
amyloid but numerous other conditions also feature amyloid deposits. Among these are
various genetic disorders but also inflammatory diseases such as rheumatoid arthritis
and atherosclerosis. As an amyloid-binding protein linked with inflammatory immune
responses SAP could play a role in a host of pathologies. It is possible that SAP is
important in coronary heart disease, since SAP has been found specifically localised to
human aortic atherosclerotic lesions (Li et al., 1995). That study provided indirect
evidence for the presence of amyloid in atherosclerotic plaques, and it has been
proposed that SAP exerts pro-atherogenic eﬀects by both accelerating the formation of
amyloid fibrils and inhibiting their degradation (Stewart et al., 2007). However, other
studies suggest that it is the small oligomeric species present early in the process of
fibril formation that are cytotoxic (Novitskaya et al., 2006), so SAP may be carrying
out a protective function by converting these into mature amyloid fibres. Further
research into SAP is clearly needed to fully understand the role this protein may play
in pathogenesis or protection against inflammatory disease.
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1.6  ZiCo: a designed switch peptide
This section will introduce the reader to ZiCo, a peptide that was designed to switch
between two folded forms upon binding zinc. I will discuss the theory behind the design
and the interplay between protein sequence and structure from a design perspective. I
will critically discuss previous work carried out on this system and explain how
obtaining high-resolution structures is crucial to validating the success of the design.
1.6.1  Protein folding and design
The key to carrying out the multitude of tasks that proteins perform in vivo lies in
their ability to adopt unique three-dimensional shapes. Proteins are synthesised as
linear chains of amino acids, which must fold into a specific conformation to allow their
biological function to be carried out. The question of precisely how proteins assume
their native structure under physiological conditions is known as the protein folding
problem, and it is widely recognised as one of the greatest current challenges in
molecular biology.
The search for an answer to the protein folding problem has taken on a new
sense of urgency in the post-genomic era because of the drive to exploit the vast
amount of information gained from genome sequencing studies. Several initiatives have
been launched to complement the human genome project with a map of the human
proteome, including the Human Proteome Project sponsored by the Human Proteome
Organisation. Indeed, developments in sequencing technology are ushering in the advent
of personal genomics, with increasingly rapid turnaround times (days as opposed to
years) and the cost of sequencing a single genome predicted to fall below £1000 in the
coming years. Structural information is key in order to take advantage of the vast sets
of protein identities generated by such projects. Obtaining experimental structures of a
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protein is a lengthy and costly process, and may not even be practicable for many
proteins due to diﬃculties in obtaining adequate amounts of material or the
amenability of the protein itself to the techniques in question. Furthermore, the true
power of such resources lies not in our ability to document the proteins present in life,
but in our ability to manipulate them. For this reason, the ability to not only predict
protein structures from sequence data alone but also to modify them in a directed way
is crucial for progress in biology and medicine.
The protein folding field has been reviewed extensively (Dill et al., 2008;
Basharov, 2003; Yon, 2002; Radford, 2000). An understanding of protein folding is of
fundamental importance to science since it relates protein function to the genetic code,
thus providing the missing link between genotype and phenotype. A principal goal of
protein folding studies is to allow any structure to be predicted from its sequence alone.
Being able to do this would revolutionise research in the biological sciences and have
profound clinical applications. A related goal involves the design and redesign of protein
sequences to adopt specific structures or perform specific functions. While there are
numerous examples of both de novo designed structures and proteins redesigned to
possess increased stability or altered binding characteristics, the successful design of
novel folds from first principles is still a challenging and complex process.
Protein folding is both spontaneous and reversible, and pioneering studies on
ribonuclease by Christian Anfinsen demonstrated that the information required to
assume a tertiary fold is contained within the primary sequence (Anfinsen and Haber,
1961). Subsequent work led Anfinsen to propose his thermodynamic hypothesis: that
the native state of a protein is the thermodynamically most favoured conformation
(Anfinsen, 1973). In 1968, Cyrus Levinthal proposed that proteins must fold via specific
pathways (Levinthal, 1968), having shown that it would take a small protein longer
than the age of the universe to fold through a random search of conformational space.
The fastest proteins are known to fold on microsecond time scales (Eaton et al., 2000),
and this large discrepancy between the calculated and observed times for protein
folding has become known as the Levinthal paradox. These early observations have
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underpinned the field of protein folding, and each addresses a broad area of the protein
folding problem: the sequence/structure relationship; protein stability; and folding
pathways.
Much work has gone into elucidating the mechanisms by which proteins fold
and important insights have been gained from experimental and theoretical approaches.
Technological advances have led to the development of new techniques enabling us to
probe folding in unprecedented detail, the most notable in recent years being force
spectroscopy, which allows the unfolding of single proteins to be measured (Fisher et
al., 1999). The emerging ideas have been unified into the now commonly accepted ‘new
view’ of protein folding. It has become clear that viewing protein folding in terms of a
randomly coiled polypeptide chain that folds into its native, lowest energy state via a
single pathway is a gross oversimplification.
Firstly, the notion that unfolded proteins exist as unstructured, random coils
has been refuted (Smith et al., 1996). Thus the unfolded state is instead considered to
be an ensemble of transient conformations of high free energy. Similarly, the native
state does not correspond to a single conformation, but to multiple folded forms that
undergo rapid inter-conversion at lower free energy. Furthermore, there is a growing
body of evidence to suggest that proteins fold co-translationally, and the validity of the
post-translational view of protein folding has been directly questioned (Basharov,
2000). Studies on α-lytic protease have shown that the unfolded and partially unfolded
states are lower in free energy than the native, directly contradicting the
thermodynamic principle (Sohl et al., 1998), and proteins are also known to fold via
multiple pathways (Weissman, 1995).
The folding process is now commonly described in terms of a funnel-shaped
energy landscape. The top of the funnel represents the vast number of possible
conformations of the unfolded state, the native state is represented as a well at the
bottom, and the kinetic and thermodynamic aspects of the folding process are
represented as bumps in the surface of the funnel. While this model unites much of our
current understanding of the principles behind protein folding, our understanding of
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how proteins fold in vivo is complicated further by the role of auxiliary proteins such as
chaperones that assist the folding process. A discussion of this topic is beyond the
scope of this text, but the reader is directed towards recent reviews (Hartl and Hayer-
Hartl, 2009; Ellis, 2006).
The study of protein folding has been revolutionised by our ability to engineer
proteins and even design them from first principles. This has been made possible both
by advances in our understanding of protein folding and by the development of new
techniques and tools with which to design and manipulate proteins (for a discussion of
recent advances in protein design methodology see Lippow and Tidor, 2007). Protein
design allows us to tease out information about the structural stability and functional
role of individual parts of the protein structure under scrutiny. In combination with
information gleaned from bioinformatics approaches, this can enable us to establish new
rules for protein folding and deepen our understanding of the relationship between
sequence and structure. Protein design often focuses on producing a single stable
structure but it is structural fluidity that underpins the function of many proteins. So it
is important not only to understand how to design stable protein folds, but also how to
engineer any required flexibility into these structures that will allow novel functions to
be created. Indeed, a blossoming area of protein design focuses on proteins whose
primary sequence encodes multiple structures, and this will now be discussed.
1.6.2  Switch peptides
Proteins have long been known to be dynamic molecules. The constant thermal motion
of atoms can result in small movements such as the flipping of side chains — which
may be important for carrying out the biological function — as well as large
conformational changes. These movements, in response to ligand binding or changes in
the local environment, underpin many normal physiological processes. The implication
of conformational changes in various diseases (Carrell and Gooptu, 1998), collectively
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known as protein conformational disorders, has led to a renewed interest in the
structural flexibility of proteins. The defining event in such diseases is a change in the
structure of a protein with no concomitant change in the primary sequence, which
results in pathogenicity either through the loss of a biological function or through the
acquisition of a toxic activity.
There has been a considerable paradigm shift away from the ‘one sequence, one
structure, one function’ hypothesis that was prevalent in the past, because it has since
become apparent that a single sequence is able to form more than one stable fold.
Examples of sequences that exhibit structural duality abound in naturally occurring
proteins (Damaschun et al., 1999; Mezei, 1998; Zhao et al., 2001). A particularly
striking example is the bacterial elongation factor EF-Tu, which contains a six-residue
sequence that completely converts from an alpha helix when GTP is bound, to beta
structure in the GDP-bound form (Abel et al., 1996). There are also numerous
examples of designed sequences capable of switching between stable conformations in
response to the local polypeptide environment (Minor and Kim, 1996), temperature
(Ciani et al., 2002), redox state (Pandya et al., 2004), phosphorylation (Signarvic and
DeGrado, 2003), solvent conditions and light (Cerpa et al., 1996). 
Of course, ligand binding also induces structural changes in proteins, and there
has been a growing trend towards the design of metal-binding peptides that produce a
measurable conformational change (Pearce et al., 1998; Shults et al., 2003). Zinc-
binding peptides have been a particular focus of recent research, largely because the
zinc finger domains on which such designs are based have been extensively studied
(Berg and Godwin, 1997). Besides furthering our understanding of protein folding, such
designed peptides have considerable practical applications as sensors in quantitative
and qualitative analyses of metal ions in environmental and clinical samples, since
protein based sensors can oﬀer unrivalled selectivity. Pursuing the design of metal
binding protein switches is attractive, then, in terms of both intellectual merit and
technology transfer.
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Another desirable property of biosensors based on conformational changes in
proteins is their intrinsic potential for reversibility. With this in mind, Cerasoli et al.,
2005, designed ZiCo, a peptide that switches reversibly between two very diﬀerent
folded forms upon metal binding. The principle behind the design involves the
combination of two diﬀerent sequence motifs into a single sequence. If the design is
successful, ZiCo will switch between a trimeric α-helical structure and a folded
monomer upon binding divalent zinc, as illustrated in Figure 1.7. The details of the
design and its applications will be outlined in the following sections.
A. B.
Figure 1.7: ZiCo design principles. A. This trimeric coiled coil structure illustrates the zinc-free
state of the ZiCo design. B. A zinc finger structure illustrates the zinc-bound state. The peptide is
designed to switch between the two folds when zinc is added to a buﬀered saline solution
containing the peptide.
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1.6.3  Design details
The design and biophysical characteristics of ZiCo will be briefly described here, but for
a fuller discussion see Cerasoli et al., 2005. The design process involved merging the
consensus sequence of a classical Cys2-His2 zinc finger and a non-canonical coiled-coil
heptad repeat, with a few added adaptations . A classical zinc finger motif contains a
single zinc ion pinched between an alpha helix and a beta turn, co-ordinated by two
cysteine and two histidine residues (see Figure 1.8). By contrast a trimeric coiled coil
consists of three alpha helices coiled around each other like the strands of a rope. 
Figure 1.8: Classical Cys2-His2 zinc finger. The zinc ion is co-ordinated by two cysteines in the
β‑turn and two histidines at the C-terminal end of the α-helix. Here the β‐structure is shown in
cyan, the helix is coloured magenta and the co-ordinating residues are highlighted in yellow.
Coiled coils are characterised by a repeated sequence of hydrophobic and polar residues,
known as the heptad repeat. When such a sequence folds as an alpha helix, the
hydrophobic residues are located in a seam that runs along one side of the helix. In a
coiled coil, the hydrophobic residues (which are distributed along the long axis of the
structure) interact in a special way known as ‘knobs-into-holes packing’, whereby a
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hydrophobic residue on one helix is buried in a hydrophobic pocket created by residues
on another helix. The concept of the heptad repeat and knobs-into-holes packing is
illustrated using the helical wheel representation of a trimeric coiled coil in Figure 1.9.
a
b
c
d
e
f
g
a
b
c
d
e
f
g
a
b
c
d
e
f
g
Figure 1.9: The heptad repeat and packing of a trimeric coiled coil model. The seven residues of
the heptad sequence repeat are labelled a–g for each of the three helices, with the coiled coil axis
running perpendicular to the page. Hydrophobic residues involved in core formation (a and d) are
shown in red, while those typically involved in electrostatic interactions (e and g) are shown in
italics.
The various features of the ZiCo sequence and their relationship to the structural
principles behind the design are depicted in Figure 1.10. Several modifications were
made to the raw sequence in order to promote structural flexibility and facilitate the
switch between the two folds. Firstly, the cysteine residues of the classical zinc finger
have been replaced by histidines, to prevent problems with oxidation. This approach to
designing a zinc finger protein has proven to be successful by Hori et al., 2000, who
showed that an H4 zinc finger peptide had a similar structure to the wild type.
Another modification to the sequence is the insertion of a stutter in the heptad
repeat, in the region corresponding to the loop linking the alpha helix and the beta
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hairpin of the zinc finger. Such stutters have been shown to disrupt the core packing of
the coiled coil structures, leading to a local unwinding of the superhelical structure.
The stutter was included with the aim of introducing a local region of destabilised core
packing to facilitate the switch to the monomeric zinc-bound form. 
A .    1        10        20
B.    PHPPHPPPHPPPHPPHPPPHPPHPPPH
C.    XXCXXCXXXXXXXXXXXXHXXXXXHXX
D.    YIHALHRKAFAKIARLERHIRALEHAA
E .    gabcdefghijkabcdefgabcdefga
Figure 1.10: Features of the ZiCo sequence showing the design principles. A. Residue number. B.
Pattern of hydrophobic (red) and polar residues (blue). C. The classical zinc finger consensus
sequence with conserved residues highlighted in yellow, showing regions of α-helix (magenta) and
β -strand (cyan). D. ZiCo sequence. E. The heptad repeat pattern showing the position of the
stutter from residues 9–12.
In solution, the peptide undergoes a conformational change on binding divalent zinc
that can be monitored by circular dichroism (CD) spectroscopy and a change in
oligomerisation state that can be followed by analytical ultracentrifugation.
Interestingly, a very similar system to ZiCo has been described more recently
(Ambroggio and Kuhlman, 2006). The computationally designed peptide Sw2 can be
switched from a Cys2-His2 zinc finger-like fold to a trimeric coiled-coil fold, in response
to pH or the presence of transition metals. This system could provide a valuable model
for comparison with ZiCo. The ZiCo peptide as described here was also used as a
template for designing a family of similar peptides based on the same core principles.
While the published data on the original ZiCo are indicative of a switch between two
alternate stable folds, high-resolution structures are the only way of confirming the
success of the design of this and the other ZiCo peptides.
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1.7  Project background
1.7.1  C1: purification, characterisation and crystallisation
Previous studies on complement component C1 have generally involved purifying the
complex by exploiting its aﬃnity for immunoglobulins or other ligands (Medicus and
Chapuis, 1980; Schiﬀerli and Steiger, 1985). Often, the individual C1 subcomponents
are separated during the purification procedure by the addition of EDTA, and the
complex is reconstituted from its purified constituents (Strang et al., 1982; Tseng et al.,
1997). However, it is also possible to gently precipitate the entire assembly from human
serum using polyethylene glycol, to give a functionally pure extract (Neoh et al., 1984).
Given that the entire structure of the complex has not yet been solved, using a novel
purification procedure introduces another variable into the search for a crystal structure
of native human C1.
Of further interest is the specific role that calcium — and possibly other
divalent metals — play in the structure and function of C1 under various conditions.
Understanding this relationship has implications both for the search for crystal
structures of the native complex and for revealing the full picture of its biological
function. An investigation into the eﬀect of various metal ions on the assembly and
activity of the C1 complex was carried out some decades ago (Ziccardi, 1983), but the
study was not exhaustive. Iron, copper and selenium are all present as trace elements in
human blood and increases in copper concentrations are generally accepted to be
associated with sites of infection and inflammation. Examining the eﬀects of
physiologically relevant conditions on native human C1 may help to further our
understanding of this key immune complex, and a model of the entire assembly would
contribute greatly to the wealth of structural information already available.
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1.7.2  SAP: investigating metal and ligand binding
Serum amyloid P component can readily be purified and crystallised using established
methods. Several crystal structures of SAP in complex with various ligands have been
solved, taking us some way to understanding the interactions of this protein in the
context of immunity. However, there has been little investigation into the eﬀect of metal
ions other than calcium on the structure of SAP at high resolution.
In the study by Thompson et al., 2002, the calcium ion in the second calcium
binding site could be replaced by cerium, suggesting that under certain conditions other
ions might bind to SAP. During inflammation various physiological changes occur,
including an increase in acidity and the concentration of copper ions in the local
cellular environment. Several studies have demonstrated a link between elevated serum
copper levels and cardiovascular disease (Malek et al., 2006; Leone et al., 2006).
Increased serum copper levels have also been shown to be characteristic of Alzheimer’s
disease (Squitti et al., 2005). This supports the theory that these diseases are caused by
an initially beneficial inflammatory response that then develops into a chronic
pathological process. One possible way in which this may occur is via positive feedback
loops that reinforce inflammatory signals in the absence of an appropriate stimulus. It
is possible that metal ions could contribute to this process by modulating the function
of certain proteins associated with regulating the inflammatory response.
With respect to SAP, there are interesting observations that hint at just such a
process. Under conditions such as those present in inflamed tissue, SAP binds to the
bacterial cell wall polysaccharide preparation zymosan much more strongly than under
normal physiological conditions (Potempa et al., 1985). It is also possible that copper
ions interact with SAP in a way that aﬀects the aﬃnity of the molecule for its various
ligands. Both SAP and C1 depend on calcium ions for structural stability and function.
An investigation into the calcium and copper binding properties of these two proteins
under relevant conditions could have interesting implications for our understanding of
their structure and biological function in health and disease. 
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1.7.3  ZiCo: design validation
The ZiCo peptides are de novo designed proteins, and the search for high-resolution
structures to verify the success of their design was a collaborative project carried out in
conjunction with the laboratory of Professor Dek Woolfson (University of Bristol, UK).
Prior to this work, ZiCo had been extensively characterised in solution studies, the
results of which are summarised in Table 1 (see p. 40). In addition, the original ZiCo
peptide had been crystallised — and several data sets had been collected — but
attempts at solving the structure by molecular replacement had not yet proved
successful.
Owing to the nature of the system, the solution behaviour of ZiCo is inherently
less straightforward than that of a typical globular protein. Consequently, the
crystallisation landscape of ZiCo in its free and zinc-bound forms is also much more
complex. As can be seen in Table 1, the melting temperature of the trimer increases
with the concentration of peptide in solution. This suggests that in the absence of zinc,
not all the peptide is present in its trimeric state but that there exists an equilibrium
between trimers and free peptide in solution. As more peptide is added, this shifts the
position of equilibrium in favour of the trimeric form.
In addition, precipitate was observed at high peptide concentrations in the
presence of excess zinc and phosphate buﬀers. It was speculated that this may be due
to the formation of zinc hydroxide at around neutral pH, while in other buﬀers such as
Tris, the excess zinc may be sequestered by buﬀer molecules. Thus both the peptide
concentration and the concentration of other solutes can have important consequences
for the structure of ZiCo in solution. This must be considered when designing
crystallisation experiments with a view to obtaining high-resolution structures of the
peptide in order to lend force to the rationale behind its design.
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Zinc
None Equimolar
Oligomerisation state Trimer Monomer
% helix 50 75
Kd
Trimer association: Zinc binding:
10–100µM 3–5µM
Tm
Concentration dependent:
23°C
50µM 10°C
100µM 14°C
200µM 18°C
Table 1: Biophysical characteristics of Zico1. Data taken from Cerasoli et al., 2005. The table
shows various features of the ZiCo1 peptide in the presence and absence of equimolar zinc
concentrations. In the absence of zinc, the peptide forms trimers with a Kd of 10–100µM and a
melting temperature that is concentration dependent. With equimolar zinc, the peptide forms
monomers with a Kd of 3–5µM for zinc binding and a Tm of 23°C.
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1.8  Project aims
1.8.1  C1: purification, characterisation and crystallisation
The aim of my work on complement component C1 is to develop a purification scheme
to isolate the native protein complex from human plasma using a combination of PEG
precipitation and chromatographic techniques. The purification strategy will be
optimised for structural studies by X-ray crystallography, with an emphasis on
achieving high purity and homogeneity of the purified product. Once purified, the
native C1 will be analysed under physiologically relevant conditions to test the eﬀect of
various metal ions and other relevant factors on the structure of the complex. Finally,
the crystallisability of complement component C1 will be explored in the hope of
obtaining usable crystals.
1.8.2  SAP: ligand binding and co-crystallisation 
With regards to SAP, the aim of my work is to investigate the ligand binding properties
of this molecule. SAP will be purified from human plasma using established methods
and the quality of the purified product will be analysed for its suitability for use in
structural studies. The metal-binding properties of SAP will be examined using the
ability of various non-metal ligands to disrupt the calcium-dependent aggregation of
SAP. This work aims to lay the foundations for other projects, including the interaction
and co-crystallisation of SAP with metal ions other than calcium.
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1.8.3  ZiCo: design validation
Finally, the goal of my work on ZiCo is to provide high-resolution structural
information about the system in order to validate the design. The original ZiCo peptide
has previously been crystallised, but no structure has yet been found. The aim is to
conduct an investigation into the crystallisability of two ZiCo peptides and build upon
the available data in the pursuit of a high-resolution structural model of both the free
and zinc-bound forms.
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Chapter 2
Background to methods
2.1  Overview
The following chapter outlines the general methods employed and discussed in this
thesis. Since the main focus of this work is the use of X-ray crystallography to
investigate the proteins under study, this chapter will begin with a general introduction
to the technique, before examining the diﬀerent steps in the progression towards solving
a structure in detail. One of the crucial requirements for structural studies is a highly
purified protein sample, so part of this chapter will deal with the process of obtaining a
suitable starting material for structural investigations by chromatographic methods.
The remainder of the chapter will explore a variety of other techniques that provide a
wealth of complementary information on the purity of a protein sample and its
structural characteristics.
There are several techniques available to probe the structure of biological
macromolecules, but X-ray crystallography is generally regarded as the gold standard in
terms of the accuracy of the structures obtained and the range of situations in which it
can be applied. While there have been interesting developments in the field relating to
the possibility of imaging single protein molecules at atomic resolution by X-ray
scattering (Shintake, 2008), the current state of technology requires the use of crystals
to generate a measurable diﬀraction signal.
Obtaining a high-resolution protein structure by the crystallographic method
essentially involves interpreting the pattern of X-rays diﬀracted by the array of identical
molecules that occupy a crystalline lattice, in order to produce a map of the electron
density within the structure. In the general set-up, a crystal is rotated within an
incident beam of monochromatic X-ray radiation and the diﬀracted rays are recorded as
a series of two-dimensional images. Using a computer to apply the mathematical
method of Fourier transforms, the intensities and positions of the reflections are
combined with information about their phases and converted into a three-dimensional
electron density map. A model can then be generated by making use of prior
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information about the specific protein under study (and the structure of proteins in
general) and progressively fitted to the experimental data until a satisfactory model of
the structure is achieved.
Compared with the task of determining the structure of a small molecule
compound, for which X-ray crystallography is also an established technique, the process
of solving a protein structure is complicated by several factors. Firstly, obtaining the
protein product in a suitably pure and stable form (and in suﬃcient quantities) for use
in crystallisation trials can be problematic. Secondly — in contrast to the simple
evaporation procedures typically used by chemists — the production of protein crystals
suitable for diﬀraction studies is generally a very intensive task that can consume vast
amounts of material and considerable lengths of time. And finally, the complexity and
sheer size of the molecules in question mean that the computational techniques for
determining the structure from the diﬀraction data are also more convoluted.
Each stage in the procedure, from preparing a pure protein sample to refining
the structural model, has its own peculiar diﬃculties and must be tailored to the
protein in question. Particularly in the case of entirely novel structures, it is not
possible to predict from the outset exactly what strategies to employ at each stage,
which means that in many cases structure solution by X-ray crystallography remains a
rather empirical procedure. The following sections will describe the various steps in the
progression towards solving a protein structure in detail.
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2.2  Protein purification
One of the most crucial steps in preparing a protein for crystallisation purposes is
purifying the protein itself. In contrast to many standard biochemical applications,
structural studies generally require a highly pure and conformationally homogeneous
sample. As a result, a multi-step procedure is generally employed to achieve the level of
purity required for crystallisation. There are a variety of methods available to purify
proteins from diﬀerent sources and the major techniques used in this work will be
outlined in the following section. In the process of designing a purification scheme, the
nature of the protein in question must be considered, for example, any ligand binding
properties may be exploited in an aﬃnity step. Furthermore, the final purified product
is best finally reconstituted and stored in a manner that maintains the protein in a
structurally stable state.
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2.2.1  Precipitation
When purifying a protein from a complex source, such as cell lysates or bodily fluids, a
common first step is to precipitate a fraction of the soluble proteins that contains the
protein of interest. This can be accomplished by adding neutral salts, such as
ammonium sulphate, or polymers such as polyethylene glycols (PEGs) to an
appropriate concentration that results in precipitation of the target protein from
solution. Proteins precipitate when the repulsive electrostatic forces between them are
reduced or when hydrophobic patches become exposed on the protein surface, causing
aggregation and precipitation.
Adding salts to a protein solution results in the bulk water becoming associated
with the salt ions, meaning that less water is available to partake in the solvation layer
surrounding the proteins. Similarly, polymers attract water molecules away from the
solvation layer around the protein, increasing protein-protein interactions and
enhancing precipitation. Compared with other methods of precipitating proteins for
further purification, the advantage of using salts and polymers is that they are less
likely to cause irreversible denaturation. The precipitated fraction will be enriched in
the protein of interest but will generally still contain a number of other proteins, which
must be removed by further purification steps, for example by separation using
chromatography.
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2.2.2  Chromatography
Chromatographic techniques allow the separation of protein mixtures by passing a
sample dissolved in a mobile phase, such as an aqueous medium, through a stationary
phase of some sort, separating the target protein from other molecules in the mixture
based on diﬀerential partitioning between the mobile and stationary phases.
Chromatography can be preparative or analytical. The former uses large amounts of
sample with the aim of purifying the desired components from the mixture, while the
latter usually uses smaller amounts of material and can be used to analyse the proteins
in a sample in terms of various properties of the components and experimental
conditions.
2.2.2.1  Aﬃnity chromatography
Aﬃnity chromatography separates proteins on the basis of a reversible, specific
interaction between the target protein and a ligand coupled to the chromatography
matrix. It is often used alone or towards the beginning of a multi-step purification
procedure, since it oﬀers high selectivity and often also high capacity for the target
protein, thus allowing considerable quantities to be extracted directly from complex
mixtures.
An aﬃnity chromatography procedure involves selecting an appropriate ligand
and coupling it to a suitable medium such that it is still free to bind the protein of
interest. The sample to be separated is applied to the column and allowed to bind to
the immobilised ligand, after which the unbound contaminants are washed from the
column. The remaining bound sample is eluted from the column either specifically, by
introducing a competing ligand, or non-specifically by changing the pH, ionic strength
or polarity so that the interactions between the sample and the matrix are weakened. 
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Finally, the purified sample may be further purified by other methods or
exchanged into a suitable buﬀer for further studies, since the elution buﬀer may be
unsuitable for downstream applications due to the presence of additives. The major
factors that aﬀect the outcome of the separation are the choice of ligand and coupling
procedure, the binding and elution buﬀers, and the flow rate during these two major
steps. By carefully optimising these parameters, a particular protein can be purified
from a complex mixture or information about its binding properties can be elucidated.
2.2.2.2  Ion exchange chromatography
A further chromatographic technique is ion exchange chromatography (IEX), where
molecules are separated based on their net surface charge. The overall charge of any
given protein will change depending on the pH of the surrounding medium and the
charge density and charge distribution varies considerably from one protein to another.
IEX exploits the fact that the relationship between pH and net surface charge is
particular to each protein. The separation of the various components of a sample occurs
as a result of reversible interactions between the charged proteins and the oppositely
charged IEX medium, which can be controlled to give preferential binding and elution
of specific molecules. At a pH above its isoelectric point, a protein will bind to
a positively charged medium or anion exchanger, whereas at a pH below its pI,
a protein will bind to a negatively charged medium or cation exchanger.
Depending on the pI of the protein and the pH at which the separation is to be
carried out, a suitable medium must therefore be selected. Since the binding of
molecules to the column is aﬀected by ionic strength and pH, the samples must
generally be prepared in the same buﬀer as that used during the binding step of the
separation procedure. As with aﬃnity methods, the sample is loaded onto the column
and any unbound substances are washed away. By changing the ionic strength
(or alternatively the pH) of the buﬀer passing through the column, the bound
49
substances can be eluted. Changing the pH directly aﬀects the interactions between the
proteins and the medium, whereas increasing the ionic strength causes salt ions or other
solutes to compete with the bound molecules for charges on the surface of the
stationary medium. Proteins with a low net charge will elute from the column first,
since they have fewer interactions with the medium, while those with a high net charge
will be retained for longer on the column and elute last. By varying the changes in ionic
strength using diﬀerent types of gradient during the elution, the separation can be fine-
tuned to give an optimal purification.
2.2.2.3  Size exclusion chromatography
Yet another purification technique useful when working with proteins is size exclusion
chromatography (SEC), also known as gel filtration chromatography, in which particles
are separated on the basis of diﬀerences in size. The sample to be separated is
suspended in a suitable buﬀer and passed through a column packed with a porous and
chemically inert medium, typically agarose, dextran or polyacrylamide beads. Smaller
molecules are able to penetrate the interior of the beads, while large particles are
excluded from the beads entirely and so only have access to a part of the column
volume, known as the void volume. The principle behind SEC is that molecules of
diﬀerent sizes will pass through the column at diﬀerent rates, based on the extent to
which they are able to penetrate the stationary phase. Large molecules, having access
to a smaller volume, elute from the column first, with smaller proteins eluting according
to their hydrodynamic properties.
While SEC is perhaps the simplest way of separating a protein mixture, a
number of factors have to be considered. In order for separation by SEC to be
successful, the particles to be separated must be loaded onto the column
simultaneously. In practice, this means that the sample must be applied in a small
volume relative to the volume of the column. In addition, the medium must be selected
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to prevent any specific interactions with the sample components and to give good
resolution over the range of molecular weights required. The size of the pores in the
matrix define an upper and a lower boundary for the size of molecules that can be
reliably separated. Above the exclusion limit, large particles elute together with the
void volume, and below the permeation limit, where small molecules can completely
penetrate the medium, smaller particles elute as a single peak.
A column can be calibrated against proteins of known molecular weights and
thus the molecular weight of the sample protein can be estimated. Strictly, the elution
of proteins from a SEC column is governed by the hydrodynamic properties of the
particles, which reflect both the size and shape of the molecule. Accordingly, a globular
protein and an extended polymer of the same molecular weight will behave diﬀerently
during the separation. Compact particles have a greater probability of entering the
pores of the matrix, since extended particles must be oriented correctly in order to gain
access to the hidden volume. Thus SEC can be used to distinguish between folded and
unfolded forms of the same protein, since the folded form is likely to elute much later.
Aside from its application for studying protein structure, SEC is generally employed in
the final stages of a purification scheme, as a polishing step. It is particularly
convenient as it allows the protein to be exchanged into a buﬀer suitable for storage or
further work, thanks to the size diﬀerence between protein and low-molecular-weight
solute molecules.
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2.2.3  Protein concentration
Once a protein has been purified, it is often necessary to concentrate the sample for
further studies, particularly if it is to be used in crystallisation trials. This was
accomplished here by the use of centrifugal filters, which contain a microporous
membrane that retains molecules above a certain molecular weight while allowing
solvent and smaller particles to pass through. Like SEC, ultrafiltration also allows
buﬀers to be exchanged quickly and easily when compared to other methods such as
dialysis.
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2.3  Protein characterisation
Proteins can be characterised by various methods, and those relevant to the
investigations presented in this thesis will be described in the following sections.
Often the aim of a biochemical study is to assess the function of a protein. This does
not require the preparation of very pure extracts. As long as inhibitors and other
destructive or damaging contaminants are removed or their eﬀects minimised,
functional assays can be performed using simple homogenates without the need to
remove other proteins present in the sample. However, for the purposes of obtaining
high-resolution protein structures by X-ray crystallography or other means, it is
necessary to ensure as pure a preparation as possible. In addition to confirming the
success of a protein purification procedure, the techniques employed in this work
provide complementary information about the solution structure and behaviour of the
systems under study.
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2.3.1  Electrophoresis
Electrophoresis is an invaluable tool in protein biochemistry, both for the purposes of
purification and as a way of analysing biomolecules quickly and cheaply.
Charged particles — proteins, for instance — will move through a porous medium
when an electric field is applied. The relative rates of migration depend on a number of
factors, including net charge, molecular mass and the hydrodynamic radius of the
molecules, as well as the properties of the medium through which the proteins are
migrating. This is the principle behind all electrophoretic methods and the present
section will outline specific techniques employed in this work.
2.3.1.1  Native PAGE
Perhaps the simplest way to analyse proteins by electrophoresis is the method known as
native polyacrylamide gel electrophoresis (PAGE). As the name suggests, the
electrophoretic separation of a protein mixture is performed under non-denaturing
conditions, allowing the native state as well as protein-protein interactions to be
maintained. There are two main flavours of the technique: blue native PAGE, which
uses the Coomassie blue dye to impart a net negative charge to the proteins; and clear
native PAGE, where the intrinsic negative charge of most proteins provides the
necessary electrostatic attraction to the anode and hence the end of the gel. Of course,
if a horizontal system is used and the sample loading wells are placed in the centre of
the gel, positively charged proteins will also migrate through the gel towards the
cathode, whereas in a vertical system these would be simply lost to the upper buﬀer
chamber. The net charge of molecules in solution can be manipulated by varying the
pH.
Only clear native PAGE was used in this work, as Coomassie binding to
proteins can cause the dissociation of protein complexes. However, because of the large
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size of the proteins being analysed, an agarose gel — with a much larger pore-size —
was substituted for the polyacrylamide gel. In a typical procedure, an agarose gel was
cast by dissolving the required amount of agarose in 100mM Tris, pH8.5 and using the
same buﬀer as a running buﬀer. Samples were also loaded in the same buﬀer containing
20% glycerol and 0.010% bromophenol blue, to monitor the progress of the run. Since
the majority of proteins are acidic, i.e. having a pI < 7, the high pH of the running
buﬀer ensures a slight negative charge. Of course, the buﬀer system can be adjusted to
accommodate the specific properties of the protein of interest or to achieve specific
desired eﬀects.
2.3.1.2  SDS-PAGE
Separation of proteins on the basis of their molecular masses alone is achieved quickly
and easily by SDS-PAGE, which is one of the standard repertoire of biochemical
techniques available for studying proteins. Briefly, the protein sample is heated to
100 °C in the presence of SDS, a detergent which binds to the polypeptide backbone in
a constant ratio and coats the protein in an overall negative charge, eﬀectively masking
the intrinsic charge of the protein. Thus the proteins within the sample become linear
structures with a uniform charge density and the electrophoretic mobilities of these
proteins will be a linear function of the logarithms of their molecular weights.
The denatured proteins can then be separated on a polyacrylamide gel
immersed in buﬀer. As the negatively charged molecules migrate in the electric field
through the pores of the gel, smaller molecules are more mobile and thus travel faster
than larger molecules. The progress of an SDS-PAGE run can be monitored using a
dye, bromophenol blue, which travels through the gel matrix ahead of the smallest
proteins because of its small size. Terminating the run once the dye front reaches the
bottom of the gel ensures that none of the proteins are lost into the surrounding buﬀer.
55
The most common buﬀer system used for SDS-PAGE is the discontinuous
Laemmli method. Discontinuous buﬀer systems, which use a diﬀerent buﬀer for the gel
and the tank, concentrate the proteins into a very tight band early in the run, resulting
in increased resolution of the resulting separation. However, continuous systems, where
the same buﬀer is used both in the gel and the tank, may also be used, although this is
much less common. The results of an SDS-PAGE separation can be visualised using one
of the staining methods outlined below.
2.3.1.3  Staining
Since most proteins are invisible during the electrophoresis run (exceptions being
proteins that are naturally coloured or have been labelled with some dye) the progress
is monitored using the small molecule dye bromophenol blue, which migrates ahead of
any proteins. However, after the run has been completed, the proteins themselves must
be visualised by some means. There are various methods to determine the positions of
proteins separated by electrophoresis within the gel, the most common being staining
with Coomassie Brilliant Blue. 
The Coomassie family of dyes are small-molecule dyes that bind non-specifically
to most proteins via interaction with certain residues (primarily lysine, arginine and
histidine), as well as through Van der Waals and hydrophobic interactions. The amount
of dye bound to each molecule is roughly proportional to the number of positive charges
on the protein. Free amino acids, peptides and proteins with a molecular weight less
than around 3kDa do not stain with Coomassie reagents. However, for most proteins,
Coomassie staining oﬀers a quick, simple and cost-eﬀective method of staining. In
addition, it is compatible with mass spectrometry and can be performed prior to
further staining with the more sensitive silver staining method.
Two Coomassie staining protocols were used in this work, which will briefly be
explained here. The standard protocol involves fixation and staining of the protein
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bands in a solution of Coomassie Blue R-250 in methanol and acetic acid for several
hours to overnight. The staining procedure can be performed rapidly on polyacrylamide
gels by heating the gel and staining solution using a microwave. Since agarose may melt
at temperatures above ~60 °C, this rapid staining method cannot be used with agarose
gels. Stained gels are subsequently incubated in de-staining solution, which removes
unbound dye from the gel so that the stained protein bands can be seen.
The second method diﬀers from the first in that instead of using dissolved dye,
the staining solution is a colloidal suspension of Coomassie Blue G-250. Unlike the
standard method, the colloidal Coomassie does not appreciably stain the gel itself but
only the protein bands, and therefore does not require a de-staining step. Protein bands
appear rapidly (< 1 hour) and the method has been reported to detect as little as 1 ng
of protein (Candiano et al., 2004), compared with a detection limit of around 100 ng for
the standard protocol.
Silver staining of proteins provides a comparable sensitivity to the colloidal
Coomassie stain outlined above, but at considerably greater expense and eﬀort. The
principle behind silver staining is that proteins bind silver ions, which can be reduced
to metallic silver to give a visible image, much like photographic film. Proteins must
first be fixed in the gel and any interfering substances must be removed by washing
before the gel is sensitised to promote silver reduction. The gel is then suﬀused with
silver solution and finally the image is developed. There are two general methods of
silver staining: one uses a silver nitrate solution and the other makes use of a silver-
ammonia complex. However, many variations on these basic protocols exist. The choice
of which silver staining protocol to use depends on various factors, such as the
formulation of the gel being stained and any requirement for downstream applications
of the stained spots. For example, fixation with formaldehyde or glutaraldehyde
dramatically improves the quality of staining but is incompatible with mass
spectrometry (Chevallet et al., 2006).
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2.3.2  Mass spectrometry
Mass spectrometry is a technique that can be used to analyse elemental composition,
obtain accurate molecular masses or gain information about the structures of
biomolecules based on measurements of their mass to charge ratio (m/z). Mass
spectrometry works by first vaporising and ionising the sample molecules to obtain
gaseous ions. There is a plethora of ways in which this can be achieved, the two most
commonly used for biological samples being electrospray ionisation and matrix-assisted
laser desorption/ionisation. Once the gaseous ions have been created, they are
accelerated by an electric field and pass into a mass analyser, which uses
electromagnetic fields to separate the ions based on their m/z ratio. Again, there are
numerous types of mass analyser, ranging from simple sector and time-of-flight
instruments to more complex ion trap and cyclotron resonance devices. Finally, the
induced electrical charge or current is measured when the ions interact with a detector,
and the signal intensity — which is closely correlated with the relative abundance of
each ion — is plotted against m/z to give the mass spectrum of the sample.
Mass spectrometry is quantitative, accurate, and capable of extremely high
resolution, able to discriminate between molecules that diﬀer by a single atomic mass
unit. This makes it a powerful tool with which to probe proteins and their interactions.
The applications of mass spectrometry to the study of biological macromolecules are
numerous and varied; this is presumably a reflection of the diversity of the available
instrumentation. Mass spectrometers are modular instruments, with diﬀerent sources
and detection methods available depending on the sample and the type of experiment
being performed. One particularly useful feature from the point of view of a structural
biologist is the ability of mass spectrometry to be coupled seamlessly to other
techniques, such as liquid chromatography.
Another interesting set-up is known as tandem mass spectrometry (MS/MS),
where several mass analysers are set up in series. Typically, sample molecules are
separated and analysed in the first mass analyser, and a subset is selected and directed
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towards a second mass analyser, filled with an inert gas. Here the sample ions collide
with gas atoms and are fragmented to produce smaller ions, which are analysed in the
final mass analyser. Alternatively, tandem mass spectrometry can be performed over
time in a quadrupole ion trap, without the need for further mass analysers.
Perhaps the most routine use of mass spectrometry in the biosciences is to
confirm the identity of a protein. Tandem mass spectrometry can be used to identify
proteins or protein fragments, but its use is not as widespread as other methods of
protein identification, such as peptide mass fingerprinting (see below). During the
fragmentation process, proteins mainly break at peptide bonds, essentially giving rise to
a number of shorter peptides that diﬀer by only a few amino acids. By comparing the
results with a database of predicted masses for many given peptide sequences, the
original sequence of the protein can be identified with an associated probability score.
2.3.2.1  MALDI-TOF and peptide mass fingerprinting
The identification of proteins and other substances is routinely achieved with ease and
speed by a type of mass spectrometry known as MALDI-TOF. Here, the sample is
mixed with an acidic matrix and a small amount is deposited onto an inert surface and
dried. A laser is used to vaporise and ionise the sample, and the particles are measured
in a time-of-flight detector. This type of mass analyser accelerates the ions through the
same potential, which ensures that the kinetic energies of the particles are equal. As a
result, the velocity of each particle depends solely on its mass, with lighter particles
travelling faster than heavier ones. By recording the time each ion takes to reach the
detector, it is possible to obtain very accurate mass measurements. If the molecular
mass of the protein is known, this can be used as a means of identification.
Of course, this method will only work with pure proteins whose molecular mass
is documented and which are not modified in any way. Unfortunately, this represents a
rather small subset of all proteins. However, a method known as peptide mass
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fingerprinting allows proteins to be easily identified from complex mixtures. Typically, a
sample is separated by two-dimensional gel electrophoresis, in which proteins are
separated first by IEF and then by SDS-PAGE in the second dimension. The
combination of these two techniques — which each have a high resolving power —
usually results in a gel where each protein is distinct from every other protein, even
when there are many hundred proteins present in the original sample.
Sections of the gel containing the proteins of interest are excised and digested
proteolytically. The resulting peptides are then analysed and their experimentally
determined masses are compared against a database that contains the masses predicted
from the digestion of a number of known proteins. Such a reference database can be
constructed by computationally cleaving a list of known protein sequences, for example
from the SWISS-PROT database. If a protein in the reference database gives rise to a
significant number of peptides that match the experimental masses, the inference is
that this protein was present in the sample.
2.3.2.2  Mass spectrometry of protein complexes
Of course, mass spectrometry in protein science is not limited to simply identifying
proteins of interest. Much more interesting information can be obtained using an
electrospray source, which allows the study of liquid samples. Here, an aqueous solution
is drawn into a fine capillary that has a voltage applied to it. The electric field distorts
the shape of the liquid surface into a cone, and at a suﬃciently high voltage, a jet of
liquid is emitted from the cone tip, resulting in a fine spray of droplets. As they move
through the source, the solvent evaporates, leaving behind gaseous ions that can then
be introduced into the mass analyser.
In contrast to MALDI-TOF, electrospray ionisation tends to produce multiply-
charged ions; and since mass spectrometry measures m/z, instead of mass directly, this
brings the analysis of larger proteins well within the mass range of many instruments.
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Furthermore, the electrospray process is ideal for studying non-covalent protein
complexes, since it is capable of transferring them into the gas phase without disrupting
the interactions that stabilise them. This makes it a powerful tool for structural
biologists, demonstrating how mass spectrometry can extend far beyond its common
use for simple protein identification.
As just noted, electrospray ionisation maintains non-covalent macromolecular
complexes intact in a mass spectrometer. This means that research ranging from the
study of simple homo-oligomers to heterogeneous assemblies of mega-Dalton
proportions can be carried out using the advantages that mass spectrometry oﬀers,
such as the need for only limited quantities of sample in experiments and the high
accuracy and resolution of the resulting data. Thus mass spectrometry is both a
complement to standard structural biology techniques like X-ray crystallography, but
also possesses unique attributes that make it a valuable tool in its own right.
Examples of mass spectrometry and its application in studies on the
architecture and biogenesis of macromolecular complexes and protein interaction
networks can be found in recent reviews (Sharon and Robinson, 2007; Gingras et al.,
2007; Heck, 2008). Mass spectrometry also finds specialised applications in identifying
and investigating metalloproteins (Shi and Chance, 2008).
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2.3.3  Dynamic light scattering
Dynamic light scattering (DLS) is another technique that can be used to determine the
size distribution of small particles in solution. It is non-destructive, and — in contrast
to the methods outlined so far — the sample can be reclaimed, making it an excellent
tool when working with precious protein samples. DLS can be used to monitor
aggregation, determine the presence of various oligomerisation states, give an estimate
of molecular shape and predict the crystallisability of a protein. Experiments are quick
and easy to perform and reactions can be monitored in real time.
2.3.3.1  Scattering theory
When light hits small particles in solution, the light scatters in all directions, provided
that the particles are small compared with the wavelength of the incident radiation.
This elastic scattering — where the kinetic energy of the particles is conserved — is
known as Raleigh scattering. If the light source is monochromatic and coherent, for
example a laser, then the scattering intensity can be observed to fluctuate over time.
These intensity variations are due to the fact that the small particles are in constant
motion, so the distance between the scatterers in solution is constantly changing. The
scattered light then undergoes either constructive or destructive interference by the
surrounding particles and the resulting variation in intensity contains information
about the movement of the scatterers.
Once intensity data have been collected, the dynamics of the particles are
derived by cross-correlating the intensity trace recorded during the experiment with
itself to generate an autocorrelation function that relates the measured intensities at
various time points. Essentially, at short time delays, there is a high correlation because
the particles have not moved far from their initial positions. As the time delay
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increases, the correlation decays exponentially to zero. This decay is related specifically
to the diﬀusion coeﬃcient of the particles, which in turn is related to their
hydrodynamic properties.
Finally, computational methods based on calculations of assumed distributions
are used to fit the correlation function. If the sample contains particles that are uniform
in size, then the decay is simply a single exponential (cumulants analysis), while a
population of diﬀerently sized particles can be fitted by more complex procedures to
the optimal number of exponentials (multimodal analysis). Thus, various properties of
the sample can be derived, including the size, shape and relative distributions of the
particles in the solution being analysed.
Scattering theory typically assumes that the particles in question are spherical.
However, an elongated molecule will give a higher apparent radius than the
corresponding sphere. This has important implications when using DLS to study
proteins. Globular proteins may be well approximated by spheres, but extended or
linearly aggregated proteins will behave diﬀerently in solution and this must be
considered or even exploited in the experimental design. Using commercially available
software, the axial ratios of spheroid particles and their associated Perrin factors can be
estimated, allowing quite complex structural information to be extracted about the
solution structure and behaviour of proteins.
2.3.3.2  Interpreting DLS data
The output of a DLS instrument typically includes the Z-average size and
polydispersity index (PDI) of a sample, as well as various particle size distributions.
The Z-average is the mean average size determined from a cumulants analysis (decay
fitted to a single exponential), while the PDI is a measure of how well the data fit this
model. In practical terms, the PDI is the relative variance of a hypothetical Gaussian
distribution centred on the Z-average size. A low PDI indicates that the sample
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contains a single population of particles with a narrow distribution of sizes, while a
high PDI indicates either a wide distribution (assuming a single population) or that
there are multiple populations of diﬀerently sized particles in the sample.
For samples with a low PDI (or that are known to be a single population) the
cumulants analysis is preferable, since it makes no assumptions about the noise in the
data (see Figure 2.1). However, for particles with a high PDI the results derived from a
multimodal analysis are generally more meaningful, since there are likely to be several
distinct populations of diﬀerently sized particles within the sample (see Figure 2.2).
The choice of which analysis to report is best made by using all of the available
information about the sample under study.
The scattering intensity of a particle is proportional to the square of its
molecular weight, in other words larger particles scatter much more strongly than
smaller particles. Therefore, even a small number of very large particles (dust,
aggregates) can significantly skew the results of the cumulants analysis. The primary
size distribution obtained from a DLS experiment is based on scattering intensity, but
this can be transformed into a distribution based on the volume of the particles
(assuming the particles are spherical). This can then be further converted into a
distribution based on particle number. Intensity distributions are typically the most
reliable, since any errors are compounded by the assumptions made in the process of
converting to volume and number distributions. An example of the various distributions
is given in Figure 2.3.
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Figure 2.1: Size distribution of 60nm latex beads. The cumulants analysis (red) gives a Z-average
size of 63.65nm, with a low PDI of 0.029. These results are in agreement with the multimodal
analysis, which shows that the distribution is monomodal with a single peak at 65.22nm.
Figure 2.2: Size distribution of a mixture of 60nm and 220nm latex beads. The Z-average size is
173.7nm, with a higher PDI of 0.196. Multimodal analysis shows a smaller peak at 64.11nm and a
larger peak 228.1nm in the size distribution by intensity. In this case, the results of the multimodal
analysis more accurately describe the sample.
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Figure 2.3: Size distribution by intensity, volume and number of a mixture of 60nm and 220nm
latex beads. The larger beads scatter more strongly in proportion to their size, so the peak at
around 220nm is much larger than the peak at 60nm in the intensity distribution (top). In the
volume distribution (middle), the peaks are of approximately equal size, showing that the particles
occupy similar volumes. Converting from a distribution by intensity to a volume distribution
assumes that the particles are spherical. When this is converted into a distribution by number
(bottom), the peak at 60nm dominates, while the peak at 220nm almost disappears. This
indicates that there are many more of the 60nm particles than the 220nm particles. Since the
initial distribution is based on intensity, any errors are compounded by subsequent transformations.
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2.3.3.3  Application to protein crystallisation
Perhaps the most interesting application of dynamic light scattering from the point of
view of an X-ray crystallographer is in gaining insights into the behaviour of proteins
under various conditions related to their crystallisation. This may range from
determining which buﬀers provide greatest stability for storage of precious protein
samples, to confirming the results of a purification or even identifying optimum
conditions for crystal growth.
Apart from the obviously useful ability to measure sample polydispersity and
aggregation, DLS also allows several other factors relevant to protein crystallisation to
be determined. The second virial coeﬃcient is a thermodynamic property that describes
the strength of the interaction between protein and solvent. This quality is linked with
the tendency of a protein to either precipitate as amorphous aggregates or form ordered
crystals at saturating concentrations. Thus DLS oﬀers both a way of optimising
crystallisation strategies and a powerful complement to the other techniques outlined in
this chapter used to examine native protein structures.
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2.3.4  Circular dichroism spectroscopy
Another highly useful technique for probing the solution structure of proteins is circular
dichroism (CD) spectroscopy, which exploits the diﬀerential absorption of left- and
right-handed circularly polarised light by chiral compounds. In the case of proteins, the
chromophores that give rise to CD signals include the peptide bond, aromatic side
chains and disulphide bonds, while associated cofactors and ligands bound in an
asymmetric environment may also contribute to the CD spectrum.
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Figure 2.4: Characteristic CD spectra of various secondary structure conformations of the
polypeptide chain. An α-helical structure gives a spectrum with two minima at around 210 and
220nm, while β -structure displays a single minimum at around 215nm. Peptides in a random coil
conformation show an inversion of the spectrum.
In the far UV region, below 240nm, absorption is primarily due to n→ pi∗ (200nm)
and pi → pi∗ (190nm) transitions originating in the peptide bond. The regularly
repeating peptide bond angles of protein secondary structural elements give rise to
characteristic spectra in this region, as shown in Figure 2.4. A protein rich in alpha-
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helical secondary structure displays minima at 208 and 222nm in the CD spectrum,
while beta structure gives rise to a single minimum at 216nm and random coils show
an inverted signal. It is thus possible to deconvolute the signal from a given protein to
obtain an estimate of the secondary structure composition, by comparing experimental
results with reference data from proteins whose structure has been solved by NMR or
X-ray crystallography.
Further structural information can be obtained from near-UV region spectra, at
260–300nm. In this region, absorption is due to aromatic side chains, giving a unique
fingerprint of the tertiary structure of the protein. This information can be useful when
comparing wild-type and mutant forms or can give evidence of a “molten globule” state.
The near-UV CD spectrum can also be sensitive to small changes in tertiary structure
resulting from ligand binding or changes in solvent conditions. The signal strength in
the near-UV region is much weaker than in the far-UV, so these studies require higher
sample concentrations and larger amounts.
During a CD experiment, the diﬀerence in absorption between the left- and
right-handed circularly polarised beams is typically recorded as a function of
wavelength and the results are commonly expressed as the molar ellipticity of the
sample, as given by the following equation:
[θ] =
θ ×M
c× l × 10
Equation 1: Molar ellipticity, [θ], is expressed in degrees cm2 dmol. The experimental values are
typically recorded as ellipticity, θ. M is the relative molecular mass of the protein being examined, c
is the concentration in g/ml and l is the path length of the CD cell in centimetres.
While CD oﬀers a powerful insight into the solution structure of proteins, it is limited
in that only an overall signal can be observed. Furthermore, obtaining estimates of
secondary structure rely on extremely accurate experimental conditions and the
availability of suitable reference data. However, CD constitutes a valuable tool for
tracking protein conformational changes, particularly where large changes in secondary
structure occur, for example in response to ligand binding or denaturation.
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2.3.5  Transmission electron microscopy
Moving away from studying proteins in solution, we come to the use of transmission
electron microscopy (TEM) in the context of structural biology. As outlined in
section 2.5, electron microscopy can be used to resolve much finer detail in a sample
than light microscopy and is therefore another valuable tool with which we can study
protein structures. There are several diﬀerent types of electron microscopy, of which
only TEM will be discussed here, it being the most applicable to the samples and aims
in question. 
As the name suggests, in TEM the electrons are transmitted through the
sample, much like light is passed through a thin specimen in light microscopy. A beam
of electrons is used as the illuminating source and electromagnetic lenses replace the
traditional glass lenses used in a light microscope. In addition, the entire assembly is
maintained under vacuum: firstly to prevent electric arcing due to the voltage diﬀerence
between the cathode and the ground; and secondly to increase the mean free path of
the electrons within the instrument, thereby allowing the electron beam to reach the
sample without being attenuated by collisions with gas molecules. Instead of using an
eyepiece, the image from a transmission electron microscope is displayed using projector
lenses. These focus electrons, which cannot be detected by the human eye, onto a
phosphor-coated screen that produces a fluorescent image where the electrons strike.
To prepare a sample for TEM, it must be thin enough so that the electrons can
pass through it. In the case of biological samples, an additional factor to consider is
that the sample must be able to withstand the vacuum inside the instrument, which
can be achieved by fixing the samples. Depending on the nature of the sample and the
purpose of the experiment, this may be done by embedding material such as cells or
tissue in a plastic resin from which thin slices can then be cut using a microtome. Once
the sample has been prepared, it is deposited onto a fine metal mesh or grid, which
allows easier manipulation and handling. An electron lucent film, such as a thin layer of
carbon, may be deposited upon the grid to aid in supporting the specimen.
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Protein particles or other solvated or suspended samples are generally placed
directly onto carbon-coated grids and may be fixated using chemical cross-linking. In
most cases, additional staining is required to reveal the ultra-structure of a specimen,
since many biological samples are virtually transparent to electrons. This typically
involves negative staining, which uses heavy metals to increase the contrast of the TEM
image. When a staining solution (e.g. uranyl acetate) is applied to the sample, the
specimen is revealed as a bright feature against a dark background under the TEM, due
to the scattering of the imaging electrons by the heavy atoms in the stain. Since the
stain is able to penetrate the sample, rather than just coating it, this allows the fine
structural detail of the sample to be observed.
Cryo-electron microscopy, on the other hand, allows the observation of samples
without requiring modifications such as fixing or staining. Instead, the sample is rapidly
frozen in liquid ethane and maintained at cryogenic temperatures throughout the
experiment. In the case of proteins, this means that their native state is preserved,
since the water in the sample freezes in a vitreous state and the sample in its solid state
is protected from the vacuum inside the instrument.
For single particles such as protein structures, hundreds and thousands of
individual molecules — each in a diﬀerent orientation — can be recorded. A three-
dimensional reconstruction can then be assembled from these series of two-dimensional
images using an imaging strategy known as cryo-electron tomography (CET). This
technique is a powerful complement to high-resolution techniques: for example, the
structures of insoluble protein assemblies — which otherwise could not be crystallised
or analysed by NMR — can be modelled by fitting high-resolution fragments that have
been solved into a molecular envelope generated by CET.
Electron microscopy is a powerful tool in the structural biologist’s arsenal. It
allows the direct visualisation of macromolecular assemblies, and low-resolution three-
dimensional structural information from cryo-electron microscopy may be invaluable in
cases where other structural modelling techniques fail. In combination with high-
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resolution structures from X-ray crystallography or NMR studies of proteins and
protein fragments, detailed models of macromolecular assemblies can be constructed,
which would not be possible using the individual techniques in isolation.
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2.4  Protein crystallisation
When embarking on the structural characterisation of a protein by X-ray
crystallography, the crucial and often the most time-consuming step is the production
of suitable protein crystals. For crystallisation to be successful, a protein must be
coaxed to precipitate into the solid phase in such a way that structural integrity is
maintained and the appropriate crystal contacts can be made that allow crystal growth
to occur. Given the nature of protein molecules when compared with small-molecular-
mass compounds, this is no mean feat.
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2.4.1  Crystallisation theory
In contrast to small molecules, which are often crystallised by simple evaporation of the
solvent to dryness, protein crystals are grown almost exclusively from supersaturated
solutions. This is a consequence of the chemical environment in which proteins have
evolved, which is characterised by aqueous chemistry within the narrow range of
temperature and pH typical of biological systems (McPherson, 2004). Although the
strategies employed in protein crystallisation experiments have been extensively refined
over the years and are now both much more diverse and rational, the basic technique
remains relatively unchanged.
Essentially, all protein crystallisation trials involve an empirical search for
suitable conditions using a combination of variables: protein concentration,
temperature, pH, precipitants such as salts or PEGs, and various other additives such
as cofactors and metal ions. Owing to the number of parameters involved, the initial
screening for suitable crystallisation conditions is generally performed in multi-well
plates, either manually or increasingly using robotics. During the experiment, the
concentration of protein and/or precipitant in solution is gradually varied, either by
vapour diﬀusion, dialysis, or free interface diﬀusion, with the aim of achieving a state of
protein supersaturation that will induce nucleation and crystal growth (Chayen, 2004).
A typical example of a crystallisation experiment is given in the phase diagram in
Figure 2.5.
At the beginning of the experiment, the conditions maintain the protein in
soluble form, but as water is removed from the crystallisation solution a state of
supersaturation is attained. Crystals grow from nuclei composed of a few ordered
molecules, and therefore a successful crystallisation experiment must induce the protein
to pass through conditions that promote nucleation as opposed to random aggregation.
As the crystals grow, the concentration of protein in the crystallisation solution
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decreases until an equilibrium is reached. An ideal experiment will produce few nuclei,
thereby maximising the amount of protein available to each growing crystal and
resulting in a handful of large crystals.
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Figure 2.5: Illustration of a typical protein phase diagram. The adjustable parameter could be
temperature, pH, precipitant concentration etc. The dashed line shows the path taken through the
various regions of the phase diagram during a successful experiment, with the starting conditions
represented by a black circle.
The path taken by a protein through crystallisation space is aﬀected by innumerable
factors, and the complexity of this process is why crystallisation is often referred to as a
black art. Nonetheless, the eﬀects of precipitants on proteins in solution can be broadly
distinguished and the kinetics of a crystallisation experiment can be understood in
terms of the various stages of crystal growth. These two key areas will be explored in
the following sections.
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2.4.1.1  Precipitant eﬀects
Precipitants can be classified as salts, long chain polymers, low molecular weight
polymers and non-volatile organic compounds, and organic solvents. These various
precipitant classes diﬀer in the mechanisms by which they induce proteins to crystallise.
Given the connate dependence of protein structures on their environment, and their
complexity in terms of the interactions both intramolecularly and with the surrounding
solvent, it is perhaps surprising that trends in the mode of action of precipitants can be
distinguished. Nonetheless, the electrostatic, hydrophilic/hydrophobic and steric
properties of the various precipitant classes aﬀord some insight into their general eﬀects
on protein structure and solubility. Of course, these generalisations apply to typical
proteins — those of intermediate molecular weight, with a globular structure and a net
negative charge at neutral pH — whereas the eﬀects on proteins which possess unusual
physicochemical characteristics are likely to diﬀer accordingly.
a)  Neutral salts and the Hofmeister series
Neutral salts primarily promote protein crystallisation by competing for the binding of
water molecules. High concentrations of neutral salts cause solvent-deprived
macromolecules to aggregate either as amorphous precipitates or as ordered crystals; a
phenomenon commonly referred to as “salting out”. The most eﬃcient protein
precipitants are multivalent anions, such as sulphates, phosphates and citrates, with
ammonium sulphate typifying precipitants in this class (McPherson, 2004). Small ions
with a high charge density like these eﬀectively strengthen the hydrophobic eﬀect by
enhancing the structure of bulk water, which consists of a quasi-crystalline network of
hydrogen bonds. Since they increase the order of water, such ions are known as
kosmotropes.
76
Anions and cations can be arranged in order of their ability to modify the
structure of water and thereby aﬀect protein solubility, a classification known as the
Hofmeister series1. Strongly hydrated, kosmotropic ions early in the series exert a
stabilising eﬀect on proteins, while chaotropic ions at the end of the series disrupt water
structure, weakening the hydrophobic eﬀect and thereby increasing the solvent
accessible surface of the protein. This has the eﬀect of destabilising protein structure,
but also promoting solubility (Collins, 2004). In addition to their eﬀects on bulk water,
neutral salts aﬀect water molecules in hydration shells around protein surfaces in a
similar manner, due to preferential interactions between solvent, solute and protein
molecules. Aside from the eﬀects on aqueous hydrogen bonding, ions and other solutes
also interact specifically with protein moieties such as the peptide backbone or side
chains, adding further complexity to the interactions governing protein crystallisation.
b)  Long chain polymers
In contrast to neutral salts, where electrostatic forces dominate interactions between
the solute, solvent and protein in solution, long chain organic polymers precipitate
proteins primarily through excluded volume eﬀects. Here, the underlying principle is
that long chain polymers, which unlike proteins have no defined solution structure,
occupy a certain volume that cannot be simultaneously occupied by any other species.
As a result, there is less solvent space accessible to any protein molecules in solution,
forcing them to aggregate and finally transition into the solid state. By far the most
common long chain polymers used as protein crystallisation agents are polyethylene
glycols, a family of hydrophilic nonionic polyether compounds with a wide variety of
uses in industry and medicine.
1. Not to be confused with the Hoﬀmeister series, otherwise known as Baywatch.
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Like the ionic precipitants discussed previously, PEGs diﬀer in their abilities to
force proteins from solution, with higher molecular weight polymers possessing a
greater capacity to drive the crystallisation process thanks to their larger excluded
volume. However, the molecular weight of the protein in question bears no relation to
the size of the polymer best used for its crystallisation, and indeed PEGs with similar
molecular weights are not necessarily interchangeable for a given protein (McPherson,
2004). This means that the search for a PEG or other organic polymer to act as a
suitable protein precipitant is unavoidably an empirical process.
c)  Low molecular weight organic compounds
This class of precipitants includes low molecular weight (< 1000) PEGs, MPD and
other small, non-volatile organic compounds. The modes of action of this class of
precipitants are variable and not entirely understood. MPD appears to be preferentially
excluded from protein-solvent interfaces due to repulsion by surface charges, while for
PEGs excluded volume eﬀects remain dominant. Other precipitants in this class, which
are commonly used as additives to supplement another major precipitant, are various
naturally occurring osmolytes such as sugars and amino acids (Bolen, 2004). As with
other precipitant classes, the interplay between solvophobic/solvophilic eﬀects, steric
factors and specific interactions with protein moieties governs the overall impact of
these precipitants on the crystallisation process.
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d)  Organic solvents
Organic solvents oﬀer yet another means of manipulating the solution conditions of a
protein crystallisation experiment by reducing the dielectric of the surrounding
medium. The introduction of non-polar solvents reduces the activity coeﬃcient of
water, making it a poorer solvent and thus pushing solvated proteins towards the solid
state (Cohn et al., 1947). Again, specific interactions with portions of the protein such
as hydrophobic side chains modulate these general eﬀects. Low concentrations of certain
solvents can act to stabilise protein structures while high concentrations act as
denaturants and others have little or no eﬀect on protein structural stability (Asakura
et al., 1978). The volatility of organic solvents means that any crystallisation
experiment in which they are employed must be carefully designed to take this into
account.
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2.4.1.2  Protein crystal growth
Protein crystallisation proceeds via distinct stages. These can be distinguished as
nucleation, growth and finally the cessation of growth. Diﬀerent processes govern each
stage and they are all aﬀected by diﬀerent factors during a protein crystallisation
experiment. These various mechanisms and the practical considerations that were
applicable to the work of this thesis will be briefly explored in the following paragraphs.
a)  Nucleation
The first crucial event during the crystallisation of a biological macromolecule is
nucleation. This process is analogous to the condensation of droplets of steam on a
bathroom mirror. A comprehensive review of the nucleation of protein crystals can be
found elsewhere (Manuel Garcia-Ruiz, 2003) but a short summary of the process will be
given here, along with experimental aspects. Thermodynamics dictates that a
supersaturated solution must return to equilibrium by segregating a solid phase until
equilibrium is established. However, in practice the threshold value of supersaturation
must be exceeded for precipitation to occur spontaneously. This paradox is resolved
when nucleation is taken into account.
Under normal crystallisation conditions, the free energy of a crystalline
aggregate follows a curved trajectory as it increases in size, first increasing to a
maximum ΔG and decreasing steadily thereafter. In contrast, the formation of
disordered precipitate follows a shallower path of decreasing ΔG with a much lower
energy barrier. The height of this initial increase in energy dictates the time required
for crystal nuclei to form, and depends strongly on the supersaturation of the protein
solution. Once a crystal nucleus has formed, it grows slowly at first, since attachment
and disassociation of individual molecules occur with almost equal probabilities. This
process is governed by the equilibrium rate constants for monomer-monomer and
80
monomer-crystal association. These two rate constants, along with the concentration of
monomers in solution, also determine the critical number of molecules required to push
the growing aggregate through its energy maximum (Durbin and Feher, 1996). Of
course, apart from the thermodynamic elements outlined above, the outcome of any
crystallisation experiment is also dictated by kinetic factors.
Understanding nucleation will not help us to avoid the necessary exploration of
the phase landscape of protein systems in the search for crystals and their atomic
structures. But a better general understanding of the nucleation process can aid in
controlling the experimental variables implicated in nucleation according to our current
understanding. The nucleation step implicitly controls the structure of the crystallising
phase and the number of particles (and thus the crystal size) appearing in a
crystallisation system (Manuel Garcia-Ruiz, 2003)
b)  Growth
When a crystal is born from its supersaturated mother liquor, it will grow until it
reaches an equilibrium with the concentration of protein in solution. Both kinetic and
thermodynamic factors aﬀect this process, and these are detailed by Chernov, 2003.
While the nucleation processes just discussed typically require high protein
concentrations, crystal growth proceeds better in a region of the phase diagram termed
the metastable zone. In this region, nucleation does not occur, but crystal growth is
able to proceed unhindered until either the equilibrium concentration is reached or the
crystal growth terminates for other reasons.
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c)  Order and disorder in protein crystals
While we typically think of crystals as idealised structures, in reality they are
imperfect. Often, the larger a crystal grows the more defects it will accumulate,
although the physical appearance of a crystal often has no bearing on the diﬀraction
quality. Of course, thanks to synchrotron sources becoming more commonly available,
as well as technological innovations in crystal handling and mounting methodology, it is
now possible to work with smaller crystals than ever before. Nonetheless, the aim of
any crystallisation experiment is to produce the best quality diﬀraction data possible,
and this requires well-ordered protein crystals.
The aim of X-ray crystallography is to determine the positions of atoms within
a macromolecule and it relies on the cumulative signal from thousands of atoms
arranged identically in each molecule occupying the crystal lattice. However, the
proteins constituting a real crystal may not all be perfectly aligned. There may be
conventional defects of the crystal lattice: point defects, which occur at a single position
in the crystal lattice; stacking faults, where the regular packing of crystal layers is
interrupted; or mosaic blocks that cause diﬀerent parts of the crystal to be slightly
misaligned. These types of disorder can usually be detected by the mosaicity. Crystals
may also exhibit twinning, which occurs when two separate crystal domains are
conjoined in such a way that their diﬀraction lattices overlap, either partially or
completely. Twinning also aﬀects the mosaicity of diﬀraction data and can be detected
by various other criteria as discussed in detail in section 6.3.3, p. 270.
In addition to the relatively macroscopic defects already mentioned,
disturbances in the crystal structure may arise through diﬀerent conformations of the
molecules themselves. For example, the protein in question may be an enzyme trapped
in various states of catalysis, or possess flexible hinge regions. While disorder in protein
crystals is generally undesirable, this type of pervasive, localised variation mainly
aﬀects the atomic B-factors of relevant parts of the protein structure, and may oﬀer
some insight into the function of the macromolecule.
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2.4.2  Crystallisation methodology
A relatively common set-up for crystallisation experiments, and the one used primarily
in the work presented here, is the hanging drop method. This involves placing a small
volume — usually between 1 and 10 µl — of protein solution on a small glass or plastic
slide (such as a microscopy cover slip) and mixing it with an equal volume of the test
solution. The cover slip is inverted and placed over a large reservoir of the test solution,
using grease to form an airtight seal, and the solutions are then left to equilibrate. As
water evaporates from the drop, the concentration of both the protein and the
precipitant increases until the water concentration in the drop matches that of the
reservoir. The drop is then observed at regular intervals using a microscope and the
results are recorded. Protein crystals can form in this mother liquor during any time
from minutes to years from the set up of the experiment, although eventually all the
water escapes from the system and the drop evaporates to dryness, destroying any
protein in the process.
2.4.2.1  Controlling nucleation and growth
Nucleation can be spontaneous (as described above) or may result from the
introduction of seeds or nucleants into the crystallisation solution. Seeds are typically
nuclei transferred by crushing or scraping crystals of the same protein that have already
grown, but are perhaps of lesser quality. Nucleants on the other hand, are unrelated
substances that have nucleation inducing properties. These may be specific minerals or
porous substances introduced as a variable in the experiment, or simply bits of dust
that have ended up in the crystallisation drop. They promote crystal growth by
providing sites for nuclei to form and result in epitaxial growth of protein crystals from
the nucleant (Chayen et al., 2006). By including seeding as a parameter in
crystallisation trials, we can control the number and size of any crystals.
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However, there are further factors to be considered. The surfaces of crystals
growing from impure samples may become poisoned and stop growing, possibly also
resulting in an increase in the disorder of the crystal. Furthermore, the protein
concentration must be just right to allow large crystals to develop. If the protein
concentration is too high, many nuclei may form simultaneously. Since each will
consume protein at approximately the same rate, this will result in the growth of
hundreds of tiny crystals. On the other hand, at low protein concentrations, where only
a few nuclei have formed, an equilibrium may be reached between the crystal and
aqueous phases before the crystals have developed to a reasonable size.
Equally, the quality and size of macromolecular crystals can be varied by
changing the parameters involved in controlling the equilibration of the drop. This can
be aﬀected by factors such as temperature, protein and precipitant concentration, and
the size of the drops. Common temperatures for performing crystallisation experiments
are 4 °C and room temperature, although some proteins require treatment at higher
temperatures for successful crystallisation (Cudney, 1999). Temperature also influences
protein and precipitant solubility, and can aﬀect nucleation rates. Drop size, or more
specifically the surface-area-to-volume ratio, is also important when it comes to
controlling the rate of equilibration in an experiment. 
2.4.2.2  Interpreting the results of a crystallisation experiment
The outcome of a crystallisation experiment can be any one of several possibilities. In
the ideal case, the result will be one or several large, well-ordered crystals. However, in
practice, this is a rare occurrence. If the path through crystallisation space has
remained primarily in the undersaturated region of the phase diagram, then the result
will be a clear drop. If the concentration of either protein or precipitant was too high,
however, then an amorphous precipitate of denatured protein will be observed. This
may also be the case if the protein is incompatible with any of the substances used in
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the test solution, or because of extremes in temperature and pH. Successful
crystallisation depends on hitting the ‘sweet spot’ in terms of experimental conditions
and kinetics that pass through the nucleation zone and into the metastable zone
allowing crystal growth to occur, while maintaining the structural integrity of the
protein. In order to assess the results of crystallisation trials, the scoring system
outlined in Table 2 was used.
Score Drop description Example
Conditions unlikely to yield crystals
0 Clear
1 Contains non-proteinparticles
2 Light precipitate
3 Heavy amorphousprecipitate
Table 2: Scores used in assessing the results of crystallisation experiments. The scores are arbitrary,
but can be grouped to reflect conditions that are either far from optimal, or close to the conditions
required for crystallisation. An example of the observed drop that corresponds to each score is
shown.
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Score Drop description Example
Crystallisation conditions close to optimal
4 Gelatinous precipitate
5 Phase separation
6 Spherulites
7 Microcrystals
8 Needles (1D crystals)
9 Plates (2D crystals)
10 Crystals (3D crystals)
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2.4.2.3  Determining whether a crystal is protein or salt
Protein crystals display a staggering range of morphologies, and a trained eye is
required to discern potential crystals from the debris and other matter that may
accumulate in the crystallisation drop. Identification of protein crystals can be aided by
various methods, such as using polarised light to test for birefringence. However, given
that protein crystallisation experiments can often also induce the crystallisation of salts
or other substances present in the test solution, observing a birefringent object in the
crystallisation drop is not always indicative of a protein crystal.
A more accurate assessment of the nature of any crystalline materials can be
made using more destructive methods. In the ‘crunch test’, a putative protein crystal is
crushed using a fine needle. If the crystal is resistant to destruction, or crushes with a
palpable ‘crunch’, then it is more than likely a salt crystal. Protein crystals, on the
other hand, are relatively soft and correspondingly fragile. This is primarily due to the
low density of bonds within the crystal contacts of macromolecular crystals and the
small size of the contact areas when compared with the whole protein surface (Chernov,
2003). 
The delicate nature of protein crystals, which is also in part attributed to a
relatively high solvent content of between 25–90% (McPherson, 2004), can be turned to
an advantage in another test. In this test, the small-molecule dye Izit (Hampton
Research, USA) is added to the crystallisation drop, where it can penetrate the solvent
channels in macromolecular crystals but is excluded from small-molecule and inorganic
crystals. This causes any protein crystals present in the drop to take on a blue colour,
allowing them to be easily identified. Unfortunately, the test is likely to interfere with
any further work on the crystals.
The ultimate test of both the nature and quality of any crystalline substances in
the crystallisation drop is, of course, the diﬀraction experiment itself. Protein crystals
are instantly recognisable by their diﬀraction patterns, which typically feature closely
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spaced spots due to the relatively large unit cell dimensions of macromolecular crystals.
Diﬀraction theory and the diﬀraction of protein crystals are covered more extensively in
section 2.5.2, p. 98.
2.4.2.4  Optimising crystallisation conditions
Often, the initial rounds of screening will yield conditions that promote crystallisation
but result in sub-optimal crystals. These may take various forms, such as hundreds of
microcrystals due to excessive nucleation; thin fragile needles and plates as a result of
rapid growth along one or two axes; or spherical crystalline bodies known as
spherulites. The conditions yielding these initial ‘hits’ can be expanded into further
screens that sample crystallisation space at much finer intervals.
Even if the initial screening did not yield crystals, similar optimisations can be
performed around conditions that yielded light, granular precipitates, or where a small
change in one of the parameters of the experiment resulted in a transition from a clear
drop to precipitate. This is because conditions such as these are likely to be located
near the metastable zone on the crystallisation phase diagram (see Figure 2.5, p. 75),
and so exploring the crystallisation space around them might result in successful
crystallisation. 
In addition to simply varying the experimental parameters to achieve optimal
nucleation and growth conditions, protein crystallographers can make use of seeding
techniques to produce the large, single crystals desired for diﬀraction purposes. These
methods involve transferring crystal nuclei from sub-optimal crystalline entities into
conditions likely to be located in the metastable zone. In this way, excessive nucleation
and rapid growth are prevented, and the results are likely to be more desirable in terms
of the number and size of crystals produced. In the case of too little nucleation,
external nucleants can be introduced to provide impurities that can act as sites for
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nucleation and growth. Furthermore, the kinetics of the experiment can be varied by
changing the drop size (surface area to volume ratio), temperature or other factors that
may aﬀect the rate of equilibration.
While in theory it would be preferable to perform an extended series of
crystallisation experiments in order to produce optimal crystals for diﬀraction, in
practice such large-scale trials are generally limited by the amount of protein material
available. This is primarily because of the high concentrations typically required for
crystallisation — often tens of mg/ml — and the arbitrary nature of the experiments.
When commencing a new crystallisation strategy, a crystallographer can use prior
knowledge about the protein in question, together with solubility information gleaned
from systematic initial screening or other methods, to tailor the strategy in order to
conserve material and maximise the chances of obtaining suitable crystals. However,
sometimes the appearance of protein crystals is a matter of sheer luck. Something as
seemingly trivial as whether the protein sample is kept on ice or held in the
experimenter’s hand while setting up the drops can mean the diﬀerence between
crystals and no crystals (Cudney, 1999). Detailed laboratory records are therefore
paramount.
The results of crystallisation trials described in this work were typically
evaluated once a day for the first week, and monthly thereafter until the drops dried up
completely or no further changes were observed. The results of the experiments were
recorded by observing each drop under a microscope using bright-field and cross-
polarised illumination. Each drop was assigned an arbitrary score, ranging from 0 for
a clear drop to 10 for three-dimensional crystals, as previously outlined in Table 2,
p. 85. This oﬀers a way of quantitating the data and allows diﬀerent crystallisation
experiments to be compared. Obtaining crystals of a protein can be a daunting task,
but is an absolutely necessary undertaking in order to unlock the protein structure
contained within. While NMR is useful for smaller proteins, larger molecules can give
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crowded spectra with overlapping peaks, making them diﬃcult to interpret.
Crystallography therefore remains the established approach for determining high-
resolution structures of large protein assemblies.
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2.5  X-ray crystallography
As already mentioned, X-ray crystallography is one of two key techniques commonly
used to obtain information about the structure of proteins at atomic resolution, the
other technique being NMR. Crystallographic analyses are applicable to a much
broader range of proteins, since there is no limit to the size of the molecule under
scrutiny; the only real requirement is that the protein must form crystals from which
useful data can be collected.
In order to obtain information about a protein at the atomic scale, a suitable
probe must be employed. Visible light has a wavelength in the range of hundreds of
nanometres, making light microscopy a good tool with which to probe samples of that
order of size and greater, such as cells and indeed the macrostructure of protein
crystals. However, if we wish to resolve finer detail, we need a correspondingly finer
probe. Electron microscopy makes use of electrons, which have a smaller wavelength
than visible light, to probe cellular ultra-structure and large protein assemblies, but it
cannot give information at the level of individual atoms. It so happens that X-rays have
wavelengths that correspond roughly to the diameter of individual atoms, at around
one Angstrom, making them a suitable probe for structural information at the atomic
scale.
Since X-ray wavelengths are so much smaller than those of visible light and
electrons, they also have correspondingly higher energies. This means that they interact
with matter in diﬀerent ways, posing a great challenge to the crystallographer. While
light and electron microscopy rely on lenses to create an image of the sample from the
scattered radiation, it is impossible to build a lens that will focus X-rays. Instead, the
image must be constructed computationally from the diﬀraction data, as will be
explained below. The following sections explain the individual steps between successful
crystallisation of a protein and the creation of a structural model at atomic resolution
based on the available information.
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2.5.1  Principles of diﬀraction
The key principle behind X-ray crystallography is the scattering of X-rays by the
electrons of molecules contained within the unit cell, the basic repeating unit that
makes up the crystal structure by translation alone. In three-dimensional crystals, the
unit cell can be described by three vectors (a, b and c) and three angles between them
(α, β and γ). Within the unit cell, individual asymmetric units may be related by
crystallographic symmetry, so that more than one identical molecule can occupy the
unit cell (see Figure 2.6). Of course, the actual number of molecules in the unit cell is
not necessarily equal to the number of asymmetric units dictated by the
crystallographic symmetry.
b
a
γ
Figure 2.6: Illustration of a simple protein crystal in two dimensions. The unit cell (outlined in bold)
can be described by the vectors a and b, which run along the x and y axes, and the angle between
them, γ. The unit cell can be repeatedly translated in all directions to map out the crystal
structure. Within a single unit cell there can be one or several protein molecules. Here, two copies
of the protein are shown, related by a 180° rotation around a symmetry axis perpendicular to the
plane of the figure.
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Crystal system Required symmetry Unit cell parameters
Triclinic None
Monoclinic 2-fold
Orthorhombic 3 x 2-fold
Tetragonal 4-fold
Trigonal 3-fold
Hexagonal 6-fold
Cubic 4 x 3-fold
Table 3: The seven crystal systems. The required symmetry of the space groups and the unit cell
parameters corresponding to each system are shown.
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The repeating nature of the crystal means a large number of molecules are arranged in
virtually identical orientations. In other words, we have a periodic array of scatterers.
When a crystal is placed in an X-ray beam, the incident rays are re-emitted in all
directions by the electrons they interact with. Under certain conditions, these interfere
constructively, producing an intense signal that can be recorded as the characteristic
spots of a diﬀraction pattern. The positions of the spots are determined by the unit cell
parameters and the intrinsic symmetry of the crystal, while the intensities of the spots
are determined by the electron density within the crystal. The electron density within
each unit cell can be described by a mathematical function and it is this function that
we wish to determine in order to model the protein structure.
 
2.5.1.1  Bragg’s law and reciprocal space 
Diﬀraction can be described in terms of the reflection of incoming rays from a set of
hypothetical parallel planes that bisect the crystal. If a detector is placed to one side of
the crystal, the scattered rays will all travel diﬀerent distances before they encounter
the detector (see Figure 2.7). Constructive interference of scattered rays — resulting in
a measurable signal — occurs when the diﬀerence between their path lengths is a
multiple of the wavelength. This is because the scattered X-ray waves are in phase, that
is, the peak of each wave is aligned with the peaks of all the other waves. These
conditions, which result in measurable diﬀraction, are defined by Bragg’s law:
nλ = 2d sin θ
Equation 2: Bragg’s law, where n is an integer, λ is the wavelength of incident radiation, d is the
distance between planes and θ is the scattering angle. 
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Figure 2.7: Bragg diﬀraction. A. To illustrate the concept of lattice planes a two-dimensional unit
cell with axes a and b is shown. A set of hypothetical parallel planes, separated by distance d, are
shown as dashed lines. The set of planes bisects the unit cell once along a and twice along b,
giving the indices (1,2) for this set. B. Two lattice planes (dashed lines) are shown separated by
distance d. The incident and reflected beams are shown as solid lines, making an angle θ with the
lattice planes. The path diﬀerence between the rays reflecting from the two diﬀerent planes is
2dsinθ.
Families of lattice planes, and their corresponding reflections, are defined by Miller
indices, written (h k l) in three dimensions. The index represents the number of times
the set of planes bisects the unit cell along the corresponding axis. As the index number
increases, the spacing between planes decreases. Atoms lying close to a set of planes
will tend to scatter in phase, so the intensity of each reflection tells us something about
the distribution of the atoms relative to the corresponding set of Bragg planes. If the
amplitude is weak, then the atoms are positioned randomly with respect to that set of
planes, while a strong reflection indicates that the atoms are concentrated parallel to
the Bragg planes. In addition, reflections with higher Miller indices contain information
about atoms that are close together in the unit cell, so the highest resolution data are
found at high scattering angles. This is a consequence of the eﬀect of reciprocal space.
A diﬀraction pattern is a representation of the real crystal lattice in reciprocal
space. The relationship between real space and reciprocal space is essentially that
points close in real space are far apart in reciprocal space. The symmetry of the
reciprocal lattice follows the symmetry of the real space lattice, and also, in the absence
of anomalous scattering, the diﬀracted intensities obey Friedel’s law:
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I(h k l) = I(-h -k -l)
Equation 3: Friedel’s law. The intensity, I, of a reflection (h k l), is equal to the intensity of the
reflection (-h -k -l). This means that the reciprocal lattice is symmetrical.
2.5.1.2  Structure factors and Fourier transforms
A structure factor is a complex number with amplitude and phase that represents the
wave resulting from diﬀraction. For several electrons distributed in space, the structure
factor becomes the sum of the individual scattering contribution of each electron. The
electron density of a protein crystal is a continuous function, so the structure factor in
this case can be expressed as an integral. The structure factor and the electron density
can thereby be shown to be related in a special way, known as a Fourier transform. It is
this relationship that allows us to calculate a model of the electron density from the
diﬀraction data of a protein crystal.
A Fourier transform is a mathematical operation that allows us to transform the
variables of complex functions. A special property of the Fourier transform is that if it
is applied to a function, and then applied again, the original function is restored. This
allows us to transform the calculated structure factor (which is the Fourier transform of
the electron density) into a model of the original electron density within the unit cell.
However, the structure factor is a complex number and possesses both amplitude and
phase. The phases of the reflections cannot be experimentally recorded, while the
structure factors cannot be calculated using the intensity data alone. This forms the
basis of the ‘phase problem’, which is described more fully in section 2.5.5, p. 109. The
importance of phase information is shown in .
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Figure 2.8: The importance of phase information. A. The images show the mathematician and
physicist Joseph Fourier (left), and the pioneer of protein crystallography, Dorothy Hodgkin (right).
B. The Fourier transform of the image of Joseph Fourier. From left to right: the logarithm of the
amplitudes, the amplitude information only, and phase information only. C. An image reconstructed
by combining the amplitudes of Fourier with the phases of Dorothy. The phases clearly contain
more information about the image than the amplitudes, since we see Dorothy in the image. D.
Images reconstructed by combining the phases of Fourier with two unrelated sets of amplitudes.
Sets of amplitudes from two unrelated images (not shown) result in a similar reconstructed image.
A good reconstruction requires both accurate phases and amplitudes to restore the original image.
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2.5.2  The diﬀraction experiment
Once a protein crystal has been grown, the first step towards structure solution is to
perform the diﬀraction experiment itself. This is generally carried out using an in-house
X-ray source, in which X-rays are produced by accelerating electrons at high voltage
against a metal target; or at a synchrotron facility, where radiation is emitted by
electrons and positrons in high-energy storage rings. The process can generally be
divided into two stages: the first being the preliminary characterisation of the crystal,
to ascertain the maximal resolution to which it diﬀracts, the space group, and crystal
quality; and the second being the collection of a usable data set (McRee, 1999).
The experimental set-up initially involves mounting the crystal on a goniometer
placed in the path of the incident X-ray beam. A metal beam-stop placed behind the
crystal prevents the direct beam from striking the detector, thus allowing the relatively
weak diﬀracted rays to be recorded. There are various possible geometries for the
diﬀraction experiment, depending on the instrumentation available, but here a rotation
instrument will be described, which uses a two-dimensional detector to collect
contiguous diﬀraction images generated by oscillating the crystal through a small angle.
However, all cases involve rotation of the crystal within the incident beam such that the
positions and intensities of all (or an appropriate number) of reflections can be
measured. In order for this to be possible, all corresponding points on the reciprocal
lattice must pass through the surface of the sphere with radius 1/λ (the Ewald sphere),
thereby fulfilling the Bragg diﬀraction conditions, as illustrated in Figure 2.9. 
An appropriate geometry is required for successful data collection, and structure
solution relies heavily on accurate definition and recording of the parameters of the
experiment. The crystal-to-detector distance must be adjusted so that the high-angle
reflections — corresponding to the highest resolution to which the crystal diﬀracts —
fall within range of the detector, if these are to be collected. Furthermore, the
oscillation angle must be adjusted depending on the unit cell size, spot size, and
resolution. In addition, the overall angle through which the crystal is rotated must be
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determined, based on the symmetry of the crystal as gauged by the preliminary
characterisation. Another consideration is the orientation of the crystal within the
beam, relative to the detector. If the crystal is rotated around a single axis, there is a
region of reciprocal space around the axis of rotation that can never be recorded,
known as the blind region. This can be problematic if the crystal is oriented such that
one of the crystal axes is along the rotation axis, as this will cause the resulting data to
be incomplete. Overall, the data collection strategy involves careful selection of
experimental parameters to yield the best possible data, and this is often achieved with
the use of sophisticated software.
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Figure 2.9: Diagrammatic representation of an X-ray diﬀraction experiment. The crystal is located
at the centre of the sphere, whose dimensions are determined by the wavelength of the X-ray
radiation. The diﬀraction pattern recorded on the detector can be regarded as the result of the
intersection of reciprocal lattice points, located on a series of parallel planes, with the Ewald
sphere. The dimensions of the reciprocal lattice are determined by the unit cell of the crystal.
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2.5.3  Cryocrystallography
The diﬀraction experiment can be performed either at room temperature, or under
cryogenic conditions. There are advantages and disadvantages to each method, and
again the choice of which strategy to pursue depends on the particular characteristics of
the crystal under study. Mounting a crystal for room temperature diﬀraction can be
achieved by sealing the crystal in a thin capillary, surrounded by the mother liquor
from which it was grown. The major advantage of room temperature experiments is
that no unnecessary stresses are placed on the fragile crystals, apart from those to
which it is exposed during handling, which can be minimised by skilful manipulation in
the hands of the crystallographer. However, crystals at room temperature are
particularly susceptible to radiation damage, since free radicals are able to diﬀuse freely
along the solvent channels within the crystal lattice and destroy bonds within and
between protein molecules. Prolonged exposure to the X-ray beam can result in visible
destruction of the crystal as crystal contacts are degraded, meaning that the amount of
data collected from a single crystal at room temperature can be severely limited.
The problem of radiation damage can be largely overcome by rapidly cooling
the crystal to cryogenic temperatures (so that the water surrounding the crystal freezes
as amorphous ice) and maintaining this low temperature state throughout the data
collection procedure. At the ~100 K temperatures typically used, the crystal lifetime is
usually prolonged by a factor of ~70 (Nave and Garman, 2005), thereby allowing a
complete data set, or even multiple data sets, to be collected from a single crystal. This
is a consequence of the dramatically reduced rates of atomic diﬀusion within the
vitreous matrix, which means that any free radicals are likely to self-quench and broken
bonds are likely to re-form, so maintaining the long-range order of the crystal.
Furthermore, the molecular motion is greatly reduced by cryogenic freezing, which can
result in the trapping of single or multiple thermodynamically favoured conformers,
with resulting eﬀects on the diﬀraction properties of the crystal (McRee, 1999).
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The water surrounding the crystal must be vitrified to prevent the formation of
ice crystals that may disrupt the protein crystal structure or obscure reflections in the
diﬀraction pattern. This typically requires a combination of rapid cooling and the
introduction of cryoprotectants, which reduce the formation of ice by disrupting the
local order of water and preventing nucleation of ice crystals. Cryoprotectants can be
divided into two classes: salts, which co-ordinate water molecules thereby reducing the
number of water molecules free to make ordered intermolecular hydrogen bonds; and
bifunctional molecules, which, being both hydrophilic and hydrophobic, can disrupt
local order without necessarily co-ordinating large numbers of water molecules. Rapid
cooling of the crystal is achieved by snap freezing it and the surrounding drop of liquid
in a stream of cold gas, usually nitrogen, which is positioned so as to maintain
cryogenic temperatures throughout the data collection procedure.
To mount the crystal for cryocrystallography, a fine fibre loop mounted on the
end of a pin is used to scoop the crystal from the surrounding mother liquor.
Cryoprotectants can be introduced — if necessary — by sweeping the crystal through a
fresh drop of the well solution used for crystallisation with an appropriate volume of
cryoprotectant added. While the advantages of cryocrystallography outlined above
generally result in increased quality of the diﬀraction data obtained compared with
room temperature experiments, the stresses placed on the crystal throughout the
procedure can cause disruption to the crystalline lattice. These stresses may arise from
the introduction of cryoprotectants and from changes in pH and in the dielectric
constant of water upon cooling. Cross-linking the crystals prior to flash freezing can
sometimes help to maintain their structural stability.
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2.5.4  Data collection and processing
Once the crystal is mounted and frozen, if desired, a few test shots are typically made
to determine the optimal geometry for the diﬀraction experiment. This involves
adjusting the detector distance, exposure time and various other parameters to obtain
the best quality data. The initial images can be processed to determine the unit cell
dimensions, predicted space group, mosaicity and other features of the crystal, which
will help in deciding on a data collection strategy.
2.5.4.1  General data processing procedure
An ideal set of diﬀraction images should be as complete as possible, meaning that the
crystal must be rotated through an angle appropriate to its symmetry to allow all
possible reflections to be detected. A low-symmetry space groups such as P1 would
require the crystal to be rotated through a full 360° to collect a complete set of
reflections, while a crystal with high-symmetry would only require a much smaller
wedge of data to be collected. In addition, the exposure time and detector distance
must be optimised to collect weak and high-resolution reflections, which fall at the edge
of the detector, while not overexposing stronger reflections in the diﬀraction image.
Other factors as diverse as radiation damage to the protein during the experiment or
the allocation of time at synchrotron sources may be factors to consider when planning
a data collection strategy.
Once a set of images has been collected, they can be processed. Nowadays, this
procedure is greatly aided by a host of computational tools, but the overall principle is
the same as for manual processing. First, reflections must be identified by comparing
their intensity with the background. This is a relatively easy task for humans, and even
computational methods of data processing may require user input to identify reflections
in an otherwise automated process. Once the spacing of the reciprocal lattice has been
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determined from the positions of the spots in the diﬀraction pattern, the unit cell
dimensions can be determined. The symmetry and mosaic spread of the crystal can also
be estimated.
The reflections are indexed, which involves assigning the Miller indices of each
recorded reflection. This is typically done using an automated procedure, during which
a likely space group may be assigned based on any symmetry present in the diﬀraction
data, systematic absences of reflections as a result of screw axes, and the unit cell
parameters. During the subsequent integration, the intensity of each reflection in the
diﬀraction image can be determined and an estimate made of its associated uncertainty.
Various corrections for variations in background, orientation and detector parameters
are applied, any symmetry-equivalent reflections are scaled and multiple observations
are merged. Finally, the structure factor amplitudes are estimated from the intensities.
As a result of this processing, various statistics can be computed to determine the
quality of the available data. Those typically cited include the mosaicity of the crystal,
the resolution range, completeness and redundancy of the recorded reflections, as well
as the I/σ(I) and the R-value for the merged data.
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2.5.4.2  Statistics from scaled and merged data
As a result of processing the diﬀraction data, various statistics can be used to assess
the quality of the data obtained and to determine information about the crystal
structure. The most important statistics are briefly described in the following section.
a)  Resolution, completeness, redundancy and mosaicity
The resolution range of the diﬀraction data greatly aﬀects the quality of any resulting
structure and is dependent on the crystal quality, the wavelength of the X-rays used in
the experiment, and the data collection parameters (crystal-to-detector distance,
exposure etc.). The completeness of the data set may be reduced if a significant amount
of data are not recorded, and this may have several possible causes. Many detectors are
square, which means that the highest resolution data are recorded in the corners. Some
high-resolution reflections may never detected, because they fall outside the area of the
detector.
Another reason for incomplete data is that reciprocal lattice points lying close
to the rotation axis will not pass through the Ewald sphere, unless the crystal is also
rotated around a second axis. For space groups other than P1 (which has no
symmetry), these missing ‘cusp’ data can be minimised by making sure that the
symmetry axis of the crystal is not aligned with the rotation axis. In this way, a
reflection that lies in the cusp will have a symmetry mate that will pass through the
Ewald sphere, and a complete set of data can be collected. Finally, the redundancy
refers to the number of observations of each unique reflection.
A further useful statistic is the mosaicity of the crystal. Diﬀerent parts of the
crystal may be slightly misaligned, causing reflections to be diﬀuse or split. Mosaicity is
the recorded rocking width of the reflection with the instrument contribution
deconvoluted out, in other words a measure of the spread of each spot in the diﬀraction
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image. It is a global measure that may be caused by various underlying pathologies in
the crystal structure. The mosaicity of a crystal appears to be the most commonly used
indicator of crystal quality in X-ray crystallography. However, other statistics can tell
us about hidden defects, such as twinning, which may not be apparent from the
diﬀraction images.
b)  Intensity statistics
The Wilson plot shows the fall of mean intensity with resolution. This takes a
predictable form for protein crystals: there is a dip at 5Å, after which the plot is fairly
linear to the diﬀraction limit. Deviations from an ideal Wilson plot may indicate a
problem with the data. Another useful indicator is the cumulative intensity plot, which
may be distorted by twinning in the crystal. The moments of the observed normalised
amplitudes may also be used to detect the presence of twinning. Intensity statistics
compare intensities to the mean intensity, and this is assumed to vary only with
resolution, so they may be distorted if there is translational NCS present.
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2.5.4.3  The Matthews coeﬃcient
The Matthews coeﬃcient (VM ) allows the estimation of the number of molecules in the
asymmetric unit. It is given by Equation 4, where V is the unit cell volume, M is the
molecular mass of the molecule, NASU is the number of asymmetric units (depending on
the symmetry operators of the space group), and N is the number of molecules in the
asymmetric unit. The most probable values of N are those which give Matthews
coeﬃcients within the empirically observed range, and data processing programs can
give an estimate of the various probabilities by comparing the calculated Matthews
coeﬃcient with distributions obtained from published structures. This allows the most
likely number of monomers in the asymmetric unit to be estimated.
VM =
V
M ×NASU ×N
Equation 4: The Matthews coeﬃcient. V is the unit cell volume, M is the molecular mass, NASU is
the number of asymmetric units (for a given space group) and N is the number of molecules in the
asymmetric unit.
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2.5.4.4  The Patterson function
As previously explained, the structure factor (which has amplitude and phase) and the
electron density are related by the Fourier transform (see p. 96). If we ignore the phase
information and perform a Fourier transform on the intensity information alone, the
result is known as the Patterson function. It is equivalent to the electron density
convolved with its inverse, and turns out to be a very useful function.
Peaks in the Patterson function correspond to interatomic vectors weighted by
the product of the number of electrons in the atoms in question. The various
applications will be discussed further elsewhere, but at this stage the Patterson function
can be used to determine the presence of any translational symmetry elements in a
crystal. This is because the vectors between equivalent atoms in translationally related
molecules will be the same and will add up to give large peaks in the Patterson
function. The position of the peaks can give information about the orientation of the
symmetry operator.
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2.5.4.5  The self rotation function
If the Matthews coeﬃcient suggests that there are two or more molecules in the
asymmetric unit, the self rotation function can be used to tell if the molcules in the
asymmetric unit are related by rotational symmetry. It also allows the orientation of
the symmetry axis is to be determined, and this information can be exploited in NCS
averaging. Like the Patterson function, the self-rotation function can also be computed
using only the unit cell parameters, spacegroup operators, and the scaled and merged
intensity data. The self rotation function essentially reveals the rotational symmetry of
the Patterson function by comparing two identical copies of the native Patterson map.
Two things aﬀect the appearance of the self rotation function: the radius of
integration and the resolution range used in the calculation. The radius of integration
excludes points further than a certain distance from the origin of the native Patterson
map. A rule of thumb is to start with a radius equal to the diameter of the molecule.
The aim is to include as many self-vectors as possible (a larger radius means sharper
peaks) while keeping the number of cross-vectors to a minimum, which can obscure any
symmetry present in the self-vectors (Doublié, 2007).
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2.5.5  Phasing
One vital piece of information that is required to transform the measured intensities
from the diﬀraction experiment into a map of the electron density within the unit cell is
the phase of each reflection. However, this crucial phase information cannot be recorded
experimentally. The resulting conundrum is known as the phase problem, and presents
a particular challenge to macromolecular crystallographers.
In the case of small molecules, the phases can be estimated by exploiting the
assumptions that the electron density must be a positive real number and that the
crystal consists of discrete atoms. The family of methods used to do this are known as
‘direct methods’, and while they work well for smaller molecules, their application to
much larger and more complex macromolecules is limited. Instead, protein
crystallographers must generally obtain phase information by other methods.
Three other principal techniques exist: molecular replacement relies on the
availability of a similar structure to the unknown structure; single or multiple
isomorphous replacement requires the attachment of atoms with high atomic number to
the protein molecules within the crystal; and anomalous dispersion methods depend on
the presence of anomalous scatterers in the protein structure itself. The following
section will describe the methods explored in this work in more detail.
2.5.5.1  Direct methods
Although direct methods are not commonly used to phase protein crystals, they are
quite appropriate for molecules of up to ~1000 atoms, and smaller peptides do fall into
this category. The basis of direct methods as applied to protein phases is the triplet
relation between phase angles, which stems from the fact that structure factors are not
independent from each other.
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For a reflection H, with indices (h k l) the structure factor can be expressed in
the following way, where ΦH is the phase of reflection H; N is the number of atoms in
the unit cell; ƒj is the scattering factor of atom j; and xj , yj , zj is the position of atom
j in Cartesian coordinates:
Equation 5: Structure factor equation
FH = |FH | exp(iφH) =
N∑
j=1
fj exp 2pii(hxj + kyj + lzj)
The intensities of reflections are directly related to the structure factor magnitude. It
follows that for strong reflections, where FH is large, then (hxj + kyj + lzj) modulo 1 will
be approximately constant for all j. In other words, for H to be a strong reflection, all
of the contributing atoms must lie near the corresponding lattice plane. For weak
reflections, the atoms are randomly distributed, as shown in Figure 2.10 (Schenk, 2007).
For two strong reflections, H and K, the electron density is likely to be found near the
intersection of the two corresponding sets of planes. If the -H -K reflection is strong as
well, it is likely that the three sets of planes intersect at a common point. This situation
is illustrated in Figure 2.11. Taking an arbitrary origin O within the system, the phase
angle of each reflection (Φ ) can be calculated as the distance from O to the nearest
member of the set of reflecting planes. From this, the triplet relation between phase
angles can be derived, which has a probability character (due to the diﬀerent possible
configurations of planes as shown below):
Equation 6: Triplet phase relationship
φH + φK + φ−H−K ≈ 0
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A. B.
Figure 2.10: Distribution of atoms contributing to strong and weak reflections. A. The reflection (h
k l) is strong when the atoms lie near the set of planes (h k l). B. A reflection is weak when the
atoms are spread out with respect to the corresponding lattice planes.
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Figure 2.11: Three sets of lattice planes perpendicular to the zone axis. A. When the reflections H,
K and -H -K are all strong, it is more likely that the three sets of planes intersect at a common
point. B. For weak reflections, the planes are less likely to intersect at a single point.
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While the direct application of this triplet phase relationship works well for determining
the phases of small compounds, several modifications are required for successful
application to protein structures. These will not be covered here, but for further
reading see Drenth, 2002. Essentially, the overall procedure for proteins involves
generating a small subset of phases (by MR or from the positions of any heavy atom),
and using phase relationships to extend and refine the remaining phases. A major
prerequisite for the use of direct methods is the availability of atomic resolution data,
and the procedure itself is very computationally intensive.
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2.5.5.2  Molecular replacement
The most common method for solving protein phases is molecular replacement, which is
currently used for up to 70% of the structures deposited in the PDB (Evans and
McCoy, 2008). In principle, MR involves using a known structure that is suﬃciently
similar to the unknown structure to provide initial estimates of the phases. A suitable
model is rotated and translated through all possible orientations and the predicted
diﬀraction is compared with the experimentally determined intensities. The best fit of
the model to the unknown target structure is found where the predicted diﬀraction and
observed diﬀraction are most similar. The phases from the model are then copied from
the model and combined with the experimental amplitudes to calculate an initial
electron density map. From there, the phase problem becomes a crystallographic
refinement problem. In contrast to other methods, MR oﬀers the advantages of being
fast, cheap and highly automated, as well as becoming more applicable as the database
of known structures expands.
The first step in an MR procedure is to select and prepare an appropriate
model. A good model will have a high similarity to the target structure, which is
generally indicated by a high degree of sequence identity, so models are generally
selected on the basis of sequence similarity searches. The next step typically involves
improving the model by removing parts of the structure that could contribute noise to
the search, such as regions of sequence diversity, loop regions and side chains, which can
be truncated to common atoms. Depending what is known about the target structure,
it is possible to split the search model into individual domains that are used as separate
MR models if conformational flexibility is expected. Modification of B factors — which
describe the degree to which electron density is spread out and thus indicate the
mobility of the atom — can also help to improve models. However, while the success of
MR searches depends heavily on having a good enough model, it is impossible to
quantify ‘good enough’ from the outset of an MR procedure.
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Since a molecule’s orientation is defined by six parameters — three rotation
angles and three translations within the unit cell — a full six-dimensional search can
take an enormous amount of time and computational power. For this reason, the actual
MR search is performed in two steps: a rotation search is carried out first, and the best
solutions from this are then tested in a translation search. The MR rotation search can
be conducted in one of two general ways, using either traditional Patterson methods or
a ‘maximum likelihood’ statistical approach.
The Patterson function is essentially the Fourier transform of the observed
intensities. A map of the Patterson function corresponds to a map of the interatomic
vectors with the weights of the vectors being proportional to the atomic scattering. For
MR, the Patterson maps of the known and unknown structures are calculated and the
model Patterson map is rotated with respect to the Patterson map calculated from the
observed data to find the best correlation. However, since the Patterson map contains
both intramolecular self-vectors and intermolecular cross-vectors between symmetry-
related molecules, the Patterson map for the MR search model is calculated in an
extremely large P1 cell. This means that only the self-vectors will be present, thus
simplifying the search, and the search is performed within a defined radius from the
origin of the Patterson function.
In contrast to Patterson-based methods, maximum likelihood methods involve
probability functions in reciprocal space. Essentially, this approach asks the question:
what is the probability of obtaining the observed structure amplitudes for any proposed
orientation (rotation and translation) of the search model? The likelihood for the model
is calculated on a grid of angles or positions and the most likely orientation of the
search model — given the observed data — is selected as the MR solution. The
mathematics behind this approach to MR will not be covered in detail here, but for a
comprehensive overview see McCoy, 2004. Maximum-likelihood MR explicitly models
errors both in the experimental data and the search model, which is one reason why
this approach is generally more robust than Patterson-based MR.
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In both cases, the user is able to fine-tune the parameters of the search, in
addition to manipulation of the model and the input data, which can dramatically
aﬀect the eﬀectiveness of the search. Since the bulk of structural information is
contained within the phases, the model used for the MR search contributes
considerably to the final solution. In order to determine whether the solution is correct,
maps phased from the solution can be inspected for new, plausible features that were
not present in the model structure. Alternatively, regions of the model can be omitted
to see if they reappear. Overall, MR oﬀers a relatively rapid and powerful method of
obtaining protein phases, provided a suitable model of the target structure is available. 
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2.5.5.3  Isomorphous replacement
Another method of obtaining phases for protein structures is through isomorphous
replacement, which comes in two flavours: multiple isomorphous replacement (MIR)
and single isomorphous replacement with anomalous signal (SIRAS). These techniques
rely on perturbing the structure factors in a way that allows the phases to be deduced. 
All the electrons in an atom scatter roughly in phase and the scattering
intensity is proportional to the square of the atomic number. Most of the atoms in a
protein are relatively light elements (carbon, oxygen, nitrogen, hydrogen) and the
contributions from these atoms will tend to cancel out, since each atom will scatter
with a diﬀerent phase angle. Introducing heavy atoms (i.e. elements possessing many
electrons) into the crystal structure significantly alters the resulting scattered
intensities, as shown in Figure 2.12. 
Only a few heavy atoms are required to produce measurable diﬀerences in the
scattered intensities, and it is assumed that the addition of heavy atoms does not
perturb the protein structure: in other words, a crystal containing only protein and a
crystal of the same protein containing heavy atoms will be isomorphous. This is
typically accomplished by soaking protein crystals in solutions of heavy metal salts.
The diﬀerence between the scattered intensities from a native crystal and a
heavy-atom derivative largely reflects the scattering contribution of the heavy atoms.
The positions of a few heavy atoms can easily be determined, for example by
computing a Patterson map or by direct methods. Once the positions of the heavy
atoms within the crystal are known, it is possible to deduce the unknown phases of the
native protein structure. 
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Figure 2.12: The eﬀect of introducing heavy atoms on the resulting structure factor. Contributions
from four individual light atoms are shown in colour. Each atom scatters with a diﬀerent phase
angle, and the structure factor is given by FP. The presence of heavy atoms within the crystal
structure causes a large change to the resulting structure factor, FPH. The contribution of the
heavy atoms is given by FH.
However, there are two possible solutions for the phase. This can be explained by
viewing the structure factors as vectors. The magnitude and direction of the vector FH
is known from the calculated phases and amplitudes of the heavy atom positions.
Furthermore, the magnitude of vectors FP and FPH are known from the observed
intensities of the native and derivative diﬀraction data. This means that the problem of
determining the unknown phase of FP reduces to the problem of constructing a triangle
connecting the vectors, given the following relationship:
FPH = FP + FH
Equation 7: Relationship between structure factors of native and derivative crystals. The structure
factor for the heavy atom derivative, FPH, is equal to the sum of the structure factors from the
native crystal, FP, and the heavy atom contribution, FH. 
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There are two possible ways in which to construct such a triangle, which give two
possible phase angles for FP and thus two possible sets of phases for the protein
structure. More information is therefore required in order to assign the phase
unambiguously. This information can be derived from another isomorphous derivative
(as in MIR) or through collecting anomalous scattering data (as in SIRAS).
Anomalous dispersion of X-rays by heavy atoms can cause a breakdown in
Friedel’s law (see Equation 3, p. 96). This can be exploited by SIRAS to remove the
need for a second derivative, and by MAD to obtain analogous information to that
gained from MIR. The strength of the anomalous scattering eﬀect depends on the
wavelength of the X-rays being similar to the natural frequency for the heavy atom.
The strong scatterers may be intrinsic to the protein structure or they may be
introduced, for example by replacing methionine residues with selenomethionine. By
collecting data at several wavelengths near the absorption edge of the element in the
crystal, phase information can be obtained. However, since anomalous scattering
methods were not used in this work, they will not be further discussed.
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2.5.6  Density modification
Once phases have been obtained by one of the methods outlined above, it is often
necessary to improve them. Depending on the quality of the diﬀraction data, in
combination with the quality of the MR model or the heavy atom positions, there may
be large errors in the resulting electron density maps. However, there are certain
features that are characteristic of a good electron density map. The techniques
collectively known as density modification seek to improve the calculated phases by
modifying the map to look like an ideal electron density map.
Protein crystals have a high solvent content, with typical crystals containing
around 50% solvent (McPherson, 2004). This means that approximately half of the unit
cell volume is likely to be disordered solvent, which should have flat, featureless electron
density. Solvent flattening is one procedure for improving the phases, which works by
adjusting them to produce featureless solvent regions.
Another means of improving phases assumes that when the same molecule
appears in diﬀerent regions of the electron density map (for example due to non-
crystallographic symmetry), the electron density of each copy is the same. By merging
the information from each copy, any random phase errors will be reduced in a process
called averaging.
Finally, we know that proteins are made up of similar atom types and therefore
diﬀerent proteins will yield similar distributions of electron density. Histogram
matching essentially matches the distribution of high and low densities in the protein
region with the expected distribution. Any diﬀerences are most likely due to phase
errors and so phases can be improved by altering the calculated electron density
distribution to more closely match the expected values.
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2.5.7  Model building and refinement
Once phase information has been obtained and an electron density map has been
calculated for the data, the next step is to build a model of the protein structure. If
MR has been used to solve the phase problem, then a relatively accurate model of the
structure has already been placed within the electron density map. However, the map
will be heavily biased towards the model used in the MR procedure, since the phases
calculated from the model contain more information than the observed intensities. In
this case, any missing or incorrect regions of the model must be fitted and the model
must be refined against the observed data in order to remove model bias.
If the phase information was gained by other methods, it is first necessary to
build a model of the protein. This is often done using automated model building and
refinement programs. These exploit the information we know about protein structures
(bond lengths, angles, the amino acid sequence) to build an atomic model that best fits
the observed electron density given these parameters. A preliminary structure is built in
interpretable regions of electron density, and through an iterative procedure of model
building and refinement (possibly combined with further rounds of density
modification) the model can be improved until it is complete or suitable for manual
inspection.
Refinement is the process of improving the model by shifting the positions,
occupancies and temperature factors of atoms within it so that the model explains the
observed diﬀraction data better. Until relatively recently, refining a model proceeded by
minimising the sum of squares of deviations between the observed and calculated
intensities. However, maximum likelihood methods are now commonly used instead of
least-squares minimisation. These rely on the same principles as the maximum
likelihood methods used in MR: asking how probable the observed intensities are from a
given model. By altering the model to make the observations more probable, the
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agreement between the model and the data is improved, resulting in a better model.
The measure of agreement is expressed by the R-factor, which is given by Equation 8.
The diﬀraction intensities are proportional to the squared structure factor magnitudes.
R =
∑ ||Fobs|− |Fcalc||∑ |Fobs|
Equation 8: The crystallographic R-factor. The sum of the structure factor amplitudes extends
over all measured reflections and their calculated counterparts.
Despite using stereochemical restraints during refinement, it is possible to over-fit or
misfit the model. This can give acceptable R-factor values even with an incorrect
model. So a modified R-factor, known as the free R value (Rfree), can be used to follow a
refinement procedure. The free R value expresses the agreement between observed and
calculated structure factor amplitudes for a ‘test’ set of reflections omitted during the
modelling and refinement process (Brunger, 1992). There is a high correlation between
Rfree and the accuracy of the model phases, and the free R value is generally believed to
be a less biased measure of refinement than the R-factor. Generally, both the R-factor
and Rfree are used to guide the refinement process, since any discrepancy between the
two could be a useful indicator in the search for accurate and correct models of protein
structures.
Refinement is the last step in solving a protein structure by X-ray
crystallography, and it is only really at this stage that all of the assumptions made
throughout the modelling process can be shown to be correct. When a model is refined
against a random set of reflections, we can expect an R-factor of around 0.6, which
indicates that the model does not accurately predict the data. If the R-factor stays
high, this may indicate an incorrectly assigned space group or problems with the data
or the model. A correct protein structure will typically have an R-factor of around 0.2
(for a well refined model at a resolution of 2.5Å).
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Chapter 3
Materials and methods
3.1  Purification and characterisation of C1
3.1.1  Materials
Frozen human plasma for the preparation of C1 was obtained from National Blood
Service (Southampton, UK). Plasma was split into 50ml aliquots, which were stored at
-20 °C. Chemicals were obtained from Sigma (Sigma-Aldrich Company Ltd., UK) unless
otherwise stated. Crystallisation reagents were purchased from either Hampton
Research, USA, or Molecular Dimensions, UK.
3.1.2  Bioinformatics
The sequence of an assembled molecule of human C1 was constructed using sequences
retrieved from the UniProtKB/Swiss-Prot database (2010). The assembled C1 sequence
was composed of 6 copies each of the C1q A, B and C sequences (accession numbers
P02745, P02746 and P02747), as well as 2 copies each of the C1r (P00736) and C1s
(P09871) sequences. The assembled C1 sequence was analysed with Protparam (Wilkins
et al., 1999). Sequence based metal binding site prediction was carried out using
sequences of the individual C1 subcomponents and MetalDetector 2.0 (Lippi et al.,
2008).
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3.1.3  Preparation of serum from human plasma
An aliquot of plasma was thawed and calcified by the addition of 50mM calcium
chloride. The sample was left to clot at room temperature for one hour and then
overnight at 4 °C. The clot was removed by centrifugation at 6000×g for 1 hour leaving
the supernatant serum.
3.1.4  Precipitation of C1 from human serum
C1 was precipitated from human plasma or serum according to the method of Neoh et
al., 1984 to prepare C1-deficient serum. PEG 6000 was slowly added to volume of
plasma or serum to a final concentration of 3.5% under constant slow stirring. The
precipitation was carried out on ice, and allowed to proceed for 30 minutes. The
precipitate was recovered by centrifugation at 6000×g for 30 minutes.
3.1.5  Purification of C1 by SEC
The precipitate containing C1 obtained by above procedure was re-suspended in
1/10–1/50 the original volume of buﬀer and clarified by centrifugation at 6000×g for
10 minutes. Buﬀers used in the various experiments detailed in Chapter 4 are shown in
Table 5. The supernatant was removed and filtered through a 0.2 µm filer before being
loaded onto a Superose 6 10/300 GL Tricorn™ high performance column (GE
Healthcare, UK). All chromatography steps were carried out using the ÄKTA FPLC™
system (GE Healthcare, UK) and chilled buﬀers. Isocratic separation was performed at
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0.5ml/min in the same buﬀer used to re-suspend the sample and 1ml peak fractions
were collected. The peak containing C1 was determined by analysing the collected
fractions by SDS-PAGE, as described on page 126.
 Buﬀer (10mM, pH 7.4) NaCl (mM)
Tris –
150
500
Phosphate 150
HEPES 150
MES 150
MOPS 150
Table 4: Buﬀers used to re-suspend precipitated complement component C1. The buﬀer used to
re-suspend the PEG-precipitated protein was matched to the buﬀer used in the subsequent
purification by size exclusion chromatography.
3.1.6  Further purification by IEX
Fractions containing C1 from the SEC purification were pooled and exchanged into
10mM Tris, pH8, 150mM NaCl. A Mono Q™ 5/50 GL column (GE Healthcare, UK)
was equilibrated with the same buﬀer and the sample was applied. The column was
washed until a stable baseline was achieved and a gradient elution was performed using
10mM Tris, pH8, 500mM NaCl (buﬀer B) to elute the bound proteins. Various
gradients used in this work are given in Table 5. Peaks eluting at 18% and 23% B were
collected in 0.5ml fractions.
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Length (CV) Gradient
20 0–100% B
20 0–100% B; held on peaks
Table 5: Gradients used in the purification of complement component C1 by IEX. Using a stepped
gradient gives a cleaner separation between peaks in the chromatogram. This process can be
automated so that the gradient is held when a peak is detected.
3.1.7  Electrophoresis
3.1.7.1  Native agarose gel electrophoresis
Samples of oxidised and reduced C1, as well as marker proteins thyroglobulin (669kDa,
pI 4.6), ferritin (440kDa, pI 4.4) and catalase (232kDa, pI 5.6) were prepared as
follows. A sample of C1 purified by SEC (see page 124) was reduced by incubating with
0.1 vol. BME for 10 min at room temperature. Stock solutions of the marker proteins
were prepared in 10mM Tris, pH 7.4, 150mM NaCl. Samples were prepared to contain
comparable amounts of protein and mixed 1:1 with loading buﬀer (200mM Tris,
pH 8.5, 20% glycerol, 0.010% bromophenol blue). Separation was performed on a 1%
agarose gel, equilibrated with 100mM Tris, pH 8.5, at 20mA for 1.5 hours and gels
were stained using Coomassie as described on page 127.
3.1.7.2  SDS-PAGE
Separations were carried out according to the standard Laemmli protocol on 12%
polyacrylamide gels.
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3.1.7.3  Staining
Gels were stained using the colloidal Coomassie Brilliant Blue staining method
described by Candiano et al., 2004. Polyacrylamide gels were stained for several hours
using a colloidal suspension of 0.12% Coomassie Blue G-250 in 20% methanol, 10%
phosphoric acid and 10% ammonium sulphate. No de-staining step was necessary with
this protocol and gels stained by this method are fully compatible with mass
spectrometry.
After staining with Coomassie, gels could subsequently be stained with silver
according to the method outlined by Bollag et al., 1996. Gels stained by this method
are not compatible with mass spectrometry but the method was chosen since all of the
required reagents were readily available.
3.1.8  Mass spectrometry
Proteins were sent for analysis by peptide mass fingerprinting at the Sussex Proteomics
Centre (UK). Samples were provided either as solution samples in low-salt aqueous
buﬀers (e.g. 10mM Tris, pH 7.4, 150mM NaCl) or as gel slices for in-gel digestion at
the facility. For in-gel digestion of individual protein bands, proteins electrophoresed on
polyacrylamide gels according to the method outlined on page 126 and stained using
Coomassie Brilliant Blue. Gel slices were prepared according to the two methods
described below.
In the first method, the stained gel was placed on a glass plate and the desired
bands were excised using a scalpel, making sure to clean the scalpel between each
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excision to prevent contamination. Once excised, each gel slice was cut into several
smaller pieces, again taking care to prevent contamination. The gel slices were placed
into clean, sealed containers for transport and samples were processed the same day.
The second method involved the same procedure described above, except that
the excision of the gel pieces was performed under a laminar flow hood. In both
methods all glassware and tools were thoroughly cleaned using detergent, followed by a
wipe with methanol and lint-free tissue. Reagents were freshly prepared and gloves were
worn throughout the electrophoresis run and the remaining sample preparation. Care
was taken to minimise exposure of the gel to dust during staining and handling.
All samples were analysed using Sequest (Thermo Fisher Scientific, USA) and
X! Tandem (The GPM, thegpm.org). Sequest was set up to search the
ipi.HUMAN.v3.72 database, assuming the digestion enzyme trypsin. X! Tandem was set
up to search a subset of the ipi.HUMAN.v3.72 database also assuming trypsin. Scaﬀold
(Proteome Software Inc., USA) was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted if they could be established at
greater than 95.0% probability as specified by the Peptide Prophet algorithm (Keller et
al., 2002). Protein identifications were accepted if they could be established at greater
than 50.0% probability and contained at least two identified peptides. Protein
probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003).
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3.1.9  Dynamic light scattering
All DLS measurements were taken on a Zetasizer Nano S (Malvern Instruments, UK)
calibrated using 60nm latex beads according to the manufacturer’s instructions.
Samples eluting directly from the chromatography column were not filtered before
being analysed, since purification buﬀers were all pre-filtered through a 0.2 µm filter,
and the FPLC system and columns also contain several further filters. In all other
cases, samples were filtered through a 0.2 µm filter prior to analysis. All attempts were
made to protect the samples from contamination by dust and other particles.
Experiments to determine the eﬀect of ionic strength, EDTA, calcium etc. on
purified C1 were carried out as follows. The various test solutions were prepared and a
sample of purified C1 was added to the desired solution so that the final concentration
of C1 was 100µg/ml, unless otherwise stated. The melting point of purified C1 was
determined using the integrated melting point determination function of the software
accompanying the instrument. Temperature was ramped up in either 1 °C or 5 °C
intervals and three measurements were taken at each temperature step, which were
subsequently averaged.
3.1.10  TEM
Preparation of C1 samples for analysis by transmission electron microscopy was carried
out according to a modified version of the method of Strang et al., 1982. C1 was
purified in 10mM MOPS, pH7, 150mM NaCl, and diluted to 100µg/ml. EDAC was
prepared at 10mg/ml in distilled water and mixed with purified C1 in a 1:10 ratio of
EDAC to protein. The reaction was allowed to proceed at room temperature for 1 hour
and terminated by exchanging the sample into 10mM Tris, pH 7, 150mM  NaCl.
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A small volume of cross-linked protein sample was dispensed onto a carbon
coated TEM support grid and negatively stained with 1% aqueous uranyl acetate. A
control sample containing only 10mM Tris, pH 7, 150mM NaCl and no protein was
prepared in the same fashion. The samples were analysed on a Hitachi-7100
Transmission Electron Microscope (TEM) with an axially-mounted Gatan Ultrascan
1000 CCD camera. 
3.1.11  Crystallisation
Appropriate protein concentration ranges for crystallisation were determined using the
pre-crystallisation test (Hampton Research, USA) according to the manufacturer’s
instructions. Crystallisation experiments were performed by the hanging drop method,
using 1µl of purified C1 and a 0.5 ml reservoir. The experiments were set up at room
temperature and transferred to 4 °C.
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3.2  Investigating the ligand binding properties of SAP
3.2.1  Materials
Frozen human plasma for the preparation of SAP was obtained from National Blood
Service (Southampton, UK). The plasma was thawed and split into 50ml aliquots,
which were stored at -20 °C. Chemicals were obtained from Sigma (Sigma-Aldrich
Company Ltd., UK) unless otherwise stated. 
3.2.2  Purification of SAP
The purification scheme used to prepare SAP was adapted from that of De Beer and
Pepys, 1982. Human plasma was incubated overnight at 4 °C under constant slow
stirring with Sepharose 4B equilibrated with 10mM Tris, pH7.4, 150mM NaCl. The
slurry was transferred to a clean XK 50/60 column (GE Healthcare, UK) and washed
with equilibration buﬀer until a stable baseline was achieved. Bound SAP was eluted
with by flushing the column with 10mM Tris, pH7.4, 150mM NaCl, 50mM EDTA.
Peak fractions were collected and pooled.
The crude SAP preparation obtained by the aﬃnity step described above was
further purified by anion exchange chromatography. A Mono Q™ 5/50 GL column (GE
Healthcare, UK) was equilibrated with 10mM Tris, pH7.4, 150mM NaCl and the
pooled fractions from the previous step were loaded on to the column. Any unbound
proteins were washed from the column using equilibration buﬀer and SAP was eluted
using a 20 CV linear gradient of 10mM Tris, pH7.4, 1M NaCl. Peak fractions were
collected and analysed by SDS-PAGE on 12% gels using the standard Laemmli
protocol.
131
3.2.3  Aggregation assays
DLS was performed using the Zetasizer Nano S (Malvern Instruments, UK) calibrated
using 60nm latex beads according to the manufacturer’s instructions. All samples were
filtered through a 0.2 µm filter prior to analysis.
A sample of purified SAP was buﬀer exchanged into 10mM Tris pH8, 140mM
NaCl and diluted to a final concentration of 50 µg/ml SAP. Calcium-dependent
aggregation of SAP was induced by the addition of 1mM calcium, pH7.4. The sample
was immediately placed in the DLS instrument and measurements were taken at 5
minute intervals for 1 hour.
After adding 1mM calcium, a further sample of SAP was incubated at room
temperature for one hour to allow aggregates to form. PE was then added to a final
concentration of 1mM and measurements were made as above. Finally, 1mM PE was
added first to a solution of SAP, followed by the same concentration of calcium before
measurements were taken.
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3.3  Methods: ZiCo
3.3.1  Materials
ZiCo95 was obtained as a 1.1mM stock solution in water from the Woolfson laboratory
(Bristol, UK). ZiCo1 was obtained lyophilised and frozen at -20°C from Eleonora
Cerasoli (Sussex, UK) and Beth Bromley (Bristol, UK). Stock solutions of 5–10mg/ml
were prepared by dissolving the peptide in water, and stored at 4°C. Chemicals were
obtained from Sigma (Sigma-Aldrich Company Ltd., UK) unless otherwise stated.
3.3.2  ZiCo95
3.3.2.1  Crystallisation
The Pre-Crystallisation Test (Hampton Research, USA) was set up according to the
manufacturer’s instructions using 1µl drops of all the various combinations of peptide
concentration, peptide:zinc ratios and sources of zinc shown in Table 6.
ZiCo95 (mM) Peptide:zinc Zinc source
0.1 1:0 ZnCl2
0.5 1:1 ZnSO4
1 1:5
1:10
Table 6: Variables used in the PCT of ZiCo95. All combinations of the factors shown were tested
to determine an optimal starting point for crystallisation trials of the peptide.
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Crystallisation trials of ZiCo95 were set up using the Stura Footprint screen (Molecular
Dimensions) and the hanging drop method using 1µl drops over a 0.5ml reservoir.
Trays were set up at room temperature and then either transferred to 4 °C or placed in
a polystyrene box at room temperature, to minimise thermal fluctuations. The reducing
agent BME was included as a parameter in the crystallisation trials at a concentration
of 1mM in the crystallisation drop. In addition, experiments were set up using diﬀerent
peptide concentrations (0.3, 0.5 and 0.8mM), crystallisation buﬀers (150mM Tris or
150mM phosphate) and temperatures (4°C and room temperature). 
Promising conditions from the initial screens were identified where an increase
in precipitant concentration resulted in a transition from a clear drop to precipitate.
These promising conditions were then expanded into further screens by varying the
precipitant concentration within the identified range and the pH by ±1 unit around the
identified condition.
3.3.2.2  SEC
A Superdex Peptide 10/300 GL column (GE Healthcare, UK) was calibrated according
to the manufacturer’s instructions. Separations were performed in 50mM Tris, pH7.5,
50mM sodium chloride, using 20nmol of peptide per run. For reduced samples, 10mM
BME was included in the sample buﬀer.
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3.3.3  ZiCo1
3.3.3.1  Crystallisation
The Pre-Crystallisation Test (Hampton Research, USA) was carried out as for ZiCo95
(see page 133). Crystallisation trials were set up using the Stura Footprint Screen
(Molecular Dimensions, UK). Again the hanging drop method was employed, using 1µl
drops over a 0.5ml reservoir. Trays were set up at room temperature and then either
transferred to 4 °C or placed in a polystyrene box at room temperature, to minimise
thermal fluctuations.
Optimisation of crystallisation conditions involved expanding initial hits into
further 4×6 screens in which the precipitant concentration and pH were incrementally
varied (see Table 33, p. 261). Growth of large, single crystals using sodium citrate as a
precipitant was encouraged by streak seeding into drops containing slightly lower
precipitate concentrations than those required for spontaneous nucleation (<0.75M).
This was done by lightly scratching the surface of a crystal with an acupuncture needle
and then touching the needle to a freshly prepared drop. The drop was placed over a
reservoir and incubated until crystals were observed.
3.3.3.2  CD
Circular dichroism spectroscopy was performed on a JASCO J-715 CD
spectropolarimeter (JASCO, UK). A sample of 100µM ZiCo in 50mM sodium
phosphate, pH7.5, 50mM sodium chloride was analysed with or without equimolar zinc
chloride present in the sample. Analysis was carried out according to the
manufacturer’s instructions.
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3.3.4  Crystallography of ZiCo1
Data were collected using a Rigaku RU-H3RHB rotating anode X-ray generator
equipped with Osmic Max-Flux optics and an RAXIS-IV++ image plate area detector.
Cryocrystallography was carried out at 100K using the MSC X-Stream cryo system.
Subsequent computational steps were carried out using various programs from the
CCP4 software suite (Collaborative Computational Project, 1994), as described in the
relevant sections. Models and maps were viewed and manipulated using the molecular
graphics program Coot (Emsley and Cowtan, 2004).
3.3.4.1  Cryoprotectant screening
Suitable conditions for cryoprotection of the crystals were identified as follows. A
sample of the mother liquor surrounding the crystals in the crystallisation drop was
flash frozen and two test shots were made (oscillation angle: 1°; exposure: 1 min; 90°
apart). The presence of ice rings in the diﬀraction pattern indicates the need for
additional cryoprotectants.
Various cryoprotectants from the CryoPro kit (Hampton Research, USA) were
tested, including glycerol, MPD and low molecular weight PEGs. The cryoprotectant
was added to well solution in 10% concentration steps until adequate cryoprotection
was achieved, confirmed by the absence of ice rings in the diﬀraction pattern. Crystals
were either immersed briefly in the final cryoprotectant solution, or transferred through
a series of solutions with increasing cryoprotectant concentrations. 
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3.3.4.2  Cryocrystallography
A single crystal grown in 0.75M sodium citrate, 10mM borate, pH8.5 was collected and
briefly immersed in a solution of crystallisation buﬀer containing 33% glycerol as a
cryoprotectant. The crystal was then flash frozen at 100K directly in the aligned
cryostream. A total of 180 images with an oscillation angle of 1° and an exposure of 1
min were collected.
3.3.4.3  Room temperature crystallography
Another crystal grown in 0.75M sodium citrate, 10mM borate, pH8.5 was mounted at
room temperature according to the method of Mac Sweeney and D’Arcy, 2003. Briefly,
the method involves mounting a crystal in a loop as for cryocrystallography and then
placing the loop inside a sealed glass capillary tube. Two orthogonal 10° wedges of data
were collected at room temperature with an oscillation angle of 1° and exposure of 10
min.
3.3.4.4  MR models
a)  Zinc finger models
The starting point for zinc finger models for molecular replacement was the structure
1ZNF, a 27-residue classical zinc finger structure determined by NMR. A single model
from the ensemble contained within the PDB file was selected and all residues were
truncated to alanine. Disordered residues from the N and C termini were also removed,
using cartoon models to determine ordered regions of secondary structure.
137
b)  Coiled coil models
Various trimeric coiled coil structures were identified by a manual trawl through the
PDB and the crystal structure 1GCM was chosen as the basis for constructing coiled
coil molecular replacement models. 1GCM is a parallel, trimeric coiled coil variant of
the GCN4 leucine-zipper dimerisation domain. It was selected as a suitable model for
the proposed ZiCo1 structure based on sequence similarities. Sequence alignment was
carried out using CLUSTAL 2.0.11.
An initial series of models was prepared by selecting a single helix from the
1GCM structure and truncating all residues to alanine. Chains of various lengths from
9 to 27 residues were generated by removing a number of residues from the N terminus.
Key residue models were constructed from a single helix of the 1GCM structure as
follows: conserved residues were left in place, conserved and semi-conserved
substitutions were truncated to the last common atom and all other residues were
truncated to alanine. The Phe10 model was constructed from a 7-residue polyalanine
helix by mutating one of the central residues to phenylalanine using Coot (Emsley and
Cowtan, 2004). Trimeric coiled coil models were generated by truncating the side chains
of all three chains of 1GCM to alanine. Models between 15 and 27 residues in length
were created by sequentially removing three residues from the N terminus.
3.3.4.5  Heavy atom soaks
The following compounds were selected from the Heavy Atom Screens (Hampton
Research, USA), based on their solubility and binding characteristics at the relatively
high pH (8.5) of the crystallisation solution: K2PtCl4, K2Pt(NO2)4, K2Pt(CN)4,
KAu(CN)4, CdCl2 and NaIrCl6. Stock solutions (10mM) of the compounds were
prepared in 1M sodium citrate, 10mM sodium borate, pH8.5. The concentration of
precipitant in the heavy atom solution was increased over that in the crystallisation
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solution, to compensate for the lack of protein. A control experiment showed that
ZiCo1 crystals grown using 0.75M sodium citrate remained visibly intact after soaking
for one hour in the 1M solution. A small drop of either 1mM or 10mM heavy atom
solution was placed on a cover slip and a single ZiCo1 crystal was placed in each drop.
Crystals were left to soak for varying lengths of time from a few seconds to several
hours over a reservoir of well solution and observed at regular intervals.
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Chapter 4
Purification and characterisation of
C1
4.1  Introduction
As the initiator of the classical pathway of complement, the first line of defence against
invading pathogens or endogenous threats, C1 is of interest from both a purely
scientific as well as a medical point of view. The experiments described in the following
chapter were designed to examine various physiologically relevant conditions on native
human C1 with a view to ultimately obtaining a structure of the entire complex by X-
ray crystallography in order to further our understanding of this important protein. As
described in Chapter 1, the approach taken here made use of a method of obtaining
functionally pure C1 that has not been fully explored in the published literature. So the
initial starting point of these investigations was the search for a purification scheme
that would allow the native C1 complex to be isolated from human blood plasma in a
form suitable for crystallisation. The following sections detail the experiments that were
performed on complement component C1 in line with the aims set out for this project
in section 1.8.
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4.2  Bioinformatic analysis
In order to obtain useful information about the C1 complex before beginning to design
a purification strategy, the protein sequence was analysed using bioinformatics tools
available on the web as described in section 3.1.2, p. 123. The calculated values for
various properties of the assembled C1 complex were useful in the absence of any
experimental data and where no other information could be obtained from the
literature.
Number of amino acids: 7232 
Molecular weight: 782835.3 
Theoretical pI: 7.25 
Extinction coefficients: 
Conditions: 6.0 M guanidium hydrochloride 
            0.02 M phosphate buffer
            pH 6.5 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm.
Ext. coefficient   851865 
Abs 0.1% (=1 g/l)   1.088, assuming ALL Cys residues appear as half cystines
Ext. coefficient   840240 
Abs 0.1% (=1 g/l)   1.073, assuming NO Cys residues appear as half cystines
Figure 4.1: Bioinformatic analysis of the complement component C1 sequence using Protparam.
The values were calculated using a sequence assembled using the various subcomponent sequences.
C1 is predicted to have a molecular weight of around 780kDa and a pI of 7.25. The extinction
coeﬃcient of C1 can be assumed to be around 1mg/ml.
Further bioinformatic analysis is complicated by the fact that C1 is a protein complex.
When assembled, some parts of the structure may be masked by interactions with other
parts of the molecule, while additional features may be formed by the interaction of the
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various subunits. The flexibility of the structure (for example the hinge regions of the
collagen helix and the modular catalytic core) means that fold prediction algorithms
are unlikely to return meaningful results. Using the assembled sequence is only
acceptable for the basic primary sequence analysis presented above, since the molecule
is not composed of a single contiguous sequence. Sequence based approaches to metal
binding site prediction did not return any predicted metal binding sites, while structure
based approaches require experimentally determined structures. While predictions of
metal binding sites could be performed using the available high-resolution structures of
fragments of the complex, the results are unlikely to be meaningful since the fragments
themselves do not reflect the true nature of the molecule.
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4.3  Purification of native complement component C1
In the following section, the development and optimisation of a novel C1 purification
strategy will be described. Although numerous purification strategies have been
reported in the literature, the reasons for developing this particular purification
procedure will be explained in the context of the aims set out for this project. A simple,
two-step purification based on PEG precipitation of human serum proteins followed by
size exclusion chromatography had already yielded promising results (Darren
Thompson, personal communication), and this formed the basis of the purification
scheme developed here.
The approach to purifying C1 outlined below is diﬀerent from previously
published methods, which are largely aﬃnity-based. Previously reported methods of
isolating C1 from human serum largely rely on its ability to bind IgG (Arlaud et al.,
1980; Medicus and Chapuis, 1980), while more recent studies use recombinant
technology to produce modular fragments of the molecule for investigation using high-
resolution structural biology techniques (Gregory et al., 2003; Budayova-Spano et al.,
2002). The aim of this project is to isolate the entire C1 complex in its native state and
in a form suitable for crystallographic studies. This novel method is non-disruptive,
versatile, and does not involve a ligand-binding step, which makes it suitable for
fulfilling the goals set out above.
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4.3.1  PEG precipitation
The starting point for the C1 purification scheme was the preparation of a crude
extract containing high-molecular-weight plasma components — including C1 — based
on the method of Neoh et al., 1984. This was achieved by slowly adding PEG 6000,
under constant slow stirring, to a volume of human plasma to obtain a final
concentration of 3.5%. The precipitation was carried out on ice and allowed to proceed
for 30 minutes. The precipitate was recovered by centrifugation. Storing the PEG
precipitated proteins for extended periods of time at 4°C gave comparable yields of
protein to those obtained from freshly prepared precipitate. For practical purposes,
50ml of plasma was used in a single preparation.
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4.3.2  Purification by size exclusion chromatography
The crude extract obtained by the PEG precipitation procedure described above is
enriched in C1 but also contains a number of other high-molecular-weight
contaminants, which can be separated out by further purification (see Figure 4.2). Size
exclusion chromatography was chosen as a suitable step to further fractionate the
extract, since this gentle method minimises disruptive forces on the C1 complex and
can easily be fine-tuned to produce an optimal purification. Furthermore, the method
does not involve binding of the complex to any substrate, since size exclusion media are
biologically inert. The following section describes the stages that were carried out in the
optimisation of this method.
4.3.2.1  Choice of size exclusion matrix
There are a variety of matrices available to choose from, with diﬀerent properties that
must be selected to best fit the requirements of the experiment. Two diﬀerent gel
filtration mediums were investigated for their suitability in the purification of C1. The
first, Superdex 200, contains dextran chains covalently attached to a highly cross-linked
agarose gel and separates proteins between 10–600kDa. The second medium chosen for
the C1 purification was Superose 6, a purely agarose-based medium that oﬀers
separation in the range 5–5000kDa. The two separations are compared in Figure 4.2.
While the majority of contaminants could be removed using either one, the greater
separation range of Superose 6 mean that better separations could be achieved using
this medium, and so all further work was carried out on a Superose 6 10/300 GL
Tricorn™ high performance column (GE Healthcare, UK). The column was calibrated
as described in Appendix I, section ii.
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Figure 4.2: C1 purification using Superdex 200. The figure shows a typical chromatogram obtained
using the Superdex 200 size exclusion medium and below it the SDS-PAGE gel of the collected
fractions. The peak containing C1 is highlighted, and fractions (grey bars) and their corresponding
gel lanes are numbered.
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Figure 4.3: C1 purification using Superose 6. This figure shows a typical chromatogram and gel
obtained when using Superose 6 as the size exclusion medium. The peak containing C1 is
highlighted, and fractions (grey bars) and their corresponding gel lanes are numbered.The results
show that a much better separation is achieved when using Superose 6 as the SEC medium. The
fractions containing C1 correspond to a single peak in the chromatogram, and show fewer
contaminants when analysed by SDS-PAGE.
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4.3.2.2  Eﬀect of buﬀers and pH on the purification of C1
The choice of buﬀer can be a critical factor in protein studies, particularly when
crystallisation is desired. Recent results (Long and Yang, 2009) have shown that far
from being inert substances, buﬀers can aﬀect protein dynamics. It is also commonly
accepted within the crystallographic community that a particular protein may be more
stable, or more amenable to crystallisation, in some buﬀers than in others. An
investigation into a suitable buﬀer for the purification of the C1 complex was therefore
deemed appropriate.
Buﬀers were selected based on various criteria, notably a high buﬀer capacity in
the physiological range and suitability for downstream applications. Tris was chosen
initially, because it is a common buﬀer for crystallisation trials (see Table 7). However,
it is known that Tris binds divalent metal ions in aqueous solution (Hanlon et al.,
1966), and it is also unsuitable for cross-linking reactions because the primary amine
competes with amide groups on the protein. As an alternative, sodium phosphate was
chosen because it is a physiological substance and compatible with downstream
applications including cross-linking by EDAC.
Buﬀer Entries
Tris 1247
HEPES 331
MOPS 40
Bicine 17
Tricine 6
Phosphate* 1381
Table 7: Buﬀers in the pH range 6.5–9 and their prevalence in the Biological Macromolecule
Crystallisation Database. Data were taken from BMCD 4.0 (Gilliland et al., 1994).
*Phosphate is commonly used as both a buﬀer and a precipitant in crystallisation.
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The choice of buﬀer (phosphate, Tris, HEPES, MES, MOPS) did not have any
noticeable eﬀect on the results of purifying C1 by the method outlined here. This
observation was supported by the results of subsequent DLS studies on the purified
complex (see Figure 4.4). This is useful information, since the choice of buﬀer is a key
variable in crystallisation trials, and so a purification buﬀer can be selected that will be
compatible with downstream screening methods. For example, while phosphate is very
popular, it also results in high numbers of false positive hits when metal salts are
included as a crystallisation variable.
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Figure 4.4: The eﬀect of diﬀerent buﬀers on C1 purified by SEC. A sample of the purified protein
was exchanged into various buﬀers and analysed by DLS. The samples show a monomodal
distribution, with a mean Z-average size of 81.36nm (±2.102nm) and a mean PdI of 0.212
(±0.012nm). This confirms that diﬀerent buﬀers do not significantly aﬀect the size of the C1
complex as determined by DLS.
While the buﬀers themselves may be inconsequential for the purification of C1, pH
aﬀects the function of C1 and therefore may alter the structure of the complex. For this
reason an investigation was undertaken into the eﬀect of diﬀerent pH values on the
purification of C1. The function of the C1 complex has previously been reported to be
greatly aﬀected by pH (Lepow et al., 1958), having optimum activity around pH7.5,
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with a sharp decrease in activity below pH6.5 and above pH8.5. At present the
literature does not indicate whether this is due to conformational or chemical changes
that render the complex inactive or whether it is due to disruption of the complex.
In light of this, it was decided that the purification of C1 would be performed at
physiological pH in order to maximise the amount of material that could be obtained
from each PEG precipitation. Since pH aﬀects C1 activity, controlling the pH during
the purification procedure could add a valuable level of control to minimise C1 activity
if so desired.
A further point to note was that calcium was included as a variable when
testing diﬀerent buﬀers, and no determinable diﬀerence was detected in the
chromatogram when the purification was carried out with or without calcium. This
suggests that any calcium ions are tightly bound to C1 and that the complex does not
require the addition of further calcium during purification.
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4.3.2.3  Eﬀect of ionic strength on the purification of C1
In addition to being sensitive to pH, human C1 has also been shown to respond to
variations in ionic strength, showing a decrease in activity below 0.1 and above 0.15
(Lepow et al., 1958). In another study, guinea pig C1 was also shown to be sensitive to
salt concentration (Colten et al., 1968). Here again, the authors propose that the
decrease in activity is due to dissociation of the complex at high ionic strength.
Various salt concentrations (0, 150 and 500mM) were explored for their eﬀect
on the elution profile of the crude C1 extract. As with the investigation into the eﬀect
of pH, equal amounts of PEG-precipitated proteins were reconstituted in buﬀers of
diﬀerent ionic strengths and the samples were then separated by size exclusion
chromatography. The resulting chromatograms and the corresponding SDS-PAGE gels
are shown in Figure 4.5.
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Figure 4.5: Eﬀect of varying salt concentrations on the recovery of C1 from the precipitate.
Equal amounts of PEG-precipitated proteins were reconstituted in 10mM MES, pH7.4, 2mM
calcium chloride, containing either 0, 150 or 500mM NaCl and separations were performed in the
same buﬀer. The C1 peak in the chromatogram is highlighted and the corresponding SDS-PAGE
gel for each salt concentration is shown. The results show that considerably more material is
recovered using 500mM NaCl in the re-suspension buﬀer than when no salt or physiological salt
levels are present.
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From both the chromatograms and the gel it can clearly be seen that re-
suspending in a buﬀer containing 500mM sodium chloride results in an increased
amount of C1 recovered from the precipitated pellet. However, changing the salt
concentration in the range tested does not appear to aﬀect the purity or overall
integrity of the complex. Despite the apparent advantages of using high salt
concentrations during the extraction, further preparations were made using
physiological salt concentrations during the purification procedure, in order to obtain
purified C1 in a its native state. However, if 500mM sodium chloride does eﬀectively
inhibit C1 action, this could be a useful adaptation to the purification procedure to
prevent any undesired reactions.
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4.3.2.4  Choice of starting material: plasma or serum
As can be seen from Figure 4.5, the fractions containing C1 that are obtained after an
initial gel filtration run contain numerous contaminating proteins. During the course of
several preparations it was observed that the purified fractions turned gelatinous upon
storage at 4°C. A possible explanation was that residual clotting factors were being co-
purified with C1 and that the calcium in the purification buﬀer was inducing clotting.
To test this hypothesis, the purification was repeated using plasma that had been
depleted of clotting factors by incubating with 10–50mM calcium overnight at room
temperature and removing the resulting clot by centrifugation. The resulting fractions
remained liquid upon storage, although some precipitation was observed after several
weeks. This suggests that the majority of clotting factors were removed by the
treatment, and indeed the resulting fractions were much cleaner when examined on
SDS-PAGE gels. Since there was an excess of calcium in the serum, no further calcium
was added to the purification buﬀer.
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4.3.2.5  Re-suspension volume
The concentration of C1 in normal human serum is 1.8 × 10-7M (Ziccardi and Cooper,
1977). This equates to 140mg/l, so in a typical preparation using 50ml of serum we
would expect to recover approximately 7mg of purified C1. From a single extraction,
the amount of protein in the pooled fractions after SEC is around 1.5mg. Since there
are still considerable amounts of other contaminating proteins, we can estimate that
less than 1.5mg of C1 is recovered of a potential 7mg, or a yield of <20%.
There are several possibilities to explain this low yield. One explanation is that
not all of the C1 present in serum precipitated in the PEG-precipitation step. However,
the original purpose of this method was to prepare C1-deficient serum (Neoh et al.,
1984) and therefore it is unlikely that a significant quantity of C1 remains in solution.
Another explanation is that not all of the precipitated C1 was re-suspended and that
some remained in the pellet of precipitated proteins. This was tested by re-extracting
the same pellet to see if more C1 could be recovered and the results are shown in
Figure 4.6.
It was found that equivalent amounts of high-molecular weight material could
be sequentially extracted from PEG-precipitated human serum. The purification
protocol was therefore modified so that the PEG-precipitate was re-suspended in 1/10
the original volume of buﬀer. This modification obviated the need to use high salt
concentrations to increase the yield of protein recovered from the precipitate.
In summary, I have demonstrated that C1 can be partially purified quickly and
easily from human plasma by a novel two-step purification. A volume of plasma was
calcified to remove the majority of clotting factors and the resulting serum was then
incubated on ice with the addition of PEG 6000 to 3.5% in order to precipitate high-
molecular-weight proteins including C1. The precipitate was recovered by centrifugation
and re-suspended in 1/10 the original volume of buﬀer (Tris, HEPES, MES, MOPS) at
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physiological pH and salt concentration, with or without physiological levels of calcium
present in the extraction buﬀer. This crude extract was purified using a Superose 600
size exclusion matrix, resulting in purified C1.
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Figure 4.6: Multiple extractions of PEG-precipitated proteins. The pellet obtained from the PEG
precipitation step was re-suspended in 1ml of 10mM Tris, pH7.4, 150mM sodium chloride and any
remaining precipitate was removed by centrifugation. A second extraction was then performed on
the remaining precipitate, and a third in a similar manner. The figure shows that similar amounts
and distributions of high-molecular-weight material were recovered from each extraction. After
approximately five extractions, most of the material in the pellet had been recovered.
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4.3.3  Summary: Purification by SEC
The optimised method for purifying C1 by SEC is as follows: a volume of frozen human
plasma is thawed and clotted with 50mM calcium chloride. The resulting serum is
precipitated with 3.5% PEG 6000 for 30 minutes on ice and the precipitate is then re-
suspended in 1/10 the original volume of buﬀer (10mM Tris, pH7.4, 150mM NaCl).
Any remaining precipitate is removed by centrifugation and filtration through a 0.2 µm
filer. The clarified sample is loaded onto a Superose 6 10/300 GL Tricorn™ high
performance column (GE Healthcare, UK) and eluted at 0.5ml/min in the same buﬀer.
Tris may be replaced with another suitable buﬀer if required.
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4.4  Characterisation of C1 purified by SEC
In order to assess whether or not the purification has been successful, the eluted
fractions were subjected to analysis by a number of complementary methods. Since the
aim of this project is to obtain native C1 in a form suitable for use in crystallisation
trials, the techniques employed were chosen so as to determine as clearly as possible
whether the purified product obtained is indeed C1 and whether it is pure and
structurally homogeneous. This following section describes the various ways in which
the results of the purification procedure were evaluated and presents evidence to
support the view that the goals set for this project have been adequately fulfilled.
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4.4.1  Characterisation of SEC-purified C1 by electrophoresis
One of the most useful methods for assessing the results of the C1 purification was
polyacrylamide gel electrophoresis under denaturing conditions, but C1 was also
analysed by various other electrophoretic methods. The results of these investigations
are presented in the following section, according to the technique employed.
4.4.1.1  Native agarose gel electrophoresis
As explained in Chapter 2, native electrophoresis is a method that separates molecules
based on their mass/charge ratio. It is gentle enough that interactions between proteins
can be maintained and is therefore suitable for the purpose of examining the assembled
C1 molecule. Owing to the large size of the complex — around 800kDa — the
separation could not be performed in polyacrylamide gels, as is usual for protein
separations. Instead, agarose gels were used, as these permit larger pore sizes and are
therefore better suited to separating larger molecules. Samples of oxidised and reduced
C1, as well as marker proteins thyroglobulin (669kDa, pI 4.6), ferritin (440kDa, pI 4.4)
and catalase (232kDa, pI 5.6) were prepared as described on page 126. The proteins
were visualised with Coomassie and the results are shown in Figure 4.7.
The results of the native separation show that the purified C1 migrates as a
single, high-molecular-weight band of approximately 750kDa. This is consistent with
the published molecular mass of the C1 complex at 790kDa. Upon incubation with the
reducing agent BME, C1 appears to split into a fragment of approximately 190kDa
and a broad band of high-molecular-weight material. The mass of the smaller fragment
corresponds roughly to that of a dimer composed of C1r and/or C1s — at around
150 kDa — and the larger matter is presumably the intact C1 complex. Reduction of
the disulphide bonds between sub-components therefore apparently leaves the majority
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of the molecules intact, with a small proportion forming dimers composed of C1r, C1s
or both. It is possible that other forces hold some parts of the complex together under
the reducing but non-denaturing conditions during the electrophoresis run.
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Figure 4.7: Native agarose gel electrophoresis of purified C1. Molecular weight marker proteins:
thyroglobulin (669kDa, pI 4.6); ferritin (440kDa, pI 4.4) and catalase (232kDa, pI 5.6). The
predicted pI of C1 is 7.3. Purified C1 was reduced by incubation with BME and the gel appears to
show two bands (red): one high molecular-weight-band between 440–669kDa, and one low
molecular weight band < 232kDa. Purified native C1 (oxidised) migrates as a single band (blue) of
over 669kDa, which corresponds to the expected molecular weight of the complex.
Native electrophoresis oﬀers comparatively low resolution compared with other
methods: the diﬀuse bands make the resulting gels diﬃcult to interpret. Nonetheless,
since it appears to be non-disruptive to the C1 complex and has recently been
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suggested as a highly eﬃcient approach to studying the structure and function of
metalloproteins (Kastenholz, 2007), native electrophoresis remains a useful tool in the
investigation into the structure of complement component C1.
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4.4.1.2  SDS-PAGE
The method of choice for verifying the purification of C1 was SDS-PAGE, since it is
quick and simple to perform, and oﬀers a high resolving power. Furthermore, the
technique is denaturing and thus allows the detection of the individual C1 components
as well as any contaminating substances that elute together with C1 during
chromatographic separations. Thus, SDS-PAGE is complementary to other techniques
used here — such as SEC, native PAGE and DLS — as it reveals information about
the individual polypeptide chains in the sample. An illustration of the results of the
purification of C1 by SEC is shown in Figure 4.8. Proteins which are clearly visible in
the crude extract have been removed by the purification and the bands corresponding
to the various C1 sub-components can clearly be seen. These are barely visible in the
impure starting material, indicating that C1 has been enriched by the purification
procedure.
When purified C1 is prepared under reducing and denaturing conditions, the
complex breaks apart into its individual sub-components. These can be seen as a
double band of approximately 80kDa, containing C1r and C1s, and a triplet of bands
at around 25kDa, which correspond to the A, B and C chains of C1q. A small amount
of very high-molecular-weight (>250kDa) material is also present, which may be
aggregated C1 or other contaminants. For comparison, a published image of reduced
and non-reduced, native and activated C1 is shown in Figure 4.9. The results under
reducing conditions are in good agreement with the C1 purified here, as shown in
Figure 4.8, with the characteristic pattern of ~80kDa and ~25kDa bands.
Under denaturing, but non-reducing conditions, a single prominent band that
does not react with silver stain is seen, with a molecular weight greater than 250kDa
(Figure 4.8). This is in contrast to the published results (Medicus and Chapuis, 1980),
which show bands corresponding to ~50kDa for C1q A–B and C–C chain dimers and
~80 kDa for C1r and C1s.
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One notable diﬀerence between the published protocol and that presented here
is the inclusion of a TCA precipitation step prior to electrophoresis; the other diﬀerence
being the method of purifying C1. Since the acid precipitation step employed by
Medicus and Chapuis simply serves to concentrate the proteins present in the sample
and the remaining acid is neutralised in the protocol described, it seems unlikely that
this is the cause of the observed diﬀerences. So perhaps they can be explained by the
diﬀerent methods of preparation.
In the published method, C1 is purified from serum by aﬃnity chromatography,
using immobilised Ig-G to bind and capture the complex, which is subsequently eluted
with high salt buﬀer (0.4M NaCl). These steps may in some way facilitate the
disruption of the complex by SDS, while the C1 isolated by the procedure described
here remains resistant to denaturation by the detergent. Alternatively, C1 purified by
this method is for some reason prone to aggregation, and the observed high-molecular-
weight band may simply be large denatured protein aggregates. It is interesting that a
high-molecular-weight band also appears under non-reducing conditions in the paper by
Medicus and Chapuis, 1980 (Figure 4.9).
With respect to the ineﬀectiveness of silver staining on non-reduced C1, a
possible explanation lies in the mechanism by which silver atoms accumulate at the
protein surface. In order for the stain to develop, a few soluble silver ions must be
reduced to silver atoms by reducing sites on proteins. These microscopic deposits then
act as a nucleus from which silver grains grow, visible to the naked eye as dark bands.
The colour of the bands varies with the size of the grains (Merril et al., 1988). It is
possible that C1 purified by PEG precipitation and SEC, whether in its native state or
present as aggregates, presents few or no reducing sites and therefore does not produce
a visible stain using silver. Without additional information, it is not possible to draw
any further conclusions about why C1 as purified here — in contrast to previous
reports — migrates with a molecular weight of greater than 250kDa by non-reducing
SDS-PAGE and does not respond to silver staining after staining with Coomassie.
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Figure 4.8: Comparison of PEG precipitated proteins and purified C1 under reducing and non-
reducing conditions by SDS-PAGE. A. Crude C1 from PEG precipitation of human serum. B. C1
purified by SEC under reducing conditions. C. Marker proteins stained with Coomassie, followed by
silver staining. D. C1 purified by SEC under non-reducing conditions, and stained with Coomassie.
Subsequent staining with silver stain did not produce any further reaction.
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in considerable losses of activity. From the known contami- 
nants, gel filtration  on Ultrogel ACA 22 was  chosen as  the  next 
step.  The  elution,profie  on  such a  column indicates  that  the 
contaminating  proteins are removed  in this  step (Fig. 1). This 
gel filtration was done in the presence of Veronal buffer ad- 
justed  to 0.4 M NaCI, as  it was  found to improve  recovery over 
physiologic ionic strength buffer. In Table I11 is summarized 
the two-step  purification of C1, which is representative of more 
than 50 individual preparations.  Since  the binding and  elution 
conditions do not involve use of low pH,  the  Sepharose-IgG 
resin does  not lose capacity with use. 
Use of NPGB in the purification. When  the  C1 purification 
was performed without  the  addition of the  protease  inhibitor 
NPGB  (1  l),  the  Clr  and  Cls  subcomponents were  found largely 
in the  activated from as determined by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) in the presence of DTT.  When 
NPGB (3 X lo-$ M) was added  to  each buffer except for the 
ACA 22 gel filtration step, the C l r  and C l s  subcomponents 
were totally in the native,  uncleaved  form as described below. 
The use of NPGB had no measurable effect on the yield of 
purified C1 when rabbit IgG was used as ligand. The use of 
NPGB is necessary for good recovery  when human IgG is used, 
probably  because, as will be discussed, the  activated  C1 is more 
susceptible to  serum  inhibitors when  bound to  human IgG. 
SDS gel electrophoresis of Cl  and Ci. Macromolecular C1 
and C i  is highly sensitive to the method of preparation for 
SDS-PAGE. A number of different procedures yielded either 
well-stained Clr,  Cls,  or A, B, and C chains of Clq,  but  not all 
with the  proper intensity. In  order  to achieve equal  penetration 
of all the C1 chains, the procedure described under Methods 
was employed. The  TCA precipitation step was  found  effective 
to  concentrate C1 as long as  the original concentration was a t  
TABLE I1 
Optimum  conditions of C1 elution from Sepharose-IgC  rabbit 
C I Recovery 
c 
0.15  M NaCI-VB 2 
0.3  M NaCI-VR 48 
0.4 M NaCI-VR 70 
0.5  M NaCI-VR 65 
0.6  M NaCI-VB 54 
50 mM diaminohutane-VBS 18" 
200 mM diamino butane-VBS 17" 
. ~~ 
Elution Buffer 
" ~~ "
" Assayed after  dialysis against SVB.  The  same recovery was found 
with direct dilution of  the  eluate into SVR  without  dialysis. 
t O 6  
100 I50 200 250 300 
Etfluenl volume lml l  
Figure 1. Second  step in the purification of C1. The C1 eluted from 
Sepharose-IgG was chromatographed on Ultrogel ACA 22 as described 
in Materials  and  Methods. 
TABLE I11 
CI purification from 100 ml of serum (7000 mg) 
Total SDecific Activ- 
Protein  ity 
Fold 
Assum-  (Effective  covery cation 
ing an  molecules) per 
7 He-  pur& 
p ' .  
= I n  mg 
- 
mg ? 
Step 1, binding/elution 32 6 .3+  10''' 70 152 
from Sepharose-IgG 
(rabbit) 
tographv 
Step 2, ACA 22 chroma- 6 2.0 X 10"" 4tih 583 
"By  using 1.5 X 10' EA4 cells in the assay descrihed in (9). one 
effective molecule per cell was generated by the addition of 0.075 ng of 
C1 that was  activated  to Ci   as  descrihed in Results. 
From the reported C1 concentration in serum of 130 pg/ml (13). 
46% recovery of C1 from 100 ml of serum should be 7 mg. 
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Figure 2. SIX-PAGE analysis  of C1 and C i  on 7% SIX-polvacryl- 
amide gels, 30 pg of C1 or C i  were applied. a )  native CI under 
nonreducing conditions. b)  native C1 reduced, c) Ciunder nonreducing 
conditions, d)  C i  reduced. 
least 0.1 mg/ml. The gels shown in Figure 2 are  representative 
of a  large number of C1 preparations. The  native C1  gel shows 
under reducing  conditions (gel b)  the previously described 94 
Kdalton Cl r  and Cls  subcomponents, as well as  the A, B, and 
C chains of Clq, which range from 30 to 20 Kdaltons. 
When the purified native C1 shown in the left-hand gels is 
incubated a t  30°C for 30 min in SVB, the C1 is completely 
activated,  as seen in reduced SDS-PAGE (gel d) in Figure 2. 
No 94 Kdalton Clr  and  Cls remain and the major cleavage 
fragments of Clf  and C1F; are  seen  at 63 and 73 Kdaltons.  A 
third, minor cleavage fragment (which must arise from C1, 
because it is not present in the nonactivated C1) also appears 
with  a m.w.  of 83 Kdaltons. It is not known if this  represents a 
C1 internal  activation  fragment  or  the result of trace protease 
action. Two low  m.w. fragments of Clf  and C1B are consistently 
found at  35 and 25 Kdaltons, which correspond to  the active 
site containing Clr  and  CIS peptides, respectively. The high 
m.w. bands seen on the reduced activated C1 (gel d) must be 
caused by the 3OoC incubation, since they  are not present in 
the  native C1. 
Figure 4.9: SDS-PAGE analysis of native and activated C1 on 7% SDS-polyacrylamide gels.
A. Native C1 under non-reducing conditions. B. Native C1 reduced. C. Activated C1 under non-
reducing conditions. D. Active C1 reduced. Taken from Medicus and Chapuis, 1980.
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4.4.2  Peptide mass fingerprinting of SEC-purified C1
The purpose of this investigation was twofold: firstly, peptide mass fingerprinting will
allow the various components of the C1 complex to be identified in the corresponding
gel sections, thereby allowing us to confirm that the purification has been successful;
secondly, the analysis will give an indication of the major contaminating proteins
present within each sample. This information is useful to monitor the eﬃcacy of the
purification and can also shed light on any proteins that may be co-purifying
specifically with the C1 complex.
Another possible method to determine the presence of a specific protein, for
example C1r, C1s or C1q, would be a Western blot. In this technique, proteins are
electroblotted from the SDS-PAGE gel onto a porous membrane, which is then
incubated with an antibody specific to the protein in question. However, anti-C1
antibodies are expensive, especially considering the need for a separate antibody
specific to each subcomponent and the limited availability of suitable commercial
antibodies. Furthermore, Western blotting can give only very limited information about
the purity of the sample. Using a mass spectrometric approach circumvents these
obstacles, and provides detailed quantitative information about the sample composition.
After electrophoresis on SDS-PAGE gels, the C1 complex purified was sent for
analysis at the Sussex Proteomics Centre (UK). The various bands observed were
excised and submitted for peptide mass fingerprinting in order to determine the
identities of the proteins contained within each band, as shown in Figure 4.10. Two
separate analyses were performed, using slightly modified gel preparation methods as
described on page 127. The results of the two experiments are compared in Table 8.
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Figure 4.10: Gel submitted for MS analysis of SEC-purified C1. The gel sections outlined in red
(A – D) were excised and submitted for in-gel trypsinolysis followed by peptide mass fingerprinting
at the Sussex Proteomics Centre.
Method 1 Method 2
Human proteins 126 (100%) 70 (100%)
Keratins 42 (33%) 12 (17%)
Immunoglobulins 32 (25%) 30 (43%)
Table 8: Comparison of two diﬀerent gel preparation methods for peptide mass fingerprinting. In
the first method, samples were prepared under normal laboratory conditions, while the second
method involved the use of a laminar flow hood to reduce exposure to contamination by keratins
from dust, skin and hair.
A major problem with this approach was contamination of the samples, both from
extraneous sources and due to the inherent complexity of the samples. When preparing
biological samples for mass spectrometry, contamination with keratin from hair, skin
and dust is almost unavoidable. In the initial experiment all glassware was thoroughly
cleaned, all reagents were freshly prepared, gloves were worn throughout the
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electrophoresis run and the remaining sample preparation, and care was taken to
minimise exposure of the gel to dust during staining and handling. However, of all 126
human proteins returned in the search, almost 60% were contaminants or high-
abundance serum proteins, with one in three proteins being contaminating keratins.
The method of preparing the samples was subsequently modified so that the gel
pieces were excised under a laminar flow hood in order to further reduce the exposure
of the samples to airborne contaminants. This method performed better, with only 17%
of the total proteins identified as keratin. However, the proportion of immunoglobulins
jumped from 25% to 43% in the second experiment. These are the most abundant
proteins found in human serum, after albumin (Diem and Lentner, 1975), and so it is
not surprising that they are prominently represented in the search results. IgG has a
serum concentration of 8–18mg/ml, compared to 0.18mg/ml for C1, making it more
abundant than C1 by a factor of around 100.
A large proportion of the proteins identified in the peptide search were
contaminating keratins or immunoglobulins, but low-abundance serum proteins could
also be identified. The combined results of the two experiments are shown in Table 9.
The returned search results were automatically filtered to exclude non-human proteins,
keratins and immunoglobulins, and the list of proteins was manually refined to
eliminate human non-serum proteins. Finally, abundant plasma proteins such as serum
albumin, lipoproteins, fibrinogen, alpha-2-macroglobulin and alpha 1-antitrypsin were
also manually excluded. These proteins are likely to be present in serum-derived
samples owing to their sheer prevalence, as they make up about 8% of total serum
protein (the majority of the fibrinogen being removed during the preparation of serum
from plasma).
All elements of the C1 complex were identified in the SEC-purified sample,
confirming that the intact C1 has been successfully purified from human serum by the
method outlined in this work. In addition, several other complement-related proteins
were identified in the purified sample, including C3, C4 and C4BP, as well as SAP and
various other proteins thought to be involved with the complement system.
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Table 9: Results of peptide mass fingerprinting on C1 purified by size exclusion chromatography.
The table shows the various C1 subcomponents and other complement-related proteins identified in
the sample. Molecular weights determined from protein sequence databases are given as a guide
only. Further information is given in the comments. Table continued overleaf (sequence coverage
data not available, protein probability scores are shown instead).
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4.4.3  Dynamic light scattering of SEC-purified C1
The acquisition of a dynamic light scattering instrument part-way into the project
oﬀered another complementary means for analysing the purified fractions. As described
in section 2.3.3, dynamic light scattering gives information about the size distribution
of particles in solution. Thus it diﬀers from PAGE and SEC as an analytical tool in
that it gives us information about more than simply the size of the molecules under
scrutiny.
The technique oﬀers other advantages too. The fact that it is non-destructive,
and can accommodate small volumes makes it ideal for use when there is only limited
sample available, or when the sample is required for further downstream applications.
Additionally, any changes in the size distribution of the sample can be monitored in
real time. Thus, time course experiments to test the eﬀect of temperature or the
addition of various substances to the solution can be performed and monitored directly.
Furthermore, DLS can be used to estimate the shape of macromolecules and make
predictions about their ability to crystallise under given conditions.
The combination of the above factors makes DLS a powerful technique for
studying macromolecules from a structural biology point of view. As with SDS-PAGE,
dynamic light scattering was used extensively throughout this work, and individual
results are presented in the relevant sections. However, an analysis of C1 purified by
SEC is shown in Figure 4.11, p. 171.
The diameter of the assembled C1 molecule has been proposed to be around
40nm (Perkins, 1985). For C1 purified by size exclusion chromatography, we see a
broad, convoluted peak in the DLS intensity plot in Figure 4.11. Multimodal analysis
gives two conjoined peaks, and is more likely to reflect the nature of this polydisperse
sample accurately. The first peak is centred at approximately 45nm, which is very close
to the proposed diameter of assembled C1 (40nm). There is a slightly smaller second
peak at around 180nm. Of course the 45nm particles are more numerous than the
larger ones present in the sample (for an overview of interpreting DLS data, see section
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2.3.3.2, p. 63). The width of the distribution indicates that there is likely to be a range
of particle sizes, possibly reflecting various diﬀerent contaminants or states of protein
association.
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Figure 4.11: Size distribution of pooled fractions SEC-purified C1 by intensity. The protein was
purified using the optimised purification procedure, and fractions corresponding to the C1 peak
were pooled and analysed by DLS. The plot shows two conjoined peaks centred at approximately
45nm and 180nm. The smaller particles outnumber the larger particles, since larger particles
scatter more strongly in proportion to their size, and there is likely to be a range of particle sizes
and association states.
When each fraction comprising the C1 peak from the optimised SEC purification
procedure was assayed individually, we can see that the size distribution varies between
fractions (see Figure 4.12, p. 172). The first fraction contains a broad peak at around
100nm, which is skewed towards the lower end of the range. In the second fraction, the
size distribution becomes bimodal. The later fractions show two distinct peaks: a large
peak at 30nm and a smaller peak at 180nm. This indicates that the C1 peak purified
by the optimised SEC procedure contains a population of particles of around 30nm,
with a smaller amount of larger particles that steadily decreases with increasing
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fraction number. Again, the size of the smaller particles is close to the proposed size of
the intact C1 complex (40nm), taking into account shape eﬀects and the limitations of
the technique.
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Figure 4.12: Size distribution by intensity of individual fractions of the C1 peak purified by SEC.
The protein was purified using the optimised purification procedure, and fractions corresponding to
the C1 peak were analysed individually by DLS: the corresponding SDS-PAGE gel is also shown
(left). The intensity plot shows how the distribution of particle sizes varies between fractions,
around two peaks at around 25nm and 180nm. In the first fraction, the larger particles appear to
dominate, with a large peak at around 100nm. As the fraction number increases, the peak at
25 nm decreases.
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4.4.4  Transmission electron microscopy of SEC-purified C1
TEM was used to examine the purified complex with a view to ultimately obtaining
improved low resolution structures by cryo-electron tomography. C1 is an ideal
candidate for this approach thanks to its large size and the symmetry present in the
assembled complex. The TEM sample preparation was carried out according to a
modified version of the method of Strang et al., 1982, which uses the zero length cross-
linker EDAC to fix the interacting C1 subunits. This water soluble carbodiimide causes
carboxyl groups to react with primary amines, resulting in an amide bond. Closely
interacting proteins may thus be covalently linked, since any exposed carboxyl groups
will bind to nearby amine side chains. Figure 4.13 shows typical views of the cross-
linked C1 sample.
Strongly negatively stained features of approximately 50nm and 200nm were
observed in all samples tested, as well as numerous diﬀuse features of approximately
50nm. The strongly stained features are comparatively few, while the diﬀuse features
are the most numerous of the features observed by TEM. The size of these ultra-
structural features also corresponds to the distribution of particle sizes as determined
by DLS, suggesting that the observed features are real and not artefacts. C1 molecules
have been shown to appear diﬀuse when visualised by this method (see Figure 4.14 and
Strang et al., 1982). It thus seems likely that the abundant diﬀuse features observed
here are C1 molecules. However more work is required to fully resolve the structural
detail of the sample.
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Figure 4.13: Cross-linked C1 analysed by TEM. A sample of purified C1 was cross-linked using the
zero length cross-linker EDAC and visualised by negative staining at 10000 × magnification. Inset:
negative control sample with no protein present. Globular negatively stained features of
approximately 50nm (black arrows) and 200nm (white arrows) were seen in the sample, which
were not observed in negative controls. In addition, numerous diﬀuse features were observed in the
C1 sample, again approximately 50nm in diameter (open arrows). The particles observed by TEM
correspond to the size distribution of particles as determined by DLS.
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Figure 4.14: Cross-linked C1 (for comparison). Cross-linked C1 at 290000× magnification, taken
from Strang et al., 1982. The C1 molecules appear diﬀuse, with little contrast against the
background and surrounded by dark halos.
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4.4.5  Storage of SEC-purified C1
Since complement component C1 spontaneously activates at 37 °C (Ziccardi, 1983), it is
possible that the purified protein may degrade on storage. For concentrated samples, a
floccular precipitate was observed after the samples were stored at 4 °C for several days.
The precipitate could not be removed by centrifugation but only by filtering the sample
through a 0.2 µm filter. To test the eﬀect of diﬀerent storage conditions, they were
compared using DLS to monitor any changes in the size distribution of the sample,
which would indicate any degradation or aggregation of the purified protein. Samples of
C1 prepared by SEC were analysed by DLS before being stored for 10 days at 4 °C or
-20 °C. The samples were then compared with the original, freshly prepared sample, and
the results are shown below in Table 10.
As can be seen, storing the sample at -20 °C produced the greatest change in the
average size of the particles within the sample. This indicates that purified C1
aggregates or precipitates upon freezing and thawing, which is not uncommon for many
proteins. Storage at 4 °C also resulted in a less pronounced increase in the diameter of
the particles, with the polydispersity of the sample remaining virtually unchanged.
Overall, the results show that the composition of the SEC-purified C1 fractions changes
on storage and this must be taken into account when performing further experiments
and must be borne in mind when interpreting the results.
Conditions Z-Average (d.nm) PdI
Freshly prepared 74.73 0.244
4°C 87.14 0.225
-20°C 96.42 0.229
Table 10: DLS measurements of SEC-purified C1 stored for 30 days under various conditions. The
results show that a small amount of aggregation occurs when the purified protein is stored for 10
days at 4 °C and -20°C. The precipitate could be removed by filtration.
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4.4.6  Summary: Characterisation of C1 purified by SEC
The optimised SEC purification procedure outlined in section 4.3 yields a sample that
is highly enriched in C1, with a small amount of contaminants. These results were
confirmed by native agarose gel electrophoresis, SDS-PAGE and DLS. Peptide mass
fingerprinting suggests that the majority of the contaminants are immunoglobulins and
other abundant serum proteins, as well as other members of complement and
complement-related proteins. In summary, the method outlined here represents a novel
way of obtaining the native C1 complex in purified form.
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4.5  SEC-purified C1 under physiologically relevant 
conditions
The results of the investigations into the eﬀects of ionic strength and pH on the
purification of complement component C1 by SEC are described in section 4.3.2, p. 146.
However, purified C1 was also studied under various other physiologically relevant
conditions using gel filtration chromatography and dynamic light scattering to
determine the eﬀect of ionic strength, pH and divalent metal cations on the sample.
Human blood plasma contains a variety of organic and inorganic molecules.
These are usually confined to a narrow concentration range, and any variation outside
of these values may be an indicator, if not a cause, of disease. Fluctuations in levels of
certain substances are also used to convey signals within and between biological
systems. For example, nerve impulses are generated by the influx of sodium ions to the
firing cell through voltage-gated ion channel proteins embedded in the plasma
membrane.
In the search for knowledge about the structure and function of C1, the eﬀect of
biologically relevant metal ions cannot be ignored. In addition to gaining insight into
the physiology of the complex, an understanding of how salt, pH and various metal ions
aﬀect C1 in solution can be of help in the search for conditions that allow
crystallisation of the assembled complex. The outcomes of these experiments are
detailed below.
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4.5.1  The eﬀect of ionic strength on SEC-purified C1
As outlined previously, the function of complement component C1 is aﬀected by
varying the ionic strength of the surrounding medium (Lepow et al., 1958; Colten et al.,
1968). The authors report a decrease in activity at ionic strengths below 0.1 and above
0.15, which is believed to be caused by dissociation of the complex. While the
investigations detailed on page 152 showed that the quality of the purification is not
appreciably aﬀected by variations in ionic strength, the purpose of the experiments
presented here was to investigate the eﬀect of ionic strength on the solution structure of
the C1 complex purified by the novel method developed in this work.
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Figure 4.15: The eﬀect of increasing concentrations of NaCl on SEC-purified C1. In the absence of
NaCl, purified C1 appears to contain larger aggregates in addition to numerous smaller particles. In
the presence of 150–1M NaCl, the size distribution is monomodal. However, the width of the
distribution indicates that the sample may contain diﬀerent populations of particles. These may be
contaminants or diﬀerent states of association of the C1 complex.
When SEC-purified C1 is buﬀer exchanged into a low ionic strength buﬀer (10mM Tris,
pH7.4), the size distribution of the particles in solution is broad and bimodal,
indicating that C1 is associating to form higher-order aggregates (see Figure 4.15). In
contrast, when the buﬀer contains NaCl at 100mM or greater concentrations, the size
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distribution becomes narrower and monomodal. A more detailed analysis is shown in
Table 11. We can see that three distinct size distribution profiles emerge depending on
the ionic strength of the sample buﬀer. When no additional salt is present in the buﬀer,
the protein population is polydisperse (PdI = 0.342), showing a bimodal distribution
with a Z-average size by intensity of around 96nm. In the presence of physiological salt
concentrations (100–200mM), the particle distribution becomes monomodal (mean PdI
= 0.199) and the mean Z-average size decreases to around 80nm. Finally, at high ionic
strength (0.5–1M salt), the mean Z-average size increases slightly to around 86 nm,
while the polydispersity remains essentially unchanged (mean PdI = 0.200).
Range NaCl (M) PdI Z-Average (d.nm)
Low 0 0.342 95.73
Physiological
0.10 0.190 80.67
0.15 0.205 80.16
0.20 0.201 80.38
High
0.5 0.205 86.26
1 0.195 85.29
Table 11: The eﬀect of ionic strength on the size and distribution of SEC-purified C1 by DLS.
Three diﬀerent states can be determined. In a low ionic strength buﬀer at pH7.4, the sample is
polydisperse with a Z-average size of around 95nm. In the presence of physiological salt
concentrations, the Z-average size decreases to 80nm and the polydispersity also decreases. At
high ionic strength, the Z-average increases again to around 85nm, while the polydispersity remains
the same.
Overall, the results here show that increasing the ionic strength does not cause the C1
complex to disassemble. Instead, at salt concentrations that fall outside the
physiological range, complement component C1 appears to have an increased
hydrodynamic radius. At low ionic strength, the combination of an increased average
size and high sample polydispersity suggest a tendency towards aggregation. However,
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at high ionic strength the polydispersity does not parallel the increase in average size.
This suggests that the population of molecules is relatively homogeneous and therefore
any changes in the apparent size of particles may be attributed to shape eﬀects
resulting from conformational changes within the molecule in response to the elevated
ionic strength of the surrounding medium.
The results of these investigations on purified C1 also explain why similar
amounts of C1 were recovered during purification using buﬀers of diﬀerent ionic
strengths (section 4.3.2.3, p. 152): if C1 were dissociating in high or low salt buﬀers we
would expect less material to be recovered, but this is not the case. Taken together
these observations are consistent with the results published by Lepow et al., 1958 and
Colten et al., 1968 and suggest that the reported decrease in activity at ionic strengths
below 0.1 and above 0.15 does not result from dissociation of the complex as previously
assumed. Instead, the decrease in C1 function must be caused by some other
mechanism, for example conformational changes making the catalytic core less
accessible or distorting the serine protease domains to render them inactive. 
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4.5.2  The eﬀect of EDTA on SEC-purified C1
The addition of 8–50mM EDTA is known to dissociate C1 into its individual sub-
components (Lepow et al., 1963; Peitsch et al., 1988). In order to determine the eﬀect
of EDTA on C1 purified by the optimised SEC procedure (as outlined in section 4.3.2,
p. 146), an aliquot of the purified complex was subjected to analytical SEC in the
presence of excess EDTA (50mM) in the sample and elution buﬀer. It was observed
that very little protein eluted from the column when EDTA was included in the buﬀers,
indicating that the sample had precipitated to a large extent. As a control, a much
smaller quantity of starting material was loaded when using physiological calcium
concentrations in the sample and elution buﬀers. The results are shown in Figure 4.16.
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Figure 4.16: The eﬀect of EDTA on SEC-purified C1 by analytical SEC. A sample of purified C1
was subjected to further size exclusion chromatography under physiological conditions (10mM
MOPS, pH7.4. 150mM sodium chloride). The buﬀer additionally contained either 2mM calcium
chloride (solid line) or 50mM EDTA (dashed line). Diﬀerent amounts of sample were loaded on to
the column to give a similar amount of eluting protein. When calcium is present, purified C1 elutes
as a single peak at around 12ml. In the presence of 50mM EDTA the peak is shifted to around
10 ml, which suggests an increase in molecular weight.
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The peak is clearly shifted to the left when EDTA was included in the sample buﬀer,
indicating that aggregates are forming. This would explain the observed decrease in
protein eluting from the column, since larger aggregates will be trapped by the in-line
filters during the chromatography run. In order to confirm that the protein particles are
indeed aggregating and to determine the eﬀect of diﬀerent EDTA concentrations on
SEC-purified C1, the sample was further analysed by DLS. The results of these
analyses are shown in Figure 4.17, which clearly shows that increasing concentrations of
EDTA cause aggregation of the sample.
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Figure 4.17: The eﬀect of EDTA on SEC-purified C1 by DLS. The C1 complex was purified in
MOPS, pH7.4, 150mM NaCl, 2mM calcium chloride and titrated with 100mM EDTA, pH7.4.
The plot shows that the Z-average size increases with increasing EDTA concentration, indicating
that EDTA induces the aggregation of C1 purified by this method.
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4.5.3  Divalent metal cations, pH and SEC-purified C1
Complement component C1 requires calcium for structural stability and functional
activity, but other divalent metal cations have also been shown to promote the
assembly of a functional complex (Ziccardi, 1983). These studies were carried out at
physiological pH and using a range of metals from the first transition period of the
periodic table.
Substance Concentration (approx.)
Total protein 60–80mg/ml
albumin 35–55mg/ml
globulins 25–35mg/ml
fibrinogen 2–4mg/ml
Sodium 135–145mM
Potassium 3.5–5mM
Calcium
total
ionised
2–3mM
1mM
Magnesium 0.5–1mM
Iron 25–200µM
Copper 10–25µM
Zinc 10–20µM
Table 12: Reference ranges for common substances in human plasma. The typical ranges are given
for abundant serum proteins and common metal ions.
Table 12 shows the most prevalent metal ions in human blood plasma, including
calcium, magnesium, copper and zinc. Calcium and zinc were shown to promote C1
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formation, while magnesium was ineﬀective and copper was not included in the study.
Copper is an essential nutrient and plays an important role in oxidative defence.
Excessive or deficient copper levels have been implicated in various diseases and the
concentration of copper is apparently increased at sites of infection or inflammation
(Uriu-Adams and Keen, 2005). Furthermore, it is generally accepted that the pH drops
at local sites of infection or inflammation, which may in turn aﬀect proteins at the site
and their interactions. In order to investigate the eﬀect of physiologically relevant
cations on C1, the purified sample was analysed by DLS in the presence of calcium,
magnesium, zinc and copper at both neutral and acidic pH.
4.5.3.1  SEC-purified C1 at physiological and acidic pH
C1 function is reported to be greatly aﬀected by pH (Lepow et al., 1958): the complex
appears to possess optimum activity at physiological pH, with a sharp decrease in
activity below pH6.5 and above pH8.5. Whether this is due to conformational or
chemical changes that render the complex inactive, or due to disruption of the complex
is unknown at present. When the SEC-purified sample was exchanged into a low pH
buﬀer (10mM MES, pH 5.5), no dramatic changes were observed in the size
distribution profile, as can be seen from the data in Table 13. This suggests that C1
does not dissociate at low pH and that a decrease in function may be explained by
conformational changes within the molecule.
Sample Z-Average (d.nm) PdI
pH7.4 80.16 0.205
pH5.5 83.64 0.203
Table 13: SEC-purified C1 at physiological and acidic pH. The slight increase in Z-average size at
pH5.5 compared with pH7.4 may correspond to conformational changes in C1.
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4.5.3.2  Divalent metal cations at neutral and acidic pH
a)  Calcium, magnesium and zinc at pH7.4
The iron in human blood is primarily found associated with proteins such as
haemoglobin or the iron transport protein transferrin, while copper is mainly bound by
ceruloplasmin. Consequently, the most common free divalent metal cations in human
blood plasma are calcium, magnesium and zinc. These were investigated for their eﬀects
on purified C1 under physiological conditions and the results are shown in Figure 4.18
and Table 14.
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Figure 4.18: Size distribution of SEC-purified C1 in the presence of various metal ions at pH7.4.
The control sample shows a broad peak in the size distribution, showing that it contains a wide
distribution of particle sizes with a Z-average of around 70 nm. In the presence of physiological
concentrations of calcium, magnesium and zinc, the particle distribution is multimodal with three
distinct populations.
In the absence of any metal ions, the sample contains a wide distribution of particle
sizes, with a Z-average of around 70nm. When physiological concentrations of calcium,
magnesium and zinc are added to the C1 sample, the particle distribution becomes
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multimodal, revealing three distinct populations. In the presence of magnesium,
aggregates of around 300nm are observed, in addition to the more numerous 40nm
particles (which are presumably the native C1 complex). The addition of calcium and
zinc, on the other hand, results in the formation of 500nm particles. 
Additive Z-Average (d.nm) PdI Pk 1 Mean Int (d.nm) Pk 2 Mean Int (d.nm)
None 69.91 0.239 93.99 -
Magnesium 47.73 0.388 42.08 310.9
Calcium 44.57 0.363 44.44 540.6
Zinc 48.17 0.322 49.44 525.0
Table 14: The eﬀect of calcium, magnesium and zinc on SEC-purified C1. When physiological
levels of various metal ions are added to the C1 complex purified by SEC, two distinct populations
are observed in the intensity distribution. The smaller particles appear to be around 40–50nm in
diameter, while the size of the larger particles appears to vary with the nature of the metal ion. In
the presence of magnesium, particles of approximately 300nm are seen, while the addition of
calcium or zinc gives 500nm particles.
These results appear to indicate that the size distribution of SEC-purified C1 is aﬀected
in diﬀerent ways by calcium, magnesium and zinc at physiological pH. However, this
may not necessarily be the case. Since the majority of the particles in the sample
correspond to C1 (with a mean size by number of around 40nm) it is possible that the
larger particles observed in the intensity distribution are simply aggregating
contaminants.
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b)  Calcium and copper at pH5.5
At sites of infection or inflammation, where C1 is likely to be found in vivo, the
concentration of copper is thought to increase, accompanied by a decrease in pH of the
local environment. Since this may have some bearing on the structure and function of
C1, purified C1 was investigated by DLS in the presence of physiological concentrations
of copper and calcium at pH5.5. The results of these experiments are illustrated below
in Figure 4.19.
The size distribution profile of SEC-purified C1 in the presence of calcium
remains similar to that observed at pH7.4. However, in the presence of copper, very
large aggregates were observed. Copper forms an insoluble hydroxide in aqueous
solutions which limits free Cu2+ concentrations to the order of 100 μM, but hydroxide
formation is slow and can require hours to equilibrate (Hidmi and Edwards, 1999). As a
further measure to prevent contamination with insoluble particles, copper solutions
were filtered before being added to C1.
As with the previous studies on calcium, magnesium and zinc, the possibility
that these are merely aggregates of contaminating proteins cannot be ignored. However,
the possibility that the conditions of increased copper concentration and low pH induce
aggregation of C1 is intriguing, and worth further investigation.
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Figure 4.19: Size distribution of SEC-purified C1 in the presence of calcium and copper at pH5.5.
At acidic pH, in the presence of physiological concentrations of calcium ions, the purified C1
sample shows a bimodal distribution of particle sizes, with peaks at 39nm and 366nm. In the
presence of 10 µm copper chloride or copper sulphate, large aggregates were observed.
4.5.4  Melting point of SEC-purified C1
Finally, the eﬀect of temperature on C1 purified by SEC was investigated by DLS in
order to determine the melting point of the protein complex. This information may be
useful in designing a crystallisation strategy, where temperature may be included as a
variable. The results of these investigations are shown in Figure 4.20, and the melting
temperature of the C1 complex is estimated to be around 40 °C.
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Figure 4.20: Melting point determination of SEC-purified C1. A sample of the pooled C1 peak was
heated slowly to 75°C and three individual DLS measurements were recorded at 5 °C intervals.
Z‑average (black) and intensity (magenta) are shown against temperature, and the melting point
as determined by the Zetasizer Nano software is indicated by the blue line. At temperatures below
40°C the Z-average and intensity remain constant, while above 40°C they increase exponentially,
indicating the presence of thermally denatured aggregates.
190
4.6  Crystallisation of C1 purified by SEC
Finally, complement component C1 that had been purified by the two step method
outlined in section 4.3.3 was subjected to numerous crystallisation trials (see p. 130 for
method). Initial attempts at crystallising the SEC-purified C1 complex began
immediately the results of crystallisation attempts using partially purified C1 are
described below.
4.6.1  Pre-crystallisation test
A pre-crystallisation test (PCT™) is available (Hampton Research, USA), which gives a
useful indication of which protein concentrations are suitable for crystal screening
purposes. Essentially, the test contains two reagents, one with a salt as the primary
precipitant and one with a PEG as the primary precipitant. Furthermore, the two
reagents are formulated at both a high and a low concentration, giving a total of four
conditions. By examining the behaviour of the target protein under these conditions,
protein concentrations which could produce an overabundance of unfavourable
crystallisation conditions (such as clear drops or heavy precipitate) can be avoided. The
PCT™ was used to determine the best concentration range for the SEC-purified C1
complex to be used in crystallisation trials.
The results of the PCT™ indicate that only the lowest concentration of C1
tested, 250 µg/ml, is immediately suitable for crystallisation trials. The results also
show that crystallisation is unlikely to occur at concentrations approaching 10mg/ml.
The results of the intermediate concentrations are ambiguous. In this case, it is
recommended that the sample be tested to determine purity and homogeneity.
While C1 purified by this method appears to be relatively pure by native and
SDS-PAGE (see section 4.4.1), the DLS data (see section 4.4.3) indicate that the
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sample is heterogeneous and this is confirmed by the results of MS analysis, which show
the presence of various contaminants (see section 4.4.2). Nonetheless, many proteins are
known to crystallise from relatively crude preparations: a famous example being
aldolase, which readily crystallises from homogenised rabbit muscle preparations
(TAYLOR et al., 1948). Furthermore, when examining only those PCT™ conditions
containing ammonium sulphate as the primary precipitant, it appears that protein
concentrations between 0.25–1mg/ml are entirely suitable for crystallisation. By
contrast, C1 purified by size exclusion chromatography precipitated in all conditions
containing PEG 4000 as the primary precipitant. This is hardly surprising given that
the purification procedure exploits the ability of low concentrations of PEG 4000 to
precipitate the protein from human serum.
Protein
concentration
(mg/ml)
A1 A2 B1 B2 Result
10 Amorphous Amorphous Granular Amorphous Dilute sample
1 Granular Amorphous Clear Amorphous Diagnostictesting
0.5 Granular Amorphous Clear Amorphous Diagnostictesting
0.25 Clear Amorphous Clear Granular Perform screen
Table 15: Results of the pre-crystallisation test on SEC-purified C1 at various protein
concentrations. All conditions contain 0.1M Tris hydrochloride pH8.5. A1: 2.0M Ammonium
sulphate; A2: 0.2M Magnesium chloride hexahydrate, 30% w/v Polyethylene glycol 4,000; B1:
1.0M Ammonium sulphate; B2: 0.2M Magnesium chloride hexahydrate, 15% w/v Polyethylene
glycol 4,000.
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The diﬀerent eﬀects of salts and PEGs on C1 can be explained by their diﬀerent eﬀects
on protein stability and solubility (see section 2.4.1.1). Based on the results of the
PCT™, one can predict that the C1 complex may be more responsive to crystallisation
conditions where a salt is used as the primary precipitant, as opposed to PEGs, since
commercially available crystallisation screens are typically formulated with high PEG
concentrations. However, it is still unclear how diﬀerent molecular weight PEGs or
other organic polymers will aﬀect the solubility of C1, or how it will behave using salts
as the primary precipitants. In light of the findings outlined above, initial crystallisation
screening with SEC-purified C1 was carried out at three protein concentrations —
ranging between 0.3 and 1mg/ml — using a variety of commercial and home-made
screens. The results of these investigations are described in the next section and
additional information can be found in Appendix I, section iii.
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4.6.2  Crystallisation kit for protein-protein complexes
The Crystallisation Kit for Protein-Protein Complexes (Sigma-Aldrich Company Ltd.,
UK) is a sparse-matrix screen that was developed to reflect the most probable
conditions for the crystallisation of protein complexes, based on a survey of the Protein
Data Bank and the BMCD (Radaev et al., 2006). Accordingly, the screen heavily
favours PEGs as the primary precipitants — as opposed to salts — since the results of
the survey suggest that these conditions are more amenable to the crystallisation of
protein complexes. Of the 48 conditions in the screen, approximately 80% contain PEG
as the main precipitant. The results of the initial screens are shown in Table 16.
As predicted by the PCT™, the results of the initial screen show that the C1
complex is much more soluble in conditions containing a salt as the primary
precipitant. Even at the maximum protein concentration tested, precipitate was only
observed in two thirds of the salt-containing conditions. In contrast, at protein
concentrations above 0.3mg/ml, C1 precipitated in all conditions that contained PEG
as the primary precipitant. The results also appear to indicate that a protein
concentration of 0.3mg/ml is not suﬃcient to produce an appropriate degree of
supersaturation in the crystallisation drop, since not one of the conditions yielded
precipitated protein.
Concentration (mg/ml) Salt conditions PEG conditions
0.3 0/9 0/39
0.5 1/9 39/39
1 6/9 39/39
Table 16: The number of conditions in which SEC-purified C1 was observed to precipitate at
various proteins concentrations. The primary precipitant is indicated as either salt or PEG.
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The observed diﬀerences between using salts and PEGs as the primary precipitant can
be explained by their distinct eﬀects on protein stability and solubility, discussed in
section 2.4.1.1. Given the observed diﬀerential behaviour of the C1 complex according
to precipitant class, it would be reasonable to screen these two diﬀerent classes of
precipitants using two diﬀerent protein concentration ranges. A concentration of
0.5 – 10mg/ml appears to be suitable for crystallisation conditions containing high salt
concentrations, while 0.3–0.5mg/ml appears to be suitable for crystallisation where
PEGs or other organic polymers are the main precipitants.
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4.6.3  Stura Footprint Screen
The Stura Footprint Screen provides an alternative approach to screening
crystallisation space using sparse matrix screens, which typically consist of empirically
selected conditions that have been previously successful in crystallising various known
proteins. Instead, the Stura Footprint Screen relies on testing the relative protein
solubility against various common precipitants in a systematic fashion. Again, the
screen is based on previously successful crystallisation conditions, which have been
expanded into a format that allows systematic screening of the protein–precipitant
solubility curve. The screen mainly contains PEGs as the primary precipitant. While
the conditions in the Stura Footprint Screen are also empirically determined, the results
of the screen may present a more detailed picture of the solubility of the protein of
interest under a range of conditions.
SEC-purified C1 was tested at a concentration of 0.4mg/ml. This concentration
was chosen based on the results of the Crystallisation Kit for Protein-Protein
Complexes, which indicates that a C1 concentration between 0.3–0.5mg/ml is likely to
precipitate an intermediate number of conditions when PEG is used as the primary
precipitant. After one month, 4/48 conditions had precipitated, while the rest remained
clear, and no further changes were observed thereafter. This indicates that the
concentration of protein used may be too low and that successful crystallisation of C1
may require protein concentrations in excess of 0.4mg/ml.
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4.6.4  Structure Screen 1 & 2
Structure Screen 1 & 2 (Molecular Dimensions, UK) are classic sparse matrix screens,
which include successful crystallisation conditions from previously published works. The
screens were designed for typical globular proteins, rather than protein complexes, and
thus feature a greater diversity of conditions containing salts as the major precipitant
than the previously tested Crystallisation Kit for Protein-Protein Complexes.
C1 was tested at a slightly increased concentration of 0.5mg/ml, and numerous
conditions produced large, three-dimensional crystals. However, on testing using the
various methods described in section 2.4.2.3, these were largely revealed to be salt
crystals. Nevertheless, several other interesting conditions could be identified and these
are shown in Table 17.
Reference Precipitants Buﬀer Additive Result
SS1–27 1.5M lithium
sulphate
0.1M HEPES pH7.5 n/a Phase separation
SS1–35 30% w/v PEG 4000
0.2M lithium
sulphate
0.1M Tris pH8.5 0.2M lithium
sulphate
Phase separation
SS2–6 1M lithium sulphate 0.1M Tris pH8.5 0.01M nickel
chloride
Phase separation
SS2 -27 25% v/v PEG MME
550
0.1M MES pH6.5 0.01M zinc
sulphate
Crystals
SS2–38 30% v/v PEG 400 0.1M sodium acetate
pH4.6
0.1M cadmium
chloride
Phase separation
SS2–39 30% w/v PEG MME
2000
0.1M sodium acetate
pH4.6
0.2M ammoni-
um sulphate
Phase separation
Table 17: Table of hits from Structure Screens 1 & 2 using SEC-purified C1. These conditions
were identified as being possible conditions for optimisation of C1 crystallisation using variables
such as protein concentration, precipitant concentration and pH. The primary precipitant, buﬀer
and any additives for each hit condition are indicated.
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Phase separation is often an indication that the conditions within the crystallisation
experiment are close to those required for crystallisation. In contrast to the other
crystals observed in these screens, those obtained using 25% PEG MME 550 in 0.1M
MES pH6.5 and 0.01M zinc sulphate were easily destroyed by mechanical stress,
indicating that these may indeed be protein crystals. This was further supported by the
observation that the crystals appear to be growing from the surrounding protein
precipitate, with clearly visible halos of depleted precipitate around the nascent
crystals, as shown in Figure 4.21.
Figure 4.21: Crystals apparently growing from precipitated protein in the crystallisation drop. The
crystallisation conditions were 25% PEG MME 550 in 0.1M MES pH6.5 and 0.01M zinc sulphate.
Two morphologies can be distinguished: cubic crystals with interior faces (top) and irregular
quatrefoils (bottom). Despite appearing to grow from precipitated protein, the crystals, if they
diﬀracted at all, showed diﬀraction patterns characteristic of salt crystals. 
A number of crystals were tested for diﬀraction. The mother liquor vitrified on flash
freezing, meaning that no additional cryoprotectant was necessary. As can be seen from
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Figure 4.21, the crystals appeared in two distinct morphologies: cubic crystals with
interior faces; and irregular quatrefoils. After numerous sacrifices, one quatrefoil was
successfully split into its four separate lobes. Each lobe was mounted individually, and
three of the cubic crystals were also tested. Unfortunately, the crystals either did not
diﬀract at all, or at best produced a few strong, widely spaced reflections, which is
characteristic of the diﬀraction pattern of salts. The depleted salt concentration in the
vicinity of the crystals may increase the solubility of the protein in this region,
explaining the halos.
Optimisation of the crystallisation conditions in terms of precipitant
concentration and protein concentration did not produce any improvement in crystal
diﬀraction. Screening around the other interesting conditions identified in the screens
also failed to produce any further protein crystals. Since the C1 complex purified by
SEC alone still contains various contaminating proteins, it may be that these are
preventing C1 from crystallising. So, the next step in the search for crystals of native
complement component C1 was to attempt to further purify the complex to remove any
remaining contaminants.
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4.7  Further purification by ion exchange 
chromatography
All attempts to crystallise C1 purified by size exclusion chromatography using the
optimised procedure (see section 4.3.3) were unsuccessful. In a bid to improve the
chances of crystallisation by removing the remaining contaminants, C1 was further
purified by ion exchange chromatography. As previously described, IEX separates
proteins according to their net surface charge. Charged proteins bind reversibly to the
oppositely charged IEX medium: a protein with pI < pH will bind to a an anion
exchanger, while when pI > pH, the protein will behind to a negatively charged cation
exchanger. For C1, the predicted pI is 7.2, so under physiological pH (7.4) the complex
is predicted to have a slight negative charge and will thus bind to an anion exchanger
such as Mono Q™.
Figure 4.22 shows the separation of the SEC-purified C1 into three major
fractions by IEX. The first peak contains unbound proteins, which appears to be
various contaminants, while intact C1 appears to elute in peak B. The corresponding
SDS-PAGE gel shows two clear bands at around 75kDa (C1r and C1s) as well as a
faint triplet at around 25kDa (C1q). There are also two weaker bands at around
50 kDa, which may be traces of the contaminants that did not bind to the column.
Alternatively these could be the heavy fragments of cleaved C1r and C1s (51 and
47 kDa, respectively), with the light fragments (27 and 28kDa) being almost
indistinguishable from the various C1q chains. The third peak shows a similar pattern
of bands to the C1 peak, although the bands diﬀer in intensity, with the band
corresponding to C1s appearing more prominent and C1r and the C1q triplet appearing
much weaker.
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Figure 4.22: Further purification of C1 using a Mono Q IEX column. The starting buﬀer (buﬀer A)
is the same as that used for the elution of C1 in the previous chromatography step, while a high-
salt buﬀer (buﬀer B) is used to elute bound proteins from the column. An SDS-PAGE gel
corresponding to the three peaks collected is also shown. Buﬀer A: 10mM Tris pH7.4, 150mM
sodium chloride; buﬀer B: 10mM Tris pH7.4, 1M sodium chloride. A. Unbound proteins. B. Intact
C1 complex. C. Unknown.
In the chromatogram, the two peaks are not fully resolved, so a likely explanation for
the observed results is that peak C contains a small amount of the tail end of peak B,
while predominantly containing an unrelated ~75kDa protein. An alternative
explanation is that the second peak contains a glycosylated form of C1. Glycosylation
can aﬀect the staining of proteins by Coomassie dyes (Darren Thompson, personal
communication), so diﬀerent degrees and types of glycosylation of the C1 complex
could explain the observed diﬀerences in the intensity of the bands between the two
fractions. Alternatively, the third peak may contain some combination of C1r and C1s,
for example the C1r2C1s2 tetramer, which may exist independently of C1q (Arlaud et
al., 1980).
It has previously been shown that the C1 complex dissociates when purified by
ion exchange chromatography in the presence of 10mM EDTA (Lepow et al., 1963). In
an attempt to purify the complex further, the Mono Q separation was performed again
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at pH8 using 10mM EDTA in the loading and elution buﬀers, and the results are
shown in Figure 4.23. In addition, the gradient was modified in an attempt to get a
better separation of the two peaks of interest. As can be seen from the gel, the
separation of C1 from the 50kDa contaminants is much cleaner: the ~50kDa bands are
found exclusively in the unbound fraction, for example.
0 10 20 30 40
Elution volume (ml)
0
20
40
60
80
100
A
b
s
o
rb
a
n
c
e
 (
m
A
U
)
0
20
40
60
80
100
%
 B
A B C
250
150
100
75
50
37
25
20
15
A
B
C
Figure 4.23: A modified further purification of C1 using a Mono Q IEX column. In this experiment,
the pH was increased and the gradient was held as each peak began to elute. Again the SDS-PAGE
gel corresponding to each peak is shown. Buﬀer A: 10mM Tris, pH8, 150mM sodium chloride,
10mM EDTA; buﬀer B: 10mM Tris, pH8, 1M sodium chloride, 10mM EDTA. A. Unbound
proteins. B. Intact complement component C1. C. Unknown. The results show that the separation
is dramatically improved using this modified method, as the eluted peaks contain fewer
contaminating proteins.
The improved separation appears to be a consequence of modifying the pH and the
shape of the elution gradient, rather than the inclusion of EDTA in the loading and
elution buﬀers. In fact, the presence of EDTA does not appear to disassemble the
complex, as expected. This observation is further supported by the results of dynamic
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light scattering studies, as described in section 4.4.3 and section 4.9.3. Further
purifications involved the use of longer step-gradients to give optimal separation of the
individual protein peaks (data not shown).
203
4.8  Summary: Purification by SEC and IEX
After a first purification step using SEC (see p. 125 and 157), fractions containing C1
are pooled and exchanged into 10mM Tris, pH8, 150mM NaCl, before being applied to
a Mono Q™ 5/50 GL column equilibrated with the same buﬀer. Unbound proteins are
washed away and the bound proteins are eluted with a step-gradient of buﬀer B
(10mM Tris, pH8, 500mM NaCl). Two major peaks elute from the column, at 18%
and 23% concentration of buﬀer B. When the corresponding fractions are analysed by
SDS-PAGE, the first peak appears to contain all components of the C1 complex, while
the second peak appears to contain two proteins of approximately 75kDa. These may
represent a contaminant, a diﬀerently glycosylated form of C1, or possibly the C1r2C1s2
tetramer.
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4.9  Characterisation of Mono Q-purified C1
In order to investigate the results of separating SEC-purified C1 by anion exchange
using Mono Q, the two eluting peaks were subjected to analysis by a number of
complementary methods. Since the aim of this project is to obtain native C1 in a form
suitable for use in crystallisation trials, the techniques employed were chosen to
determine as clearly as possible whether the purified product obtained is indeed C1,
and whether it is pure and structurally homogeneous. This following section describes
the results of these investigations, and indicates that the quality of purified C1 has
been improved by using IEX as a second chromatography step in the purification
procedure. 
4.9.1  SDS-PAGE analysis of Mono Q-purified C1
Since native agarose gel electrophoresis does not yield any additional useful information
to that obtained by SEC, the characterisation of Mono Q-purified C1 by electrophoretic
methods was restricted to SDS-PAGE. In addition to being able to resolve individual
polypeptide chains in a sample, the separation can be performed with or without
reducing agent, which can give information about the presence of any disulphide bonds.
The detergent in the sample buﬀer causes proteins to unfold into linear polypeptide
chains. However, in the absence of reducing agents, any chains linked by disulphide
bonds will remain associated. Native C1 contains numerous disulphide bonds within
and between the individual components of the complex. Since investigations of reduced
and oxidised C1 that had been purified only by SEC yielded unusual results (see section
4.4.1.2), analysis of the Mono Q-purified C1 was also carried out in the presence and
absence of the reducing agent BME. The results are shown in Figure 4.24.
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Figure 4.24: Oxidised and reduced SDS-PAGE gels of the two major peaks eluting from a MonoQ
separation of SEC-purified C1. A. Samples run in the absence of a reducing agent show mainly
high-molecular-weight-aggregates, some of which did not fully enter the gel, as well as a faint band
at around 75kDa in Peak 2. B. The same samples run in the presence of BME show that Peak 1
contains all the C1 sub-components (C1r and C1s at ~75kDa; C1q at ~25kDa), as well as some
high-molecular-weight aggregates, while Peak 2 contains a protein of approximately 75kDa.
The results show that C1 further purified by IEX behaves comparably to C1 simply
purified by SEC alone when subjected to SDS-PAGE in the absence of reducing agent.
Two bands at approximately 150 and 250kDa are observed, which are also seen with
reduced intensity under reducing conditions. Interestingly, these are close to the
predicted molecular weights of dimers composed of C1r and/or C1s (~150kDa) and the
C1r2C1s2 tetramer (~300kDa). The bands may simply be contaminants, or they may
represent disulphide-linked forms of the C1r and C1s components.
In addition, the results show that there is unlikely to be any intact C1 at all in
the second peak eluting from the Mono Q column. A single ~75kDa band is seen under
reducing conditions and is also faintly visible when the sample remains oxidised. This
indicates that the unknown protein is linked by disulphide bonds to form a complex
that is too large to enter the gel.
206
4.9.2  Peptide mass fingerprinting of MonoQ-purified C1
Solution samples of the two major peaks eluting from further purification of C1 by
anion exchange were submitted for peptide mass fingerprinting (see page 127). The aim
of these investigations was to determine the nature of the proteins eluting from the
Mono Q anion exchange column during the final purification stage. Since each peak is
likely to contain only a few proteins — and in order to minimise handling and exposing
the samples to sources of contamination — peptide mass fingerprinting and MS/MS
analysis were carried out directly on the solution samples.
The samples contain most of the same contaminating proteins identified
previously in SEC-purified C1 (keratins, immunoglobulins and other abundant serum
proteins). However, of 44 proteins identified with a minimum probability of 99.99%,
15 were complement-related proteins. C1r and C1s were conclusively identified in both
major peaks eluting during the final purification, while C1q was only detected in the
first peak. Complement-related proteins identified in Mono Q-purified C1 and their
distribution between the two peaks are shown in Table 18 and Figure 4.25.
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Table 18: Complement-related proteins identified in Mono Q-purified C1. The table shows the
complement-related proteins identified in each peak eluting from the final purification step. The
molecular weight, protein identification probability and peptide sequence coverage is indicated for
each protein identified in the sample. C1r and C1s are present in both peaks, while C1q was
detected in the first peak only.
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2 11 3
Peak 1 Peak 2
Figure 4.25: Venn diagram showing the distribution of unique, complement-related serum proteins
between the two major peaks eluting from Mono Q purification of complement component C1.
Minimum protein probability: 50%; minimum peptide probability: 95%. Proteins detected in peak 1
but not in peak 2 were: complement factor H and C1q. Proteins in peak 2 but not peak 1 were:
galectin 3-binding protein, complement component C9 and mannan-binding lectin serine protease 1
(MASP-1). 
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Figure 4.26: Quantitative analysis of C1 subcomponents and C1 inhibitor identified in the two
major peaks eluting from Mono Q purification of C1. The normalised spectrum count provides
quantitative information about relative abundances between samples. It is calculated by averaging
the number of identified spectra in each sample and then the number of spectra assigned to a
given protein is multiplied by the ratio of the average spectrum count to the number of spectra in
that sample. The first peak to elute from the Mono Q column gives a high normalised spectrum
count for C1-INH and C1r, with C1s and C1q detectable to a lesser extent. In the second peak to
elute, the normalised spectrum count of C1-INH and the various C1 subcomponents is decreased,
with C1q not detectable at all. This suggests that the first peak contains the native C1 complex,
while the second peak may contain smaller amounts of C1 (or the C1r2C1s2 tetramer).
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When the normalised spectrum count of C1 subcomponents in each peak is compared,
we see C1 appears to be enriched in the first peak, with C1q also present in the sample
(Figure 4.26). Apolipoprotein B-100 and complement component C3 appear to have
equal normalised spectrum counts across both samples, while the remaining proteins
are more abundant in the second peak (data not shown). These results, in combination
with the information from SDS-PAGE analyses, indicate the first peak contains
primarily the intact native C1 complex.
In the second peak the normalised spectrum count of the various C1
subcomponents is decreased, while C1q was not detected in the sample at all. This
suggests that the second peak may contain smaller amounts of C1 (or the C1r2C1s2
tetramer). However, C1q is known to be resistant to trypsinolysis (Reid, 1979; Tissot et
al., 2005), which may also explain the low abundance of C1q peptides. C1-inhibitor
(C1-INH) was also identified in both samples, with a similar normalised spectrum count
profile to C1r and C1s.
Two proteins could be identified with a minimum protein probability of 50% in
the first sample, but not the second. These were complement factor H and C1q.
Conversely, three proteins were detected in the second sample but not the first: galectin
3-binding protein, complement component C9 and mannan-binding lectin serine
protease 1 (MASP-1). The results suggest that the native C1 complex is enriched in the
first peak eluting from the final purification step, while the second peak contains mainly
contaminants.
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4.9.3  Dynamic light scattering of Mono Q-purified C1
The results outlined in section 4.4.3 show C1 purified by size exclusion chromatography
is polydisperse and shows two broad peaks in the size distribution by intensity. The
first peak is centred at approximately 45nm, which is close to the proposed diameter
(40nm) of the assembled C1 complex (Perkins, 1985). The second peak is at around
180nm. The majority of particles in the sample are the smaller, 45nm particles (for an
overview of interpreting DLS data, see section 2.3.3.2). Finally, the width of the
distribution indicates that there is likely to be a range of particle sizes, likely due to the
presence of various diﬀerent contaminants that could be removed by further purification
using ion exchange chromatography. The various fractions eluting from the Mono Q
column were analysed by DLS, and the results are shown in Table 19.
Sample PdI Z-average (d.nm) MW (kDa)
Unbound 0.317 17.63 548
Peak 1 0.292 27.16 1510
Peak 2 0.124 27.44 1540
Table 19: Dynamic light scattering analysis of the various fractions obtained by further purification 
of complement component C1 by IEX. 
The second peak eluting from the column is likely to contain the intact C1 complex, as
determined by SDS-PAGE and peptide mass fingerprinting. While the sample and
buﬀers were all filtered through a 0.2 µm filter during further purification by the Mono
Q method, purified C1 contains particles of around 200 nm that can be removed by
further filtration. The results of dynamic light scattering studies on purified C1 are
shown in Figure 4.27 and Table 20.
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Figure 4.27: Size distribution by intensity of Mono Q-purified C1. The unfiltered sample shows a
bimodal distribution, while the filtered sample shows a monomodal distribution, indicating that the
larger particles may be removed by filtering through a 0.2 µm filter.
The intensity plot of the unfiltered sample shows a bimodal size distribution, with the
majority of particles around 30nm in diameter and a small population of larger 200nm
particles, according to multimodal analysis. When the sample is filtered, the size
distribution becomes monomodal, with a Z-average size of 36nm.
Sample PdI PdI Width(d.nm)
Z-Average
(d.nm)
Pk 1 mean int.
(d.nm)
Pk 2 mean int.
(d.nm)
Unfiltered 0.252 59.55 118.6 28.94 192.4
Filtered 0.278 19.12 36.25 43.34 -
Table 20: DLS analysis of Mono Q-purified C1. The protein concentration was 0.1mg/ml in
10mM Tris, pH7.4, 150mM NaCl. The unfiltered sample shows a bimodal size distribution, with
the majority of particles around 30nm in diameter. By filtering the sample through a 0.2 µm filter,
the size distribution becomes monomodal. The results of cumulants and multimodal analysis
correspond, giving a particle size of around 40nm for Mono Q-purified C1.
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The results of cumulants and multimodal analysis are in close agreement (36.25nm and
43.34nm respectively) and the PdI width substantially decreases when the sample is
filtered, indicating that a single population of molecules is present in the sample.
However, the polydispersity remains high, which suggests that while the particles are of
relatively uniform size, some structural diversity still exists within the population of
purified C1 molecules.
213
4.9.4  Storage of Mono Q-purified C1
To test the eﬀects of storing C1 for a prolonged period of time, a freshly purified
sample was analysed by DLS and stored at 4 °C for 30 days. The sample was then re-
analysed and the results are shown in Table 21. It appears that C1 aggregates slightly
upon storage under the conditions tested. However, that the high-molecular-weight
material could be removed by filtration through a 0.2 µm filter. The resulting protein
solution was comparable to freshly purified C1 in terms of particle size and
polydispersity. Therefore C1 further purified by IEX can be stored at 4 °C for the
period of one month at least without significant degradation in sample quality, and any
aggregates can be simply removed.
Day Z-Average (d.nm) PdI
0 29.86 0.205
30 33.38 0.268
Diﬀerence + 3.52 + 0.063
Table 21: Eﬀect of storing Mono Q-purified C1 at 4°C. The protein was stored in 10mM Tris,
pH8, 150mM NaCl. After 30 days, a small increase in the Z-average size and the polydispersity
was seen, indicating some aggregation had occurred. However, the aggregates could be removed by
filtration to restore the original values.
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4.10  Mono Q-purified C1 under relevant conditions
Purified C1 (see section 4.8 for purification details) was investigated under various
conditions to determine the eﬀects of ionic strength, pH, and biologically relevant
divalent metal cations on the complex. The results of these experiments are described
in this section. These investigations were designed to complement the experiments
previously performed on SEC-purified C1 (see section 4.5), and formed the basis of
projects completed by other members of our laboratory.
4.10.1  The eﬀect of ionic strength on Mono Q-purified C1
Published reports suggest that the function of the C1 complex is aﬀected by changes in
the ionic strength of the surrounding medium due to dissociation of the complex at
high ionic strength (Lepow et al., 1958; Colten et al., 1968). However, the investigations
detailed in section 4.5.1 showed that ionic strength does not aﬀect the solution
structure of SEC-purified C1 as would be expected if C1 were dissociating at high ionic
strength. Distinct size distribution profiles emerge depending on the ionic strength of
the sample buﬀer.
When no additional salt is present in the buﬀer, SEC-purified C1 is polydisperse
with a Z-average size of around 96nm. In the presence of physiological salt
concentrations, the Z-average size decreases to around 80nm and the size distribution
becomes monomodal. At high ionic strength the Z-average size increases slightly to
around 86nm with no further change in polydispersity. These results suggest that
fluctuations within the physiological range of ionic strength do not appreciably aﬀect
the structure of SEC-purified C1, while extreme values caused the sample to aggregate,
rather than dissociate. It is not clear whether this eﬀect was due to the presence of
contaminants that were still present in the SEC-purified sample.
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Further purification by IEX removed several remaining contaminating proteins,
so Mono Q-purified C1 was analysed for comparison. The eﬀect of various salt
concentrations on the size distribution by DLS is shown in Table 22. Again, distinct
profiles emerge, although the diﬀerence between them is smaller. In the physiological
range, the sample has a Z-average size of around 40nm. At high ionic strength, this
increases slightly to around 42nm. From multimodal analysis, we can see that the
change in Z-average size corresponds to an increase in the mean size of the first peak in
the intensity distribution.
NaCl (mM) Z-Ave (d.nm) PdI Pk 1 Mean Int (d.nm)
150 40.99 0.375 36.28
200 40.08 0.365 35.99
300 40.09 0.367 35.03
500 41.68 0.374 36.86
1000 41.54 0.360 39.10
Table 22: The eﬀect of ionic strength on the size and distribution of Mono Q-purified C1 by DLS.
Distinct states can be determined, as for SEC-purified C1, except that the diﬀerence between them
is much subtler. In a low ionic strength buﬀer at pH7.4 and in the presence of physiological salt
concentrations, the sample is polydisperse with a Z-average size of around 40nm. At high ionic
strength, the Z-average increases to around 42nm.
These results suggest that high ionic strength does not in fact dissociate the C1
complex purified by the method outlined in section 4.8; a small increase in the size of
the 30–40nm particles is observed instead. Since these are the most numerous particles
in the sample, it is reasonable to conclude that the C1 complex is stable across the
physiological range of ionic strengths at pH7.4, while high salt concentrations cause a
slight increase in the hydrodynamic radius of the molecule. This may indicate a
conformational change, which could explain the loss of function described by others.
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4.10.2  The eﬀect of EDTA on Mono Q-purified C1
The addition of EDTA is known to dissociate C1 into its individual sub-components
(Lepow et al., 1963). Adding increasing concentrations of EDTA to SEC-purified C1
causes aggregation of the sample (see Figure 4.17, p. 183), although whether this is
caused by aggregation of the C1 complex or contaminating proteins remains unclear.
Since the majority of contaminating proteins could be removed by further purification
of the complex, the Mono Q-purified C1 was analysed in the presence of various EDTA
concentrations, and the results are presented in Figure 4.28, Figure 4.29 and Table 23.
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Figure 4.28: The eﬀect of EDTA on the size distribution by intensity of Mono Q-purified C1.
As can be seen from the intensity distribution, adding EDTA to purified C1 causes a
small amount of larger aggregates to form. At high EDTA concentrations (150mM),
some very small particles are observed, in addition to a similar distribution of 40nm
particles (which correspond to the proposed diameter of the native C1 complex). The
0.75nm particles observed in the presence of high concentrations of EDTA correspond
to a predicted molecular weight of 1.7kDa. This is extremely small, and thus does not
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suggest that C1 is dissociating into its individual subcomponents. These observations
are consistent with the results presented in for SEC-purified C1, but are in stark
contrast to published literature on the subject.
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Figure 4.29: The eﬀect of EDTA on the size distribution by volume of Mono Q-purified C1. When
the intensity distribution is transformed into a volume distribution, we see that the 0.75nm
particles make up 30% of the scattering matter in the sample at high EDTA concentrations. The
increase in volume at low EDTA concentrations is also more obvious.
EDTA
(mM) PdI
Z-Average
(d.nm)
Pk 1
intensity
(d.nm)
Pk 2
intensity
(d.nm)
Pk 1
volume
(d.nm)
Pk 2
volume
(d.nm)
0 0.278 36.25 43.34 886.2 23.56 -
25 0.358 42.95 50.47 534.6 26.60 -
50 0.335 39.90 47.06 378.1 26.87 -
150 0.431 43.34 53.64 500.4 0.7543 32.37
Table 23: The eﬀect of EDTA on Mono Q-purified C1. The sizes determined by volume rely on a
number of assumptions, and should be used as a guide only.
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4.10.3  Calcium and EDTA at acidic and neutral pH
To complement the studies on SEC-purified C1 (see section 4.5.3), Mono Q-purified C1
was analysed by DLS at acidic and neutral pH. In addition, the eﬀect of calcium and
EDTA under these conditions was investigated. The results of these experiments are
presented in this section.
4.10.3.1  Mono Q-purified C1 at physiological and acidic pH
When the Mono Q-purified sample was exchanged into a low pH buﬀer (10mM MES,
pH 5.5), no significant changes were observed in the size distribution profile. The results
of DLS analysis at physiological and acidic pH are shown in Table 24. Although the
Z‑average size appears to increase, in terms of volume the particles that constitute the
majority of the scattering content of the sample remain virtually identical in size at
both pH values. The function of the C1 complex is reported to be greatly aﬀected by
pH (Lepow et al., 1958), with a sharp decrease in activity below pH6.5. This may be
due to conformational changes that render the complex inactive, since C1 does not
appear to dissociate or aggregate significantly at pH5.5.
pH PdI Z-Average(d.nm)
Pk 1 intensity
(d.nm)
Pk 2 intensity
(d.nm)
Pk 1 volume
(d.nm)
5.5 0.448 50.33 44.13 260.6 27.30
7.4 0.377 45.52 42.41 332.2 27.95
Table 24: The size distribution profile of Mono Q-purified C1 at acidic and physiological pH. No
significant changes are observed between pH7.4 and pH5.5.
219
4.10.3.2  The eﬀect of calcium on Mono Q-purified C1
a)  Calcium and EDTA at pH7.4
When physiological concentrations of calcium are added to SEC-purified C1, the
particle distribution is multimodal: the more numerous 40nm particles correspond to
the proposed diameter of native C1, while larger 500nm particles may be aggregating
contaminants. Since these aggregates were likely removed by the subsequent purification
step, the eﬀect of calcium on Mono Q-purified C1 was determined at physiological pH.
After addition of 2mM calcium chloride to the sample (which corresponds to
physiological levels of calcium ions in human blood plasma), the sample was further
titrated with EDTA. The results of these investigations are presented in Figure 4.30
and Table 25. Physiological concentrations of calcium do not appreciably aﬀect the size
of purified C1 determined from the intensity distribution (42.41nm and 43.01nm for
the control and calcium samples, respectively). Adding EDTA to the sample produced
results comparable to those detailed on page 217.
0
5
10
15
20
0.1 1 10 100 1000 10000
V
ol
um
e 
(%
)
Size (d.nm)
Size Distribution by Volume
Control, pH 7.4
2 mM CaCl
2
2 mM CaCl2 + 2 mM EDTA
2 mM CaCl2 + 50 mM EDTA
Figure 4.30: Eﬀect of calcium and EDTA on the size distribution by volume of Mono Q-purified C1
at pH7.4. No appreciable changes are observed in the presence of 2mM calcium at physiological
pH. The addition of EDTA causes a slight increase in the mean particle size.
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Sample PdI Z-Average(d.nm)
Pk 1
intensity
(d.nm)
Pk 2
intensity
(d.nm)
Pk 1
volume
(d.nm)
Pk 2
volume
(d.nm)
Control 0.377 45.52 42.41 332.2 27.95 424.1
2mM CaCl2 0.331 42.78 43.01 362.1 26.89 484.9
2mM CaCl2
+ 2mM EDTA 0.419 53.50 43.89 305.2 27.32 389.8
2mM CaCl2
+ 50mM EDTA 0.357 68.02 52.39 384.3 31.08 489.5
Table 25: The eﬀect of calcium and EDTA on Mono Q-purified C1 at pH7.4. Adding physiological
concentrations of calcium to the sample does not aﬀect the size of the purified C1 complex, as can
be seen from the volume distributions.
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b)  Calcium and EDTA at pH5.5
The local environment at sites of infection or inflammation — where C1 is likely to be
found in vivo — is thought to be acidic, at around pH5.5. SEC-purified C1 does not
appear to be greatly aﬀected by physiological calcium concentrations at low pH, with
the size distribution profile remaining similar to that observed at pH7.4. For
comparison, the size distribution profile of Mono Q-purified C1 is shown in Figure 4.31
and Table 26. Physiological concentrations of calcium do not appreciably aﬀect the size
of purified C1 determined from the intensity distribution (44.13nm and 43.11nm for
the control and calcium samples, respectively), and these results closely correspond to
those obtained at pH7.4 (see page 220).
However, when the distribution is converted into a volume distribution, it
appears that there is a subtle increase in particle size on the addition of calcium, which
is not reversible by the subsequent addition of EDTA. In the absence of any additional
calcium, the C1 complex appears to have a hydrodynamic radius of around 27nm. On
the addition of 2mM calcium, this appears to increase to approximately 32nm, an
increase of 5nm overall. While this is an interesting finding, transforming the original
size distribution by intensity into a distribution by volume relies on a number of
assumptions, and amplifies any errors in the original analysis. Therefore, the solution
behaviour of purified C1 in the presence of various biologically relevant divalent metal
cations is worth further investigation. However, this was deemed a suitable point to
conclude these particular experiments within the context of the present work.
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Figure 4.31: Eﬀect of calcium and EDTA on the size distribution by volume of Mono Q-purified C1
at pH5.5. In the presence of physiological calcium concentrations, the mean size of the particles
appears to increase slightly. This change is not reversible by the subsequent addition of EDTA.
Sample PdI Z-Average(d.nm)
Pk 1
intensity
(d.nm)
Pk 2
intensity
(d.nm)
Pk 1
volume
(d.nm)
Pk 2
volume
(d.nm)
Control 0.448 50.33 44.13 260.6 27.30 296.7
2mM CaCl2 0.230 126.2 43.11 252.8 31.08 268.2
2mM CaCl2
+ 2mM EDTA 0.267 187.8 39.48 178.2 31.64 175.7
2mM CaCl2
+ 50mM EDTA 0.238 160.5 43.43 247.5 32.34 258.7
Table 26: The eﬀect of calcium and EDTA on Mono Q-purified C1 at pH5.5. The size distribution
by volume indicates a subtle increase in the size of the C1 particles on the addition of physiological
calcium concentrations at acidic pH. However, determining volume distribution relies on a number
of assumptions, and may not always be reliable.
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4.10.4  Melting point of Mono Q-purified C1
The final purified C1 sample was investigated by DLS in order to determine the melting
point of the protein complex, and the results of this experiment are shown in
Figure 4.32. The melting temperature of the C1 complex is estimated to be around
40°C, which corresponds to the melting temperature of SEC-purified C1. There appear
to be three distinct size distribution profiles, according to fluctuations in the Z-average
size and intensity. From 20–35°C, there are small fluctuations, while between 35–40°C
these fluctuations appear to diminish. Above 45 °C both size and intensity fluctuate
dramatically, indicating thermal denaturation of the C1 complex. This information may
be useful in designing a crystallisation strategy in the search for high resolution
structures of this key immune protein.
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Figure 4.32: Melting point determination of Mono Q-purified C1. The Z-average (red) and
intensity (green) are shown versus temperature and the melting point was determined by the
ZetaSizer Nano software as 24°C. However, a melting point around 40–45°C seems like a more
reasonable estimate and corresponds to the melting point determined for SEC-purified C1. There
appear to be three distinct regions of the graph. From 20–35°C, there are small fluctuations in the
Z‑average size and intensity. Between 35–40°C, the fluctuations appear to diminish, while above
45°C both size and intensity fluctuate dramatically.
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4.10.5  The eﬀect of Mono Q-purified C1 concentration
The physiological concentration of C1 is 0.14mg/ml, while crystallisation appears to
require concentrations around 1mg/ml. Mono Q-purified C1 was analysed by DLS at
two diﬀerent protein concentrations in order to determine the eﬀect of varying the
concentration on the size distribution of particles in the sample. This may be useful
information during crystallisation trials and any further solution experiments on the
purified complex. The results of these analyses are shown in Table 27.
Concentration
(mg/ml) Z-Ave (d.nm) PdI
Pk 1 Mean Int
(d.nm)
Pk 2 Mean Int
(d.nm)
0.1 40.99 0.375 36.28 327.3
1 36.17 0.280 35.99 455.2
Table 27: The size distribution of Mono Q-purified C1 at diﬀerent protein concentrations. At
physiological concentrations in a physiological buﬀer the sample is polydisperse, with a Z-average
size of 41nm. At 1mg/ml, the Z-average size decreases to 36nm and the PdI also decreases.
Higher protein concentrations apparently cause the sample to become more homogeneous, which
could be beneficial for crystallising the C1 complex.
At a protein concentration of 1mg/ml, the sample appears to be more homogeneous.
This is indicated by a lower PdI and Z-average size, which closely corresponds to the
results of multimodal analysis: 36.17 nm by cumulants analysis compared with
35.99 nm for the first peak in the intensity distribution. These results suggest that the
high protein concentrations used in crystallisation trials may be favourable for the
structural stability and homogeneity of the C1 complex.
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4.11  Crystallisation of Mono Q-purified C1
Complement component C1 that had been purified by the three-step method outlined
in section 4.8 was subjected to crystallisation trials. Since Structure Screen 1 & 2 had
given promising results for SEC-purified C1, these were the first conditions tested. The
results of these investigations are presented in the following section.
4.11.1  Pre-crystallisation test
Again, the PCT™ (Hampton Research, USA) was used to determine the best protein
concentration for crystallisation trials of the C1 complex further purified by Mono Q.
The results showed that the removal of contaminating proteins by IEX improves the
solubility of the sample. Concentrations of 1–5mg/ml were shown to be an appropriate
starting point for these crystallisation trials, much higher than the concentrations
indicated for C1 purified by SEC alone (0.25–1mg/ml).
4.11.2  Structure Screen 1 & 2
Since Structure Screen 1 & 2 had resulted in a few promising conditions with SEC-
purified C1, these were taken as a starting point for the crystallisation of the refined C1
preparation. Screens were set up using both 1 and 5mg/ml protein concentrations. The
results after one month at 4°C are summarised in Table 28. Out of a total of 96
conditions, around 40% resulted in clear drops for both protein concentrations, which is
ideal. While a corresponding 60% of drops resulted in precipitate or phase separation,
there was a considerable diﬀerence in the quality of the precipitates obtained with the
diﬀerent protein concentrations. At 1mg/ml most of the precipitate was classified as
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light or heavy amorphous precipitate, indicating denatured protein. In contrast, at
5mg/ml the majority of precipitates were scored as gelatinous precipitates, which are
likely to be more ordered aggregates.
Protein concentration
1mg/ml 5mg/ml
Clear 38 37
Precipitate 45 26
Gelatinous precipitate 13 32
Phase separation 1 1
Table 28: Structure Screen 1 & 2 crystallisation data for Mono Q-purified C1. The table shows the
number of drops observed in the various states described. The screens were carried out at 1mg/ml
and 5mg/ml concentrations of the C1 complex.
In addition, three conditions were observed that appeared to show aggregates or
crystals forming from precipitate at 5mg/ml protein concentration. These are
illustrated in Figure 4.33. All conditions feature a salt as the primary precipitant, which
reflects the results of crystallisation trials using SEC-purified C1 (see section 4.6). The
crystals were too small to be tested for diﬀraction, and further crystallisation of C1 was
not pursued due to time constraints on the project. While it is not certain that the
crystals obtained are indeed protein crystals, the results presented here will hopefully
form the foundations for further experiments in the search for high-resolution structures
of the native complement component C1.
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0.4M sodium tartrate
0.2M Magnesium formate
1.6M sodium citrate, pH6.5
Figure 4.33: Aggregates and crystals in screens of Mono Q-purified C1. The aggregates (top),
spherulites (middle) and crystal (bottom) appear to be growing from precipitated protein within the
crystallisation drop. All conditions feature a salt as the primary precipitant and are at close to
neutral pH.
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4.12  Discussion
The aim of the work on complement component C1 was to develop an optimised novel
purification scheme to isolate the native protein complex from human plasma, with an
emphasis on obtaining a highly pure and homogeneous purified product for use in
crystallisation trials. In addition, physiologically relevant conditions (including pH,
ionic strength, and divalent metal cations) would be tested for their eﬀect on the
structure of the complex by dynamic light scattering, and the crystallisability of
complement component C1 was to be explored.
Prior to the work described in this thesis, complement component C1 has been
purified by exploiting its aﬃnity for immunoglobulins or other ligands (Medicus and
Chapuis, 1980; Schiﬀerli and Steiger, 1985). For further biochemical and structural
studies, individual C1 subcomponents are typically separated by adding EDTA to
dissociate the complex, and C1 is reconstituted from its purified constituents (Strang et
al., 1982; Tseng et al., 1997). However, the entire assembly can be precipitated from
human serum using polyethylene glycol to give a functionally pure extract (Neoh et al.,
1984), and this formed the basis for the novel purification scheme described in this
chapter.
Complement component C1 has been successfully purified from human serum by
an optimised method that does not rely on IgG binding. First, high-molecular-weight
compounds are precipitated from serum using polyethylene glycol. The precipitate is
then reconstituted and separated by size exclusion chromatography using Superose 6 in
a physiological buﬀer. Finally, the peak containing C1 is collected and further purified
by anion exchange chromatography using a Mono Q column. When purified by this
method, C1 was shown to be pure by SDS-PAGE and dynamic light scattering.
The various peaks that eluted during the final anion exchange step of the
purification were analysed by peptide mass fingerprinting and tandem mass
spectrometry. These investigations served a twofold purpose: firstly, peptide mass
fingerprinting allowed the various components of the C1 complex to be identified in the
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corresponding samples, confirming that the purified protein was indeed C1; secondly,
the analysis gave an indication of the major proteins present within each sample, and
their relative abundance. Contamination with keratin from hair, skin and dust is often
a problem when protein samples are analysed by mass spectrometry, and samples
prepared from human serum may still contain traces of highly abundant proteins. Since
the samples contain highly purified protein, peptide mass fingerprinting could be
performed directly on the solution samples, thereby minimising the exposure to sources
of contamination.
Various contaminants such as keratins, immunoglobulins and other abundant
serum proteins were identified in both samples. However, around one third of the
proteins identified were complement-related proteins. C1r and C1s were conclusively
identified in both major peaks that eluted during the final purification, while C1q was
only detected in the first peak. When the normalised spectrum count of C1
subcomponents in each peak is compared, we see C1 appears to be enriched in the first
peak compared with the second. All other low-abundance complement-related serum
proteins were more abundant in the second peak.
In combination with the SDS-PAGE analyses, this indicates that the first peak
contains the intact native C1 complex in a highly purified form. However, a number of
additional proteins were identified by mass spectrometry. C1-inhibitor (C1-INH) was
identified in both samples, with a similar normalised spectrum count profile to that of
C1r and C1s. Two further proteins could be identified with a minimum protein
probability of 50% in the first sample, but not the second. These were complement
factor H and C1q. Conversely, three proteins were detected in the second sample but
not the first: galectin 3-binding protein, complement component C9 and mannan-
binding lectin serine protease 1 (MASP-1).
The physiological role of C1-INH is to control the auto-activation of C1, and
C1-INH also inhibits MASP-1 and MASP-2 (Beinrohr et al., 2008). A concentration of
22% of the normal serum value is suﬃcient to control spontaneous C1 activation
(Windfuhr et al., 2005). The presence of C1 inhibitor in both samples suggests that at
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least a portion of the purified complexes may be inhibited by binding to C1-INH.
Factor H is a control protein that regulates the alternative pathway of the complement
system and has been shown to interact with complement component C3.
Galectin-3‐binding protein has been implicated in inflammation in rheumatoid arthritis
(Ohshima et al., 2003); complement component C9 is one of the terminal members of
the complement cascade; and MASP-1 associates with the mannan-binding lectin of the
lectin pathway of complement (see section 1.4.1, p. 9). Factor H is relatively abundant,
while the remaining proteins are associated with the MBL complex, which is
structurally homologous to complement component C1. Thus, while the first peak
separated by the final purification step appears to contain C1, the second peak appears
to contain MBL, or its sub-components. 
The purified samples were further analysed by DLS, in order to determine the
suitability of the purified C1 for crystallisation. Mono Q-purified C1 was shown to
contain a single size distribution of particles by intensity of around 40nm. This closely
matches the proposed diameter of assembled C1 (Perkins, 1985). However, the width of
the distribution suggests that some structural diversity exists within the population of
purified C1 molecules. This may be due to diﬀerent conformational states of the
complex or the presence of contaminants of a very similar size.
Complement component C1 purified by this method appears to be relatively
robust. It can be stored at 4 °C for a period of one month without significant
degradation in the quality of the sample. Furthermore, it does not dissociate under
conditions of high ionic strength or in the presence of EDTA. This is in contrast to
published reports that employ aﬃnity purification methods.
Published reports suggest that the function of the C1 complex is aﬀected by
varying the ionic strength of the surrounding medium (Lepow et al., 1958; Colten et al.,
1968). The authors propose that the observed loss of activity is caused by dissociation
of the complex at ionic strengths outside the range of 0.1–0.15. However, the results
outlined on page 215 suggest that high and low ionic strengths do not dissociate C1.
Instead, a small increase in the hydrodynamic radius of the complex is observed at salt
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concentrations outside the physiological range at pH7.4. This increase in the size of the
C1 complex likely results from conformational changes within the molecule, which could
explain the loss of function at high and low ionic strength described by Lepow et al.,
1958 and Colten et al., 1968. Furthermore, diﬀerences in the structural profile of the
purified C1 complex were observed at high and low ionic strength: at low ionic
strength, C1 appears to have a tendency towards aggregation, while at high ionic
strength only the shape of the molecule appears to be aﬀected. This suggests that
diﬀerent mechanisms may be responsible for the loss of function at low ionic strength
compared to the loss of function at high ionic strength.
Overall, the findings presented here support the idea that C1 is only
functionally active within a narrow range of ionic strengths, corresponding to the
physiological range of human blood plasma. While the biological implications of these
findings are unclear, there may be more pertinent implications for the crystallisation of
the C1 complex. For example, moderate salt concentrations are required for the
complex to adopt a native state, while elevated concentrations such as those used in
crystallisation may aﬀect the conformation adopted by the molecule and alter it so that
is does not accurately reflect the physiological molecule.
EDTA is commonly used to dissociate the individual C1 subcomponents after
purification by aﬃnity methods. Here the C1 complex was purified by the novel method
combining PEG precipitation with gentle size exclusion chromatography, and the eﬀect
of EDTA on the resulting C1 was evaluated. Adding EDTA to Mono Q-purified C1
causes a small amount of larger aggregates to form. At EDTA concentrations higher
than those typically required to dissociate the complex (see for example Lepow et al.,
1963), 0.75nm particles are observed in addition to the 40 nm C1 particles. These
correspond to a predicted molecular weight of 1.7kDa, which is extremely small, and
therefore does not suggest that C1 is dissociating into its individual subcomponents.
These observations are in stark contrast to published literature on the subject, which
shows that the complex is disassembled in the presence of EDTA, since this sequesters
the calcium required by the C1 for structural stability.
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One possible explanation for this inconsistency can be found in the diﬀerent
methods of C1 preparation. As explained in section 1.7.1, p. 37, previous purification
protocols have relied on the aﬃnity of C1 for IgG in order to selectively separate the
complex from contaminating proteins. Typically, the individual sub-components are
further purified by dissociating the complex via the addition of EDTA, and the C1 is
finally reassembled from its pure constituents. However, in the method presented here
the complex is gently precipitated from human serum — along with other high-
molecular-weight proteins — and further purified in physiological or near-physiological
buﬀers. The process of binding and release from IgG during aﬃnity purification
methods makes C1 susceptible to dissociation by EDTA whereas C1 dissociation is
apparently prevented when C1 is purified by gentle methods. This suggests that some
factor may be associated with C1 that prevents dissociation by EDTA and is removed
during binding of the C1 complex to IgG and other ligands.
Peptide mass fingerprinting analysis of purified C1 showed that C1-INH was
also present in the sample. During complex formation, C1 inhibitor dissociates C1r and
C1s from the activated C1 macromolecule. However, it may also suppress spontaneous
activation of C1 via a reversible interaction with C1r and C1s (Davis et al., 2008).
Interestingly, C1 inhibitor also regulates lectin pathway activation via inactivation of
MASP-2 (Kerr et al., 2008). This could explain why C1-INH is found in both purified
C1 and also in the sample thought to contain MBL, the homologue of C1 in the lectin
pathway.
If IgG is used to purify the complex, either the inhibitor is likely to be
displaced, or the method will simply not purify inhibitor-bound C1 complex. The
presence of C1-INH in the sample of C1 purified by the novel method described here
suggests that it may be bound to C1. Furthermore, this interaction may be causing the
complex to resist disassociation by EDTA. It is possible that binding C1-INH alters the
aﬃnity of the C1 complex for calcium or otherwise protects the bound metal ions
required for structural stability from being sequestered by EDTA. 
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The results presented on page 188 suggest that purified C1 may form large
aggregates in the presence of physiological copper concentrations at low pH. Vigorous
aggregation of serum amyloid P component also occurs in the presence of copper at
acidic pH (Potempa et al., 1985). Since the copper concentrations used in those studies
were much higher than physiological copper concentrations, the authors considered the
solubility characteristics of copper at acidic pH values. However, no insoluble copper
complexes in the absence of SAP were identified in control studies. The authors
concluded that local environments enriched in copper at acidic pH — such as sites of
infection and inflammation — may trigger SAP auto-aggregation and potentiate SAP
binding to those ligands (e.g. C4-binding protein) for which SAP aggregation is a
requirement.
It is possible that a similar mechanism of aggregation exists for C1, which may
have some relation to its function in vivo. Studies carried out in our laboratory by Katy
Ginger suggest that both copper and zinc specifically interact with C1 and cause
inhibition of the protease activity of the complex. However, whether these are
exclusively due to C1, or to what extent MBL and/or other co-purifying proteins
contribute to these observations is unclear. However, the interaction of both
complement component C1 and SAP with copper and calcium under physiological and
pathological conditions is clearly a phenomenon that merits further exploration.
Initial investigations into the crystallisability of the complex have been carried
out in the search for high-resolution structures by X-ray crystallography. Protein
concentrations of 1–5mg/ml were shown to be an appropriate starting point for the
crystallisation of complement component C1. The concentration of protein required for
crystallisation is inversely proportional to its molecular weight and so a large protein
such as C1 may be expected to crystallise at these lower concentrations.
Purified C1 was subjected to crystallisation trials using Structure Screen 1 & 2,
since these had shown promising results using C1 samples at intermediate stages of
purification. Around 60% of the conditions tested resulted in precipitate or phase
separation, and there was a considerable diﬀerence in the quality of precipitates
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obtained with the diﬀerent protein concentrations. At 1mg/ml most of the precipitate
showed denatured protein, while at 5 mg/ml the majority of precipitates showed more
ordered states, including aggregates apparently growing from precipitate, spherulites,
and small crystals. These promising conditions all feature a salt as the primary
precipitant, suggesting that electrostatic interactions may be stabilising the C1
complex. By contrast, precipitates were obtained in many conditions using PEG as the
primary precipitant.
These observations are not surprising, considering that low concentrations of
PEG are used to precipitate the complex from serum. Furthermore, the experiments
described in section 4.10.1, p. 215 show that high ionic strength induces a small
increase in the hydrodynamic size of the C1 complex, instead of causing dissociation as
previously assumed. In addition, the results presented in section 4.10.5, p. 225 show
that a the C1 population becomes more homogeneous at higher protein concentrations,
such as those used during crystallisation. This may be a consequence of the equilibrium
between any free subunits and the C1 complex: in accordance with Le Chatelier’s
principle, increasing the protein concentration will shift the position of equilibrium
towards the state of lowest molecularity, in this case the assembled complex. Thus the
combination of high protein concentration and ionic precipitants appear to oﬀer an
environment conducive to the crystallisation of complement component C1.
Another variable to consider in the future search for C1 crystals would be
temperature. As described in section 4.10.4, p. 224, C1 is aﬀected by temperature.
Below 35°C there are small fluctuations in the Z-average size and intensity by DLS,
while between 35–40°C these fluctuations appear to diminish. Above 45 °C both size
and intensity fluctuate dramatically, indicating thermal denaturation of the C1
complex. These results suggest that C1 is most stable within the narrow range of
temperatures corresponding to its physiological milieu, at around 37°C. The
crystallisation attempts described here were carried out at 4 °C, since the low
temperature allows a gradual equilibration of the crystallisation drop with the reservoir
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solution and may slow down any undesirable auto-activation of the complex. However,
given the decreased stability of the complex at temperatures below around 35°C, better
results may be achieved at higher crystallisation temperatures.
The crystals obtained during the initial crystallisation trials were too small to
be tested for diﬀraction, so there is considerable scope for further work on the
crystallisation of complement component C1. In addition to expanding the scope of
crystallisation trials as discussed above, the purified C1 sample may yet contain other
complement-related proteins and high-abundance serum proteins, so further purification
or alternative purification methods could also be explored. Mono Q-purified C1 may
also be a more suitable sample than SEC-purified C1 for electron microscopy. Finally,
the interaction of purified C1 with divalent metal cations — and also C1 inhibitor —
merit further investigation. However, the aims set out for this project have been
adequately fulfilled.
A novel purification scheme to isolate native complement component C1 from
human plasma was developed, using a combination of PEG precipitation, size exclusion
chromatography and anion exchange chromatography. All of the C1 subcomponents
were shown to be enriched in the purified sample by SDS-PAGE and mass
spectrometry. Dynamic light scattering studies showed a single population of particles
around 40nm in diameter, which corresponds to the estimated size of the C1 complex.
Therefore C1 has been purified by a new procedure in a form suitable for
crystallisation. In addition, investigations into the eﬀects of relevant metal ions on the
structure of the purified complex under physiologically relevant conditions were
pursued. Finally, the crystallisability of complement component C1 was explored in the
hope of achieving usable crystals. Several promising conditions were found, and this
project therefore reached a natural conclusion in accordance with its objectives and the
available time and resources.
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Chapter 5
Investigating the ligand binding 
properties of SAP
5.1  Introduction
Serum amlyoid P component is a member of the pentraxin family, which also includes
the acute phase protein, C-reactive protein (CRP). Pentraxins are highly conserved and
are characterised by their calcium-dependent ability to bind a variety of ligands.
Interestingly, SAP activates complement by binding to C1q (Ying et al., 1993).
In human serum, SAP exists as a pentamer (Hutchinson et al., 2000), while in
the presence of EDTA, SAP forms stable decamers composed of two pentamer rings
interacting face to face (Pepys et al., 1997). X-ray and neutron scattering data showed
that SAP pentamers were reproducibly obtained in the presence of calcium at pH5.5 or
in the presence of MOβDG and calcium at pH6.0–8.0, while SAP decamers were
obtained in the presence of EDTA between pH5.5–8.0 (Ashton et al., 1997). In the
presence of excess calcium, isolated human SAP auto-aggregates and precipitates from
solution. This calcium-dependent self-assembly of SAP pentamers into larger aggregates
is inhibited by all known ligands (Thompson et al., 2002).
The secondary structure of human SAP and CRP in the presence of calcium,
magnesium, and phosphorylcholine has also been investigated using Fourier transform
infrared spectroscopy (Dong et al., 1994). Significant diﬀerences were noted in the
response of SAP compared with CRP. Calcium-dependent changes were observed in the
secondary structure of SAP, but the spectrum was not aﬀected by magnesium.
Furthermore, phosphorylcholine in the presence of calcium did not aﬀect the FTIR
spectrum of SAP. These findings suggest that members of the pentraxin family — such
as SAP and CRP — display calcium-dependent secondary structure conformational
changes but diﬀer in their responses to phosphorylcholine and magnesium.
These properties are thought to be relevant to the incompletely understood
biological function of these highly conserved proteins, which includes activation of the
complement system and association with amyloid deposits. The aim of the work on
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SAP was thus to perform preliminary studies on the eﬀect of metal cations on the
ligand-binding and structural properties of SAP under physiologically relevant
conditions.
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5.2  Purification of SAP
The purification scheme used to prepare SAP was adapted from that of De Beer and
Pepys, 1982, using ion exchange chromatography instead of size exclusion as the final
chromatography step. This method of preparing SAP relies on its calcium-dependent
aﬃnity for agarose and is described fully in section 3.2, p. 131. Briefly, human plasma is
incubated with an agarose-based gel filtration medium in the absence of any additional
calcium (the calcium naturally bound to SAP being suﬃcient for the interaction with
agarose to occur). Any SAP molecules in the sample bind to the medium, while
unbound contaminants can be washed away. Finally, SAP is eluted with excess EDTA,
which sequesters calcium ions and thus disrupts the binding of SAP to the column. The
eluted fractions still contain some contaminants, but these can be removed by IEX
using a MonoQ column and NaCl gradient to leave a single 25kDa protein — pure
SAP — on SDS-PAGE gels as shown in Figure 5.1.
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Figure 5.1: SAP in various stages of purification. A.Fraction eluted from a Sepharose 4B column.
Numerous bands can be seen, indicating that the sample is still relatively impure. B.Fraction eluted
after further purification using a MonoQ column. A single 25kDa band is clearly visible, indicating
that SAP is present in a highly purified form.
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Purified SAP was exchanged into an EDTA-free buﬀer (10mM Tris, pH7.4, 150mM
NaCl) and analysed by DLS to determine the size distribution of particles in the
sample. The results are summarised in Figure 5.2 and Table 29. The sample was shown
to contain a single species of approximately 10nm in diameter according to the
intensity distribution. In the presence of EDTA, this corresponds to a molecular weight
of around 250kDa, although in the absence of EDTA, the molecular weight is
apparently closer to 150kDa. This shows that in the absence of EDTA or metal ions,
purified SAP is present as a 125kDa pentamer in solution. The diﬀerence in the
observed size by intensity can be explained through the shape eﬀects of the ring-like
SAP structure on the apparent hydrodynamic radius. SAP decamers, which consist of
two pentamer rings stacked face to face, have a more globular shape that more closely
corresponds to the spherical approximation used in molecular weight calculations.
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Figure 5.2: Size distribution by intensity of purified SAP by DLS. The figure shows a monomodal
distribution of particles approximately 10nm in diameter. The concentration of SAP was 10µM
(10mM Tris, pH7.4, 150mM NaCl, 50mM EDTA).
EDTA Size (d.nm) % Pd MW (kDa)
+ 12.62 40.9 251
- 10.24 32.5 154
Table 29: Measurements derived from the DLS analysis of purified SAP. The estimated size,
percentage polydispersity and molecular weight are indicated. The results show that SAP is a
decamer in the presence of EDTA, and a pentamer in 10mM Tris, pH7.4, 150mM NaCl.
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5.3  Aggregation assays
In the absence of calcium, SAP forms stable decamers composed of two pentamer rings
interacting face to face (Pepys et al., 1997). In the presence of excess calcium, isolated
human SAP auto-aggregates and precipitates from solution. This calcium-dependent
self-assembly of SAP pentamers into larger aggregates is inhibited by all known ligands
(Thompson et al., 2002). One ligand with particular physiological relevance is
phosphatidylethanolamine (PE).
This phospholipid is usually found in the inner leaflet of the plasma membrane,
along with phosphatydilserine (PS) and phosphatidylinositol. In contrast, the outer
leaflet typically features phosphatidylcholine, sphingomyelin and a variety of
glycolipids. However, during the early stages of apoptosis, this asymmetry breaks down
as PE and PS flip-flop from one side of the membrane to the other (Familian et al.,
2001). Thus PE may be implicated in the biological function of SAP. In order to
investigate the interactions between calcium, SAP and PE, aggregation assays were
performed and monitored by DLS.
Under physiological conditions, SAP forms pentamers with a molecular weight
of 125kDa. When calcium is added, two distinct peaks are observed in the particle size
distribution determined by DLS (see Figure 5.3). The smaller size peak is representative
of pentameric SAP, while the larger size peak is caused by aggregation of SAP
pentamers via AB face-to-face stacking mediated by bound calcium and Glu-167
(Thompson et al., 2002). The calcium-dependent aggregation of SAP over time is
shown in Figure 5.3. When SAP is calcified and then PE is added to the sample, the
aggregation of SAP continues, but at a reduced rate (Figure 5.4). However, when PE is
added to SAP first and the sample is subsequently calcified, no aggregation is observed
(Figure 5.5). These results clearly demonstrate the inhibition of calcium-dependent
aggregation of SAP by its binding of the ligand PE.
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Figure 5.3: Aggregation of SAP monomers on the addition of calcium. This figure shows time-
courses of DLS measurements from the two major peaks in the size distribution profile of SAP
after calcium is added to the sample. Physiological concentrations of SAP (50 µg/ml) were
prepared in 10mM Tris pH8, 140mM NaCl and the sample was calcified with 1mM calcium,
pH7.4. DLS measurements were taken at 5 min intervals from the introduction of the calcified
sample into the machine. A. Two distinct peaks are observed in the size distribution: peak 1
corresponds to SAP, while the second peak is indicative of SAP aggregates. For each peak the
particle size (solid line) and intensity (dashed line) are shown. The figure shows the disappearance
of SAP pentamers (peak 1) and the appearance of aggregates (peak 2) after the addition of excess
calcium. B. Aggregating SAP shows increasing polydispersity with time. This likely reflects the
increasingly heterogeneous population of aggregates.
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Figure 5.4: Adding PE to calcified SAP does not inhibit the further aggregation. Physiological
concentrations of SAP (50 µg/ml) were prepared in 10mM Tris pH8, 140mM NaCl. After adding
1mM calcium, the sample was incubated at room temperature for one hour to allow aggregates to
form. Finally, PE was added to a final concentration of 1mM and DLS measurements were taken
every 5 minutes. The plot shows that adding PE to the calcified sample does not inhibit the
calcium-dependent aggregation of SAP.
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Figure 5.5: PE prevents calcium-induced SAP aggregation. Physiological concentrations of SAP
(50 µg/ml) were prepared in 10mM Tris pH8, 140mM NaCl. In this experiment, PE was added
first to a final concentration of 1mM, followed by the same concentration of calcium before DLS
measurements were taken every 5 minutes. The results show that when PE is present before
calcium is introduced, the calcium-dependent aggregation of SAP is inhibited by PE.
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5.4  Discussion
The experiments described in section 5.3 provide a simple and rapid method for
determining the eﬀect of metal- and ligand-binding by SAP. These formed the basis for
further studies carried out by other members of our laboratory, and this work is
currently ongoing. The findings presented in this thesis, and their implications within
the context of the investigations carried out by others, will be discussed in this section.
Serum amyloid P component has been found to associate in vitro with PE in
the experiments described in section 5.3, and with a variety of other polysaccharides
and proteins in the presence of calcium at neutral pH in the published literature. Thus
the method for assaying the eﬀect of divalent metals on ligand-binding and auto-
aggregation described here may be extended to other ligands. The role of divalent
cations and acidic pH on the binding of SAP to the ligand zymosan has been previously
investigated by Potempa et al., 1985, since they may play a role in the biological
function of the molecule. The authors reported that binding occurs not only in the
presence of calcium but also in the presence of copper and zinc, and that SAP did not
bind the ligand in the absence of added metal or in the presence of various other metal
cations that may be present in normal human blood plasma.
Whereas calcium-mediated SAP-zymosan binding decreases at low pH, copper-
mediated binding increases substantially. Thus, in addition to calcium at neutral pH,
both copper and zinc — at neutral and in particular at acidic pH values — mediate
SAP binding to polysaccharide ligands. This suggests that SAP may well be considered
a copper- as well as a calcium-dependent protein, and that this reactivity is favoured
under those conditions of lowered pH which may result from metabolic processes
occurring at local sites of inflammation (Potempa et al., 1985). Similarly, copper-
dependant conformational changes and a modulation of the protease activity of the
complex by diﬀerent metal cations were observed in SAP in work carried out by Sasha
Derrington in our laboratory.
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Serum copper levels increase during inflammation, most notably in association
with elevation of ceruloplasmin, a copper-transport protein that donates copper to
enzymes such as cytochrome oxidase. This process is greatly enhanced in an acidic
environment (Owen, 1975), which is a feature of sites of infection and inflammation.
Furthermore, a selective precipitation between SAP and ceruloplasmin was identified by
Uhlenbruck et al., 1978. It was proposed that at low pH, a copper exchange reaction
could thus occur between ceruloplasmin and SAP (Potempa et al., 1985).
Experiments performed in our laboratory by Sasha Derrington showed that SAP
and ceruloplasmin formed stable complexes, suggesting that a copper exchange reaction
may take place between the two proteins. Clearly, the role of ceruloplasmin and copper
under physiological and pathological conditions in the structure and function of SAP is
a matter that remains to be fully explored. The results presented here may oﬀer a rapid
and simple method for assaying the metal- and ligand-binding properties of serum
amyloid P component, and further studies examining the role of these metals and pH
could contribute to understanding the physiological role of SAP.
At an SAP concentration of 1mg/ml — in the range of concentrations required
for crystallisation (Wood et al., 1988) — 1mM calcium was suﬃcient to cause rapid
SAP auto-aggregation. However, by keeping the concentrations of both protein and
metal suﬃciently low, auto-aggregation of SAP can be avoided (Potempa et al., 1985).
The results presented in section 5.3 show that calcium-dependent aggregation could be
detected by dynamic light scattering even at physiological SAP concentrations in the
presence of 1mM calcium. These observations may be consistent with the findings
described by Potempa et al., 1985, since dynamic light scattering allows the detection
of even small numbers of aggregated particles, whereas these may not have been
observed in the original study.
Vigorous aggregation of SAP also occurs in the presence of copper
concentrations above 0.5mM at acidic pH (Potempa et al., 1985). The authors
concluded that local environments enriched in copper at acidic pH — such as sites of
infection and inflammation — may trigger SAP auto-aggregation and potentiate SAP
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binding to those ligands (e.g. C4-binding protein) for which SAP aggregation is a
requirement. The results of these auto-aggregation experiments have implications for
the crystallisation of SAP, which readily forms crystals in the presence of calcium and
PEG 6000 at pH5.5. Interestingly, a copper-dependent aggregation at acidic pH is also
observed with complement component C1 (p. 188 for results and p. 234 for discussion).
When all the available information is taken into account, the picture that
emerges is that copper and zinc may replace the calcium in the binding pocket of SAP
(and possibly also in calcium-binding sites on C1). The Kd of calcium binding to SAP
has been estimated at 0.1 µM and 1.5mM for each of the two binding sites respectively
(Heegaard et al., 2006). Thus, calcium II is held much more loosely by the molecule
than calcium I. When all of these observations are taken together, they suggest that at
least one of the calcium-binding sites on SAP may instead be occupied by a copper,
zinc or other divalent metal ion under certain conditions.
This opens up the possibility of crystallising SAP bound to diﬀerent divalent
metal ions, and co-crystallising SAP with diﬀerent divalent metal ions and ligands.
If SAP can be successfully crystallised with copper in place of calcium then near-UV
CD spectroscopy or X-ray absorption spectroscopy (EXAFS) could be used to study
the local geometry of the co-ordinated metal ion. Particle-induced X-ray emission
(PIXE/microPIXE) can provide a quantitative analysis of the metal content of a
protein sample, which could give information about the occupancy of the metal site.
Finally, fibre diﬀraction and TEM could be explored as a means of studying the stacks
of aggregated SAP pentamers that form in the presence of calcium and copper.
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Chapter 6
Validation of the ZiCo design
6.1  Introduction
As described in section 1.6, ZiCo is a small peptide designed to switch between an
oligomeric coiled coil and a zinc finger fold on binding zinc. The design was used as a
template to create a family of peptides based on the same principles, incorporating
various sequence features in order to determine their eﬀects on folding and stability.
Two members of this family were obtained from Prof. Dek Woolfson: the original
design, ZiCo1; and the modified peptide ZiCo95.
The diﬀerences between the two peptides are illustrated in Figure 6.1. ZiCo1
contains four histidine residues while the ZiCo95 sequence displays the classical zinc
finger motif, containing two cysteine and two histidine residues. This renders ZiCo95
more vulnerable to oxidation and the formation of disulphide bonds within or between
peptide molecules. Other modifications include the addition of glutamate residues,
making ZiCo95 much more negatively charged at a given pH than ZiCo1 (as illustrated
by the peptide charge calculations in Appendix II, section i).
A .    1         1 0         2 0
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Figure 6.1: A comparison of the ZiCo1 and ZiCo95 sequences. A. Residue number. B. ZiCo1
sequence. C. ZiCo95 sequence. Residues involved in zinc binding are shown in yellow and identical
residues are shown in black. The key modifications involve the substitution of cysteines for two of
the histidine residues, and the incorporation of glutamate residues.
The overall goal of this project was to develop a crystallisation strategy for both the
metal-free oligomer and the zinc-bound monomer forms of both peptides that would
lead to high-resolution structures. These are valuable in terms of testing our
understanding of the rules that govern protein folding, which has practical implications
for designing proteins with novel functions for use in industry and medicine. 
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6.2  Crystallisation of ZiCo1 and ZiCo95
Prior to the work described here, diﬀracting crystals of ZiCo1 had been grown by David
Papostolou using a peptide concentration of 2.25mM ZiCo and 0.4M LiSO4 as the
precipitant at near neutral pH in the presence of 1mM zinc chloride. However, all
attempts to solve the structure using MR had proved unsuccessful. It was thus decided
that the screening of new conditions to complement those already tested could be
valuable in terms of yielding alternative crystal forms from which a structure solution
might be found.
In designing a crystallisation strategy for the two ZiCo peptides, a number of
factors were considered. Firstly, many of the standard commercially available screens
are optimised for globular proteins, using conditions that have been shown to
successfully yield crystals. However, ZiCo does not fit the typical profile for a globular
protein because of its small size and structural flexibility. It has been shown to be
highly sensitive to varying buﬀers, pH, zinc and salt concentrations (Eleonora Cerasoli,
personal communication). In light of this fact, a systematic approach was favoured over
the sparse-matrix style screens used in the previous crystallisation attempts, in the
hope that this would give a clearer understanding of the solubility and crystallisability
of the ZiCo peptides. The Stura Footprint screen (Molecular Dimensions, UK) was
chosen as a starting point to explore the crystallisation conditions of ZiCo1 and ZiCo95
because it allows systematic screening of the protein solubility curve against commonly
used precipitants at basic, acidic and neutral pH.
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6.2.1  ZiCo95 crystallisation attempts and analysis
One of the first steps in the endeavour to crystallise ZiCo95 was to establish an
appropriate concentration of both peptide and zinc in the crystallisation solution.
Increasing the concentration of zinc ions should drive the equilibrium towards the zinc-
bound monomer, which could be an important factor in any crystallisation attempts.
The Pre-Crystallisation Test™ (Hampton Research, USA) was used to identify a
suitable peptide concentration and peptide:zinc ratio for the initial screening as
described on page 133. The results of the PCT™ indicated that 0.5mM peptide would
be a suitable concentration for screening purposes. A positive result was obtained with
1:0, 1:1, 1:5 and 1:10 peptide:zinc ratios using zinc chloride, so these conditions were
used to set up the initial screens.
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6.2.1.1  Crystallisation trials
Numerous attempts were made to crystallise ZiCo95, using the Stura Footprint Screen
(Molecular Dimensions, UK) as a starting point. While none of the initial screens gave
any crystals, the systematic nature of the screens meant that promising conditions
could be identified for further exploration. Such conditions were identified where an
increase in precipitant concentration resulted in a transition from a clear drop to
precipitate. The sudden phase transition suggests that the conditions border a region of
the protein solubility curve that includes the nucleation and metastable zones required
for crystallisation. Finer sampling of this region of crystallisation space may yield the
right conditions for protein crystals to form and grow.
Peptide:zinc Precipitant Buﬀer pH
1:1 15–24% PEG 600 0.2M imidazole malate 5.5
1:1 20–25% PEG 4K 0.2M imidazole malate 7.0
1:1 17.5–22.5% PEG 10K 0.2M imidazole malate 8.5
1:1 < 0.75M ammonium sulphate 0.15M sodium citrate 5.5
1:1 < sodium/potassium phosphate n/a 7.0
1:1 < 1M citrate 10mM sodium borate 8.5
Table 30: Promising conditions from initial ZiCo95 crystallisation screens. This table shows
conditions that resulted in a transition from a clear drop to precipitate in the initial screen using
0.5 mM ZiCo95 and a range of peptide:zinc ratios. These promising conditions were then expanded
into further screens by varying the precipitant concentration within the identified range and the pH
by ±1 unit around the identified condition.
Table 30 shows the conditions that were used as starting points for further exploration
of the crystallisability of ZiCo95. By varying the precipitant concentration and pH, the
promising conditions from the initial screens were expanded into further 4 × 6 screens.
253
Since cysteines are present in the ZiCo95 sequence, the reducing agent BME was
included as a parameter in the crystallisation trials. In addition, experiments were set
up using diﬀerent peptide concentrations (0.3, 0.5 and 0.8mM), crystallisation buﬀers
(150mM Tris or 150mM phosphate) and temperatures (4°C and room temperature).
Despite extensive attempts to crystallise ZiCo95, none of the conditions tested
produced crystals of the peptide.
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6.2.1.2  SEC analysis
In order to further understand the solution behaviour of ZiCo95, samples were analysed
by SEC in the presence and absence of various additives. The column was calibrated
according to the manufacturer’s instructions and the separations were performed in
50mM Tris, pH7.5, 50mM sodium chloride, using 20nmol of peptide per run. Multiple
peaks were seen in the chromatogram both with and without an equal concentration of
zinc chloride in the sample and elution buﬀers, as shown in Figure 6.2. When the
peptide was reduced by the inclusion of BME in the sample buﬀer, ZiCo95 eluted as a
large single peak with a predicted molecular weight of 7.9kDa, together with a small
amount of higher molecular weight material both with and without zinc (see
Figure 6.3).
The results of the SEC analysis show that ZiCo95 exists as a heterogeneous
population of oligomeric species in solution, in both the presence and absence of zinc.
The zinc-free peptide appears to be relatively uniform in terms of the number and type
of oligomers observed: most of the peptide molecules assemble into trimers — as
designed — with only a small proportion forming tetramers. In the presence of zinc,
ZiCo95 displays a much more heterogeneous population of oligomeric states. Most of
the peptide is found as pentamers, followed by trimers and finally a small proportion of
monomers. This behaviour may explain the lack of success in crystallising ZiCo95, since
a key requirement for successful crystallisation is generally a homogeneous population
of protein molecules. As Figure 6.2 shows, ZiCo95 forms multiple oligomeric species in
both the presence and absence of zinc. Increasing the peptide concentration is likely to
shift the balance of equilibrium towards oligomeric states, contributing to heterogeneity.
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Figure 6.2: Elution profile of ZiCo95 in the presence and absence of equimolar zinc chloride.
Various oligomeric states can be distinguished and identified by their calculated molecular masses.
The results show that in the absence of zinc, ZiCo95 exists primarily as a trimer, with a small
amount of a tetrameric species. In the presence of equimolar zinc, a small amount of monomer is
observed, with larger amounts of trimeric and tetrameric assemblies.
Results subsequently obtained from the Woolfson laboratory show that in the presence
of equimolar zinc, a significant portion of ZiCo95 is bound to two zinc ions. At high
concentrations, such as those used in the crystallisation trials, the peptide precipitates
spontaneously from solution. This is likely to be due to cross-linking of the peptides via
bound zinc, suggesting that it may be impossible to crystallise ZiCo95 in its zinc-bound
form. In light of these findings, and due to time constraints, further attempts to
crystallise ZiCo95 were not pursued.
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Figure 6.3: Elution profile of reduced ZiCo95 in the presence and absence of equimolar zinc
chloride. The peptide elutes as a large peak with a predicted molecular weight of 7.9kDa, together
with a smaller peak corresponding to an aggregated state. The same elution profile is observed
both in the presence and absence of equimolar zinc.
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6.2.2  ZiCo1 crystallisation and optimisation
ZiCo1 was obtained lyophilised and frozen at -20°C from Eleonora Cerasoli (Sussex,
UK) and Beth Bromley (Bristol, UK). Stock solutions of 5–10mg/ml were prepared by
dissolving the peptide in water, and stored at 4°C. The Pre-Crystallisation Test
(Hampton Research, USA) indicated that a 1mM solution of the peptide in 10mM
phosphate, pH7.5, 50mM NaCl and an equimolar concentration of zinc were suitable
for crystallisation purposes.
6.2.2.1  Crystallisation trials
The initial systematic screens produced a number of crystals when zinc was included in
the sample solution, and when both PEGs (Table 31) and salts (Table 32) were used as
the primary precipitant. The results show the stark diﬀerences in crystal morphology
obtained when using salts as opposed to to PEGs. Conditions containing PEGs gave
rise to numerous small, irregular crystals, while conditions with salts produced larger,
single crystals. ZiCo1 crystallises at varying pH values, with the best crystals obtained
between pH7 and 8.5. This corresponds to the pH at which the peptide has been
characterised in solution, so any structural information derived from these crystals is
likely to be relevant to validating the design of this novel peptide.
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Table 31: Initial hits from PEG conditions of the Stura Footprint screen
Precipitant pH Result Crystal morphology
30% MPEG 550
0.1M HEPES
8.2 Birefringent granule
40% MPEG 550
0.1M HEPES
8.2 Dark granule
36% PEG 600
0.1M HEPES
7.2 Birefringent cluster
36% MPEG 2000
0.1M sodium cacodylate
6.5 Birefringent granule
33% PEG 600
0.2M imidazole malate
5.5 Irregular
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Table 32: Initial hits from salt conditions of the Stura Footprint screen
Precipitant pH Result Crystal morphology
0.75–1M citrate
10mM sodium borate
8.5 Triangular prism
1.32M NaH2PO4/K2HPO4 7.0 Triangular prism
1–1.5M ammonium sulphate
0.15M sodium citrate
5.5 Triangular plate
2M ammonium sulphate
0.15M sodium citrate
5.5 Rod-like plate
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6.2.2.2  Optimisation
In order to maximise the number, type and quality of crystals available for further
experiments a series of optimisation steps were carried out on each of the initial hit
conditions. These involved expanding each set of conditions into a 4×6 screen in which
the precipitant concentration and pH were incrementally varied (see Table 33). Only
the optimisation of the sodium citrate conditions yielded an improvement in terms of
giving large, three-dimensional, single crystals with no visible flaws. These could be
further improved by streak seeding into drops containing slightly lower precipitate
concentrations than those required for spontaneous nucleation (< 0.75M citrate).
Precipitant Buﬀer pH
20–35% MPEG 550 0.1M HEPES 6.5–9.0
30–45% MPEG 550 0.1M HEPES 6.5–9.0
10–40% PEG 600 0.1M HEPES 5.5–8.0
10–40% MPEG 2000 0.1M sodium cacodylate 5.5–8.0
10–40% PEG 600 0.2M imidazole malate 5.5–8.0
0.5–1.5M citrate 10mM sodium borate 6.5–9.0
0.5–1.5M NaH2PO4/K2HPO4 5.5–8.0
1–2M ammonium sulphate 0.15M sodium citrate 5.5–8.0
1.5–2.5M ammonium sulphate 0.15M sodium citrate 5.5–8.0
Table 33: Optimisation of ZiCo1 crystallisation conditions.The table shows how the initial hit
conditions were expanded to give a set of 4×6 screens in an attempt to optimise the crystallisation
of ZiCo1. Only the condition using citrate as a precipitant produced improvements in the quality of
crystals obtained.
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After six months, fresh drops of ZiCo1 prepared from the original batch of peptide no
longer produced crystals. A further batch of peptide was provided courtesy of Beth
Bromley, which also failed to produce crystals in any of the conditions tested. Both
batches of peptide were analysed by CD spectroscopy and compared with the original
data, as shown in Figure 6.4.
The first batch after six months shows no signal, which suggests that the
peptide has degraded, thus explaining why no crystals could be produced. The second
batch of peptide shows a much weaker signal than the first, which indicates that the
peptide is less folded. In addition, the minimum at 209nm is more pronounced than
that at 222nm when compared with the original measurement, which is suggestive of
an increased contribution of random coil to the CD spectrum. As a result of these
observations, further crystallisation attempts were abandoned, and work proceeded
with the limited number of crystals obtained.
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Figure 6.4: Comparison of ZiCo1 batches in 50mM sodium phosphate, pH7.5, 50mM sodium
chloride. The CD spectra of 100µM ZiCo were recorded in the absence (solid lines) or presence
(dotted lines) of equimolar zinc chloride. The first batch after six months is shown in black, while
the second batch is shown in red. The original spectrum of the first batch is shown for comparison
in grey. The results indicate that there is considerable variability between batches, and that the
peptide has degraded over time.
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6.3  Data collection and analysis
Following successful crystallisation of the ZiCo1 peptide in 0.75–1M citrate,
10mM sodium borate, pH8.5, data were collected using a Rigaku RU-H3RHB rotating
anode X-ray generator equipped with Osmic Max-Flux optics and an RAXIS-IV++
image plate area detector. Cryocrystallography was carried out using the MSC
X‑Stream cryo system.
6.3.1  Data collection
A single crystal grown in 0.75M sodium citrate, 10mM borate, pH8.5 was collected and
briefly immersed in a solution of crystallisation buﬀer containing 33% glycerol as a
cryoprotectant. The crystal was flash frozen at 100 K and a total of 180 images with an
oscillation angle of 1° and exposure of 1 min were collected (see Figure 6.5). Upon close
inspection of the diﬀraction images, it was observed that some reflections exhibited
split diﬀraction spots, suggesting disorder in the crystal.
To determine whether this was an inherent feature of the crystals or due to the
addition of glycerol as a cryoprotectant, a second crystal grown under the same
conditions was mounted at room temperature according to the method of Mac Sweeney
and D’Arcy, 2003, and several images were collected with an oscillation angle of 1° and
exposure of 10 min. These show well-defined spots to the resolution limit (see
Figure 6.6), which indicates that the crystals do not tolerate the addition of glycerol.
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Figure 6.5: Diﬀraction pattern of ZiCo1 using 33% glycerol as a cryoprotectant. The inset shows
pathological spot splitting that was characteristic of crystals treated with cryoprotectants.
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Figure 6.6: Room temperature diﬀraction of ZiCo1. The inset shows clear, single spots with no
obvious pathologies. The diﬀraction at room temperature was much weaker than at 100 K,
resulting in a large background contribution from the solvent, and weaker reflections. 
At room temperature all crystals tested diﬀracted relatively weakly and it was not
possible to process the resulting data, ruling out room temperature data collection as
an option. Testing with other cryoprotectants such as MPD and PEGs produced similar
pathological diﬀraction to that observed when glycerol was used. Gradually transferring
the crystals to the final cryoprotectant concentration in small concentration steps also
did not oﬀer any improvement, so an alternative strategy was sought for cryoprotection.
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During optimisation of the crystallisation conditions, crystals were successfully grown
using higher concentrations of sodium citrate as a precipitant. At 1M sodium citrate,
the mother liquor vitrified upon freezing, so for crystals grown at this concentration no
further cryoprotection was necessary. The diﬀraction images showed clear, single spots
and a total of 360° of data were collected with an oscillation angle of 1° and exposure of
1 min (see Figure 6.7).
Figure 6.7: Diﬀraction of ZiCo1 crystals grown in 1M citrate, 10mM borate, pH8.5, without any
additional cryoprotectant. The inset shows clear, single spots with no obvious pathologies and a
large number of strong reflections. This indicates that high concentrations of citrate act as a
suitable cryoprotectant for crystals of ZiCo1 grown under these conditions.
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6.3.2  Data processing
The raw data were processed with MOSFLM (Leslie, 1992), which suggested P3 as the
most likely space group. The unmerged data were also analysed using Pointless (Evans,
2006), which suggested P312 as the most likely space group. At this stage, it is not
possible to assign a space group unambiguously and consequently, the data were
processed in various space groups for comparison. Intensities were scaled and merged
using Scala from the CCP4 software suite (Collaborative Computational Project, 1994)
and the resulting statistics are shown in Table 34. The statistics show that the data
process sensibly in all three space groups shown, with processing in P312 giving a slight
increase in the value of Rmerge when compared with P3 (4.9% as against 4.8%). 
P1 P3 P312
Unit cell parameters 32.0   32.1   57.6
90.3    90.1   119.8
32.1   32.1   57.6
90    90   120
Resolution (Å) 25.0–1.6
Reflections 71884
Unique 18543 7661 4342
Completeness (%) 68 85 90
Multiplicity 3.6 9.4 16.6
Rmerge (%) 7.1 4.8 4.9
I/sd(I) 14.5 37.6 48.7
Table 34: Comparison of processing statistics in various space groups. The predicted space group is
P312, which gives good completeness and multiplicity and an acceptable Rmerge value. Processing in
P3 also gives similar values, while the statistics in P1 are shown for comparison.
In order to determine the most likely number of molecules in the asymmetric unit for
the various space groups, the Matthews coeﬃcient and solvent content were calculated,
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along with their associated probabilities for each number of molecules in the
asymmetric unit (NASU). The results are presented in Table 35. Six molecules were given
as the most likely number in the unit cell for space groups P3 (NASU = 2) and P312
(NASU = 1), while in P1 the most likely number was seven (NASU = 7). In space group
P3, the VM for a single molecule (5.36 Å3 Da-1) and the corresponding solvent content
(77%) are improbably high (P(NASU) = 0.01). However, there are reported structures
with solvent contents in this region Dias, 2002, so while it is improbable that we have
one molecule per asymmetric unit in P3 (or indeed three molecules per asymmetric unit
in P1) there is still a small possibility that this may be the case.
Space group NASU P(NASU) overall VM (A3 Da-1) VS (%)
P1 6 0.31 2.68 54.10
7 0.38 2.30 46.45
P3 2 0.79 2.68 54.10
P312 1 1.00 2.68 54.10
Table 35: Matthews’ coeﬃcient in various space groups. The most likely number of molecules in
the asymmetric unit (NASU) for each space group is shown, as well as their associated probabilities.
The corresponding Matthews coeﬃcient (VM) and solvent content (VS) are also indicated. 
269
6.3.3  Twinning tests
Crystal twinning is a growth disorder that occurs when two or more crystals of the
same species intergrow in a way that results in good molecular packing but violates
crystal symmetry (Yeates and Fam, 1999). Twinned crystals are thus composed of
multiple domains whose orientations are related in some way. While some twinned
crystals are instantly recognisable by their shape, many appear to be single crystals,
and the presence of twinning can only be detected from the diﬀraction data.
6.3.3.1  Types of twinning
If the crystal lattices of individual domains are superimposable in only two dimensions,
the result is known as ‘non-merohedral’ or ‘epitaxial’ twinning. This is easily recognised
from the diﬀraction pattern, which will display multiple interpenetrating lattices.
However, if the lattices of the twin domains overlap in all three dimensions the
situation becomes more complicated. This type of twinning is known as ‘merohedral’
twinning and manifests itself in crystal systems where the unit cell parameters allow
the possibility of higher symmetry than the true symmetry of the crystal. This is
generally the case with trigonal, tetragonal, hexagonal and cubic systems, although
monoclinic, triclinic and orthorhombic systems may also exhibit twinning if the unit
cell parameters allow it. Merohedrally twinned macromolecular crystals are almost
always composed of just two distinct domains related by a twofold symmetry operator,
and this special case is termed ‘hemihedral’ twinning.
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6.3.3.2  Implications for structure solution
While the diﬀraction pattern of merohedral twins may look normal, owing to the
superimposability of the lattices, each recorded intensity actually contains contributions
from the two twin-related reflections in a ratio that is dependant on the volume
occupied by each twin domain. As a result, the diﬀraction pattern acquires varying
degrees of additional symmetry as imposed by the twin law. If one domain is much
larger than the other, then the crystal is partially twinned. In this case, the true
crystallographic intensities can be recovered mathematically at the expense of
magnifying the measurement errors by a factor of roughly 1/(1-2α), where α is the
twin fraction.
However, as the volumes of the twin domains approach equality and α
approaches 0.5, the measurement errors become increasingly large, and so for a
perfectly twinned crystal it is impossible to mathematically de-twin the data. The
diﬀraction pattern will display erroneously high symmetry, and if twinning is not
detected, the true space group may never be established. If the twinning is detected,
such a case may be solved either by searching for new crystals with partial or no
twinning, or by attempting to determine the structure without knowing the true
crystallographic intensities. This is possible in practice by using molecular replacement.
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6.3.3.3  Detecting merohedral twinning
There are numerous indicators of twinning, several of which were detected in the ZiCo1
data. Firstly, the crystal system appears to be trigonal, in which twinning is common.
Secondly, the Rmerge for the higher symmetry space group P312 is only slightly greater
than that for P3, which is characteristic of twinned data (CCP4 Wiki). In the case that
the data are twinned, the most likely scenario is that the true space group is P3, with a
twinning operator that mimics the symmetry of P312. Consequently, the P3 data were
subjected to various twinning tests.
As mentioned previously, in the case of hemihedral twinning, each measured
reflection will have contributions from both twin domains. It is unlikely that these will
both have extremely high or extremely low intensity values, so the distribution of
intensities in a twinned data set will follow a sigmoidal distribution, where there are
fewer extreme values than expected. Indeed, the intensity distributions of the ZiCo1
data set as determined by TRUNCATE (French and Wilson, 1978) indicate that the
crystal is twinned (see Figure 6.8). Furthermore, plots of the kth moments of E, another
indicator of twinning, are close to the predicted values for a perfectly twinned crystal
(see Figure 6.9).
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Figure 6.8: Intensity distribution of P3 data. The observed intensity distribution of acentric
reflections is sigmoidal, and does not correspond to the calculated theoretical distribution. This is a
known indicator of twinning.
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Figure 6.9: Plot of the kth moments of I for ZiCo data processed in space group P3. The expected
values for perfectly twinned data are shown (dashed lines). The moments lie close to the values
expected for a perfectly twinned crystal.
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6.3.3.4  SFCHECK
Further twinning tests were performed using SFCHECK, which determined the
twinning operator to be (h+k, -k, -l) with a twin fraction of 0.471 in space group P1
(see Figure 6.10). In P3, the twinning operator was given as (-h, h+k, -l) with a
twinning fraction of close to 0.5 (see Figure 6.11). In space group P312, the data
appeared to be twinned by (-h, -k, l) with a twin fraction of 0.2. This suggests that the
crystal is almost certainly twinned, and de-twinning the data in P3 of P1 would be
impossible. Several other crystals were tested and all exhibited a similar degree of
twinning, so the decision was made to proceed with the available data and to attempt a
solution via molecular replacement.
274
!"#$%"$#&'()%"*#'+,&%-
....
!(+/0+1'234354
6
(
7
6(7
89:;*<'=:*"'>?@*A&#)::'B''CC34'DE4F
5355 53G2 53CH 53H4 5325
'''G5
'''45
'''C5
'''I5
'''H5
'''J5
'''25
'''K5
GLM
M H32G 43KJ G3N5 G3IC D
89:;*<'O:*"
D
5355 53G2 53CH 53H4 5325
''G35
''435
''C35
''I35
GLM
M H32G 43KJ G3N5 G3IC D
P="9%):'#&;*:$"9*<
P="9%):'#&;*:$"9*<'Q*#')"*R'S9",'?'B'5
P="9%):'#&;*:$"9*<
+*R=:&"&<&;;
5355 53G2 53CH 53H4 5325
''534
''53I
''53J
''53K
''G35
GLM
M H32G 43KJ G3N5 G3IC D
+*R=:&"&<&;;
T@;")<M>(F'B'6!>(F7L6(7
/
535 534 53I 53J 53K G35
''534
''53I
''53J
''53K
''G35
+$R$:)"9A&'M9;"#9U$"9*<'*Q'/
/'B'VW>,GF!W>,4FVL>W>,GFXW>,4FF
"S9<!*=Y',X-Z!-Z!:
D[9;'*#M&#Z''"*:Y''''4''''''5355J
"S9<<9<\'Q#)%"9*<B''53I2G
53I
53C
534
53G
535
D
:=
,
)>
"S
9<
<
9<
\
'Q
#)
%"
9*
<
FB
'G
L4
'!
'6
/
7
O)#"9):']S9<<9<\']&;"
"
#
C5
'M
&\
J5
'M
&\
N5
'M
&\
!"&#&*\#)=,9%'=#*^&%"9*<'*Q
",&')A&#)\&M'#)M9):'%*R=:&"&<&;;
=*:)#'%**#M9<)"&;'*Q'",&
%#_;")::*\#)=,9%):')[&;
" #
, '''KN32I '''4N32H
- '''KN3JI '''N5355
: ''''5355 ''''5355
535
G35
:&
A
&:
'*
Q'
%*
R
=
:&
"&
<
&;
;
5355 53G2 53CH 53H4 5325
''G3H
''435
''43H
''C35
GLM
M H32G 43KJ G3N5 G3IC D
"S9<<9<\'"&;"'''6WE4'''7L6W7E4
)A&#)\&M'A):$&
4'!'$<"S9<<&M'M)")'`''G3H'!'"S9<<&M'M)")
O&#Q&%"']S9<<9<\'"&;"
Figure 6.10: SFCHECK output for the ZiCo data processed in P1. The Wilson plot shows some
deviation between 3–2Å, and the data are relatively complete. The partial twinning test gives a
twinning fraction of 0.471 and the perfect twinning test shows that the data is perfectly twinned
over part of the resolution range.
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Figure 6.11: SFCHECK output for the ZiCo data processed in P3. The Wilson plot shows some
deviation between 3–2Å, and the data are complete to around 2Å. The partial twinning test gives
a twinning fraction of 0.492 and the perfect twinning test shows that the data is perfectly twinned
over part of the resolution range.
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Figure 6.12: SFCHECK output for the ZiCo data processed in P312. The Wilson plot shows some
deviation between 3–2Å, and the data are complete to around 2Å. The partial twinning test gives
a twinning fraction of 0.201 and the perfect twinning test shows that the data is perfectly twinned
over part of the resolution range.
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6.4  Molecular replacement
Molecular replacement was chosen as an initial approach to obtain phases that would
allow the crystal structure of ZiCo1 to be solved, since it can be applied in the case of
twinned crystals. In order for molecular replacement to be successful it requires a
suitable model that is suﬃciently similar to the unknown structure to provide initial
estimates of the phases to allow a structure solution to be found. The traditional
approach to selecting a model involves searching for known structures that bear a
significant sequence similarity to the unknown protein structure to be solved. However,
because of the novel nature of the ZiCo sequence this approach was not suitable and
models were instead chosen based on the principles of the ZiCo design, in the hope that
the crystallised structure would be suﬃciently similar to the proposed structure to
allow a solution to be found.
6.4.1  Zinc finger model
ZiCo1 crystallised in the presence of zinc, so the initial working hypothesis was that the
peptide had crystallised as a zing finger. The PDB was initially queried for C2H2 zinc
fingers containing the motif X2CX2C12H5H2 that characterises the ZiCo1 sequence. It
was assumed that the peptide would fold in the same manner as naturally occurring
zinc fingers that feature cysteines in place of the histidine residues substituted in the
designed ZiCo sequence. This search revealed no known structures featuring the motif,
so the decision was made to proceed with an arbitrarily chosen zinc finger structure,
1ZNF, which was determined by NMR.
A model was constructed by selecting a single structure from the ensemble
contained within the PDB file, truncating all residues to alanine and removing
disordered residues from the N and C termini. An extensive search using a number of
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diﬀerent molecular replacement programs ensued, but no solutions were found.
Consequently, it was posited that ZiCo1 diﬀered greatly from the model, or that it may
not have crystallised as a zinc finger.
The next step undertaken was to determine whether the unknown structure did
in fact contain zinc, which could potentially be used to obtain phase information using
anomalous scattering techniques. Zinc atoms are much heavier than the other contents
of the unit cell and should therefore scatter incident X-ray radiation more strongly.
Strongly scattering atoms can be located by searching for large non-origin peaks in the
native Patterson map. A native Patterson was calculated using the program FFT (Ten
Eyck, 1973) and PEAKMAX was used to search for peaks. The output is given below
in Table 36, with peaks listed in order of their normalised heights.
Table 36: Native Patterson peak list. The first peak is the origin peak.
  Order No. Site Height/Rms    Grid      Fractional coordinates   Orthogonal coordinates
     1    1    1   86.31     0   0   0   0.0000  0.0000  0.0000     0.00   0.00   0.00
     2    7    4    8.18    59   0  10   0.9833  0.0000  0.0922    31.50  -0.03   5.31
     3   13    4    8.18     1   0 100   0.0106  0.0000  0.9078     0.25  -0.33  52.29
     4   14    4    6.54    59   0 100   0.9833  0.0000  0.9062    31.42  -0.33  52.20
     5    8    5    5.53     0   4  19   0.0000  0.0635  0.1741    -1.03   1.71  10.03
     6   11    7    5.04     4   4  91   0.0622  0.0668  0.8255     0.84   1.57  47.55
     7    3    2    4.81     0   6   6   0.0000  0.0995  0.0565    -1.59   2.76   3.26
     8   12    6    4.75    56   0  91   0.9373  0.0000  0.8252    29.95  -0.30  47.54
     9   15    3    4.06    54   1 105   0.9025  0.0139  0.9521    28.60   0.04  54.85
The first peak in Table 36 is the origin peak, and all other peaks are much less
prominent (< 15% of origin) and have fractional co-ordinates close to the origin, so can
be assumed to be shoulders of a broad origin peak. No other significant non-origin
peaks were found, indicating that zinc was not present in the crystal and hence
implying that ZiCo1 had not crystallised as a zinc finger.
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6.4.2  Single helix models
Since the crystals did not appear to contain zinc, it was concluded that ZiCo1 had
therefore not crystallised as a zinc finger, despite the presence of zinc in the
crystallisation conditions. An alternative hypothesis was that ZiCo1 may have instead
crystallised in its trimeric, alpha-helical form, so to test this idea the molecular
replacement searches were repeated with a helical model.
The PDB entry 1GCM is a parallel, trimeric coiled coil variant of the GCN4
leucine-zipper dimerisation domain, which was selected as a suitable model for the
proposed ZiCo1 structure. A sequence alignment shows key similarities and diﬀerences
between the two sequences (see Figure 6.13). An initial series of models was prepared
by selecting a single helix from the 1GCM structure and truncating all residues to
alanine. Chains of various lengths from 9 to 27 residues were generated by removing a
number of residues from the N terminus.
1GCM                             XRMKQIEDKIEEILSKIYHIENEIARIKKLIGER 34
ZICO1                            -YIHALHR---KAFAKIARLERHIRALEHAA--- 27
                                   :: :.    : ::** ::*..*  :::     
Figure 6.13: Sequence alignment of ZiCo1 and 1GCM. Conserved residues are marked with an
asterisk (*), conserved substitutions are marked with a colon (:), and semi-conserved substitutions
are marked with a period (.).
Molecular replacement was attempted in AMoRe, Molrep and PHASER (McCoy et al.,
2007) using data indexed in P3. The initial searches were unsuccessful, with AMoRe
and Molrep failing to find any solutions at all, while those found by PHASER appeared
unlikely to be correct. The best solution from PHASER was using a 24 residue
polyalanine model and searching for two copies in the asymmetric unit. The Z-scores
for the rotation function and translation function for each copy were RFZ = 3.7;
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TFZ = 4.7 and RFZ = 2.8; TFZ = 6.0, while correct solutions typically have Z-
scores > 5 and > 8 for the rotation and translation functions respectively. However,
inspection of the maps in Coot (Emsley and Cowtan, 2004) revealed the presence of
additional features in the maps suggestive of side chains, suggesting that the solution
may be correct despite the low scores (see Figure 6.14).
Figure 6.14: Detail of MR solution using a 24 residue polyalanine search model in P3.
The calculation was carried out in space group P3, searching for two copies per asymmetric unit.
Maps are contoured at 1.5 σ, with electron density (blue) and an mFO-DFCalc diﬀerence map
showing regions of positive (green) and negative (red) density. The positive density (right) is
indicative of a side chain.
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Figure 6.15: Packing of MR solution using a 24 residue polyalanine search model. The calculation
was carried out in space group P3, searching for two copies per asymmetric unit. Maps are shown
contoured at 2 σ, viewed along the coiled coil axis (top) and from the side (bottom). The three
helices that form the coiled coils are related by crystallographic symmetry.
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The linear arrangement of the polypeptide chain in a coiled coil structure may explain
why no single solution was found in the MR attempts using a coiled coil model. Since
the Patterson map contains both self-vectors and cross-vectors between symmetry-
related molecules, the search is performed within a defined radius from the origin of the
Patterson function. This works well for globular molecules, but in the case of elongated
molecules (such as a single helix) the intramolecular vectors may be much longer than
the intermolecular vectors. Reducing the radius of the search may improve the results
to a point, although no significant improvements in the outcome of the MR procedure
were found when this was attempted.
In terms of maximum likelihood, the low scores might again be explained by the
unusual structure of a single helix model. The translation function is generally applied
after the rotation function, to pick out the correct position of the molecule within the
unit cell. However, a single polyalanine helix translated to various positions along its
axis may give a set of highly similar scores for the translation function, meaning that
no single solution stands out. Finally, the solution of the phase problem for the ZiCo1
data by MR using a single polyalanine helix as a model might be hampered by the
presence of twinning.
On inspection of the maps, the order of side chains could not be determined, so
manual model building attempts using the results of these MR searches were not
pursued further. The results of molecular replacement are biased towards the input
model used in the search. This is because the phase information, which is taken from
the model structure, contains more structural information than the experimentally
recorded intensities. The more similar the model is to the actual structure, the less
biased the resulting electron density maps will be, and so one way of producing better
maps is to improve the model. To try to improve, the quality of the ZiCo1 maps a
series of modified MR models were constructed.
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6.4.3  Key residue models
Polyalanine models are useful when there are large diﬀerences between the sequences of
the model and target structures or when the position of side chains is uncertain. In the
case of ZiCo1, the structure is novel and no suitable sequence model exists, so adding
side chains to the model means that there will be many more atoms that are more
likely to be incorrectly positioned, thereby making it a worse model. However,
estimating which side chains are likely to be in a fixed position and only adding these
to the model may oﬀer an improvement. Side chains likely to be in a fixed position are
those involved in strong interactions: in this case the hydrophobic and electrostatic
interactions at the coiled coil interfaces. In addition, aromatic side chains may oﬀer
recognisable features in the electron density. Furthermore, the central portion of the
helix is likely to be more folded, as coiled coils have a tendency to fray at the ends
(Prof. Woolfson, personal communication). The sequence in Figure 6.16 shows key
residues highlighted in the ZiCo1 sequence.
Y I H A L H R K A F A K I A R L E R H I R A L E H A A
1         1 0         2 0       
 
Figure 6.16: ZiCo1 sequence with key residues highlighted. Hydrophobic (red), basic (green) and
acidic (purple) residues are shown. Another key residue is the phenylalanine (F) at position 10.
This has a characteristic aromatic side chain, which may oﬀer a recognisable feature in the electron
density. In addition, the residue is located in the central region of the sequence, which is likely to
be folded and in a fixed position.
A particularly interesting residue is the phenylalanine at position 10 (Phe10). It
possesses a benzene ring functional group, which has a very characteristic shape, and is
located in the central third of the sequence. There is a four residue insert in the heptad
repeat at position 9. This is designed to introduce a local unwinding of the helix and
corresponds to the turn linking the α-helix and β-sheet regions of a classical zinc finger
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(see Figure 6.17). While this may destabilise the region of the structure near Phe10, the
residue is likely to be located on the outside of the coiled coil, due to its bulky size and
its position in the heptad repeat (which corresponds to position b in the register). For a
discussion of coiled coil sequences, please refer to section 1.6.3.
F V C E V C T R A F A R Q E H L K R H Y R S - - H T N
Y I H A L H R K A F A K I A R L E R H I R A L E H A A
g a b c d e f g h i j k a b c d e f g a b c d e f g a
  *   *             *      *
1         1 0         2 0       
1ARD
ZiCo1
Figure 6.17: Alignment of the ZiCo1 sequence with the sequence of a classical zinc finger. The
sequence register is shown on the first line, with the insertion in the coiled coil heptad repeat
highlighted in blue. An aligned classical zinc finger sequence (PDB ID: 1ARD) shows the position
of the β-hairpin (yellow) and the α-helix (magenta). The position of the stutter in the coiled coil
sequence corresponds to the loop linking the β-hairpin with the α-helix.
The Phe10 model was constructed from a 7-residue polyalanine helix by mutating one
of the central residues to phenylalanine using Coot (Emsley and Cowtan, 2004). This
procedure places a side chain in the most likely conformation according to a library of
information about bond lengths and angles in protein structures. The model was used
to search for MR solutions in space group P3, where two molecules are predicted to
occupy the asymmetric unit. However, PHASER failed to find a second copy due to
steric clashes.
Seven residues correspond to two turns of an alpha helix, so the second solution
may be overlapping the first, for example by being placed a turn above or below in the
helix. While the top scores for a single molecule were low (RFZ = 3.12; TFZ = 3.06),
this can be explained by the incompleteness of the model, which may be only around
10–25% of the scattering contents of the unit cell. The results of a search for a single
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copy of the Phe10 model in P3 are shown in Figure 6.14. Despite the low scores, clear
helical density can be seen above and below the model, including features that resemble
additional side chains.
Figure 6.18: MR solution using a 7-residue Phe10 model in P3. The map is contoured at 1.5 σ and
shows clear helical density above and below the model. Additional features indicative of side chains
can be seen below the phenylalanine ring.
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6.4.4  Trimeric coiled coil models
The molecular replacement using PHASER was repeated, using a 24 residue trimeric
coiled coil as a search model. The model was again generated by truncating the side
chains of PDB entry 1GCM to alanine. The search was performed using data indexed
in P1 and allowed a search for two copies of the trimer.
Several similar solutions were found and the best result had relatively high
scores of RFZ = 5.3; TFZ = 100.0 and RFZ = 5.9; TFZ = 7.5 for the two respective
copies. The likelihood log gain (LLG) increases from 168 for the first copy, to 362 for
the second. This suggests that these two copies of the trimer describe the observed data
more accurately than a single trimer. The corresponding electron density maps are
shown in Figure 6.19. These show the close packing of the coiled coil trimers within the
crystal structure with this solution.
While the MR attempt using a trimeric coiled coil model in space group P1
appears to have been successful (TFZ = 7.5), it was still not possible to model the
resulting density manually. In an attempt to dock the sequence of the ZiCo1 peptide
onto the models obtained by MR, these were used as input for an automated model
building procedure, as described in the next section.
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Figure 6.19: MR solution for a 24-residue polyalanine trimeric coiled coil model in P1. The electron
density is shown looking down the coiled coil axis (top) and from the side (bottom). This solution
shows good packing of the molecules, with six helices in the unit cell.
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6.5  Automated model building and refinement
ARP/wARP is a software package that combines electron density interpretation with
maximum likelihood refinement in REFMAC to perform automated model building
including automated protein main chain tracing, sequence docking, ligand and solvent
building (Perrakis et al., 2001). The results of successful MR searches were used as a
starting point for this procedure, which was run using default settings. The best
solution was using a single helix model in space group P3; the results are illustrated in
Figure 6.20. Two chains with 49 residues were docked (99% complete) with an R-factor
of 0.35. Further refinement using REFMAC gave an Rfree of 0.28, while the R-factor
decreased to 0.23.
Figure 6.20: Model of ZiCo1 in P3 built using ARP/wARP. Chains: 2; residues docked: 49;
estimated correctness of the model: 99%. Sequence coverage is 98%; R-factor = 0.35.
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6.6  Ab initio phasing
While the refined model appears to be correct, although not complete, the phases are
likely to be heavily biased towards the initial model used in molecular replacement. One
way of obtaining unbiased phases is by using direct methods. These are limited to small
molecules and high-resolution data, but may just be applicable to ZiCo1. The peptide
contains a predicted 469 atoms (including hydrogens) and the maximum resolution of
the data is around 1.6Å.
The CCP4 program ACORN (Foadi et al., 2000) can be used to calculate the
electron density for a small molecule starting from random positioning of atoms. It
requires atomic resolution data (better than around 1.2Å) and can solve structures up
to several thousand atoms. To solve the protein phases ab initio, a substructure
composed of a small fraction of the scattering matter of the unit cell is positioned. This
is used to generate a starting set of phases that are slightly better than random, and
the full structure is then developed from this phase set. The positions of the atoms are
refined and the phases are improved using density modification procedures over the
course of several cycles.
The maps calculated using ACORN for ZiCo are poor but unbiased (see
Figure 6.21). They clearly show regions of density corresponding to approximately 3
turns of a helix, arranged in a trimer. The helical axes are parallel to the
crystallographic c axis, and the ends of the helices are poorly defined. Individual
polyalanine helices can be positioned in the density, as well as a trimeric coiled coil.
However, the maps were too poor for automated model building and could not be
interpreted well enough to begin manual model building. However, they do clearly
demonstrate the trimeric, helical nature of the ZiCo1 crystal structure and corroborate
the results obtained by molecular replacement.
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Figure 6.21: Electron density maps calculated ab initio using ACORN. The top view shows a view
along the c-axis of the crystal, showing a clear region of electron density running roughly parallel to
the axis. This corresponds to the predicted dimensions of an extended ZiCo molecule. The bottom
view shows the same electron density but viewed from the side, perpendicular to the c-axis. The
density in the central portion of the helix is relatively well-defined, but the density at the ends of
the helix appears to splay outward, and becomes more diﬀuse.
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6.7  Experimental phasing attempts 
Alongside the computational approach to obtaining phases for the ZiCo1 structure,
experimental phasing attempts were also carried out. Heavy atom compounds were
selected on the basis of their reactivities at the given pH and other considerations. The
compounds were dissolved in well solution (1M sodium citrate, 10mM sodium borate,
pH8.5) at 10mM, and a small drop of the heavy atom soak solution was placed on a
cover slip. A single ZiCo1 crystal was placed in each drop and left to soak for various
lengths of time, from a few seconds to several hours, over a reservoir of well solution.
The following compounds were tested at 10mM concentrations: K2PtCl4, K2Pt(NO2)4,
K2Pt(CN)4, KAu(CN)4, CdCl2 and NaIrCl6.
In all conditions tested, the ZiCo1 crystals visibly deteriorated (see Figure 6.22).
The observed cracking of crystals upon soaking with heavy atom compounds could be
due to a number of factors: manipulation of the crystal; diﬀerences in pH or protein
concentration between the mother liquor and the soak solution; or the chosen
concentration of heavy atoms in the soak may simply have been too high.
Figure 6.22: A crystal of the ZiCo1 before and after being soaked in a heavy atom solution.
A single crystal of the peptide is shown (left). After soaking with well solution containing 10mM of
various heavy atom compounds, the crystal visibly deteriorates and takes on a crazed appearance. 
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Mechanical stresses due to manipulation of the crystal are unlikely to be the cause of
the observed cracking, since the crystals have proved to be stable when handled
previously. Diﬀerences in pH between the natural mother liquor and the halide soak
were ruled out, since both solutions had a pH of 7.9. The crystals were stable for
several hours in the well solution, so the cracking was caused directly by the
introduction of heavy atom compounds.
The experiments were repeated with 1mM heavy atom solutions, with similar
results, although the crystals soaked in K2PtCl4 and K2Pt(NO2)4 appeared to remain
intact. These crystals were flash frozen without any additional cryoprotectant, and 180°
of data were collected for each derivative. However, the data could not be processed due
to high mosaic spread, suggesting that while the crystals may appear intact, they may
have deteriorated on a microscopic level. This would seem to suggest that the
introduction of heavy atoms is causing structural changes in the crystal that lead to its
destruction. These may be due to the heavy atoms interfering with crystal contacts, or
the induction of a conformational change in the ZiCo1 molecule on binding the heavy
atom compounds.
Attempts at stabilising the crystals using higher concentrations of precipitant,
adding a grain of heavy metal compound directly to the drop, and co-crystallising the
peptide and heavy metal were unsuccessful. Since the computational attempts to solve
the phase problem had yielded good results, experimental phasing using heavy atom
compounds was abandoned as an approach to obtaining phase information for the
ZiCo1 peptide.
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6.8  Discussion
The goal of this project was to provide high-resolution structural information about the
ZiCo1 and ZiCo95 peptides, in order to validate their design and gain an insight into
their structural properties. In a wider context the aim of the ZiCo project is to gain an
insight into the process of how to incorporate structural flexibility that bestows a novel
function into the de novo design of a stably folded structure. Understanding the precise
interactions that contribute to a successful protein design — which can only truly be
achieved through high-resolution structures — will contribute to the development of
robust and reliable methods of designing proteins with new and useful functions
(Lassila, 2010).
Prior to the work described in this thesis, the ZiCo1 peptide had been
crystallised using a peptide concentration of 2.25mM and 0.4M LiSO4 as a precipitant,
in the presence of 1mM zinc chloride at pH7.5. Since the crystallisation conditions
contained significant zinc concentrations, it was proposed that the peptide had
crystallised as a zinc finger. However, MR searches using a zinc finger model proved
unsuccessful. Small helical fragments fared better, and it was initially assumed that
these corresponded to the short alpha helix of the classical zinc finger structure.
Alternatively, the crystal could contain the peptide in an unexpected conformation
owing to the relatively low concentration of zinc in the crystallisation drop. In addition,
the data quality left room for improvement (see Table 37), so new crystallisation
conditions for ZiCo1 and an improved data set were implicit goals in this work.
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Data set 1 Data set 2
Unit cell parameters 32.1 32.1 57.5
90    90   120
32.1   32.1   57.6
90    90   120
Resolution 25.0–1.0 25.0–1.6
Reflections 28951 71884
Unique 25081 7661
Completeness (overall –outer shell) 78–17.9% 84.8–29.1%
Multiplicity (inner–outer shell) 2.8–1.3 11.1–3.5
Rmerge (%) 5.5 4.8
I/sd(I) 16.6 37.6
Table 37: Data processing statistics for two ZiCo1 data sets. Data set 1 was collected by David
Papapostolou and Nigel Brisset at the ESRF in Grenoble. Data set 2 was collected as described in
section 6.3 ZiCo1 appears to have crystallised in the same unit cell and space group under both
crystallisation conditions. While data set 1 extends to a maximum resolution of 1Å, the second
data set is more complete and has a lower Rmerge.
Crystallisation of both peptides was attempted, but was unsuccessful for
ZiCo95. Consequently, the solution structure of ZiCo95 was investigated using size
exclusion chromatography. Analysis by SEC in a stabilising buﬀer showed that ZiCo95
exists as a heterogeneous population of oligomeric species, in both the presence and
absence of zinc. The zinc-free peptide appears to form mostly trimers — as predicted
by the design — with a small proportion forming tetramers. In the presence of zinc,
ZiCo95 displays a much more heterogeneous population of oligomeric states. Most of
the peptide is found as pentamers, followed by trimers, and finally a small proportion of
monomers. When a reducing agent was included in the sample buﬀer, the peptide
appeared to form a dimeric species that does not respond to zinc addition.
These results suggest that crystallising ZiCo95 in the zinc-bound form may be
impossible, since a heterogeneous population of protein molecules is unfavourable for
crystallisation. Furthermore, the behaviour in the presence of a reducing agent suggests
that the peptide may not be folding as a zinc finger at all. A reducing agent causes any
disulphide bonds between cysteine residues in the classical zinc finger motif to be
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broken, leaving them free to co-ordinate zinc ions. However, since the peptide forms
stable dimers in the presence of a reducing agent, it is possible that the peptides are
associated via strong hydrophobic or electrostatic interactions. If these forces are
stronger than the favourable dynamics exerted by zinc binding, this may explain why
ZiCo95 does not respond to the addition of zinc under reducing conditions.
The ZiCo95 sequence contains a higher proportion of positively charged (K) and
negatively charged residues (E) than the ZiCo1 sequence, and is more negatively
charged at a given pH than ZiCo1. This fact lends support to the idea that electrostatic
interactions between peptides may dominate over any decrease in entropy from
adopting a coiled coil or zinc finger fold for ZiCo95. The notion that the peptide may
not be correctly folded as either a trimeric coiled coil or a zinc finger is borne out by
NMR studies of the peptide (Prof. Woolfson, personal communication). Therefore, the
search for high-resolution structures of ZiCo95 was concluded, while the work with
ZiCo1 continued.
It proved possible to crystallise the ZiCo1 peptide under a number of conditions.
There was a noticeable diﬀerence in crystal morphology between conditions containing
PEG as the primary precipitant and those containing salts, suggesting that electrostatic
interactions may play a role in stabilising the ZiCo1 crystal structure. Large, single
crystals of ZiCo1 were grown in the presence of equimolar zinc, using sodium citrate as
the precipitant. These could be cryogenically frozen without additional cryoprotectant,
and diﬀracted to 1.6Å (see Table 37 for data processing statistics). Surprisingly, the
crystals do not appear to contain zinc. This can be inferred by the absence of large,
non-origin peaks in the native Patterson map, as would be expected to result from
vectors between any electron-dense zinc atoms. Furthermore, no molecular replacement
solutions could be found when a classical zinc finger was used as the search model,
although molecular replacement with helical models gave more promising results.
Using a single 24-residue polyalanine helix in space group P3 gave the best
results, although various diﬀerent models were explored in all predicted space groups.
These included a model featuring the key Phe10 residue (as well as numerous other key
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residues) and trimeric coiled coils of varying lengths. The results of molecular
replacement in P3 using the model described showed that ZiCo1 has apparently
crystallised as a trimeric coiled coil. This was surprising, given the high concentrations
of zinc required in order for the peptide to crystallise. This puzzling behaviour might be
explained by the concentration-dependence exhibited by the peptide (see section 1.7.3).
The melting temperature of the trimer increases with the concentration of
peptide in solution, suggesting that as the peptide concentration increases, the position
of equilibrium is shifted in favour of the trimeric form over a random coil in the absence
of zinc. The ZiCo1 crystallisation conditions initially show precipitated protein, with
crystals being observed a few days later. This suggests that the combination of zinc and
precipitant causes enough of the peptide (and zinc) to be removed from the solution to
allow trimeric nuclei to form. As peptide is incorporated by the growing crystals, the
precipitated protein is consumed. However, if this unique process is what drives the
crystallisation of the ZiCo1 peptide, it may be impossible to crystallise the zinc-bound
form. Nonetheless, the results of the molecular replacement corroborate the previous
biophysical studies carried out by others that suggest that the ZiCo1 peptide folds as a
trimeric coiled coil.
In the MR solution in space group P3, the helices making up the coiled coil are
related by crystallographic symmetry, and there are two helices in the asymmetric unit.
A similar solution was found using a trimeric coiled coil model by searching in space
group P1, which has no crystallographic symmetry elements. This placed six individual
helices in the unit cell, as two trimeric coiled coils related by a non-crystallographic
symmetry axis running parallel to the long axis of the cell. In addition, all the ZiCo1
crystals tested exhibit signs of being almost perfectly twinned. This is demonstrated by
the results of twinning tests, leading to considerable ambiguity about the true space
group of the crystal.
The predicted space group is P312, which relates molecules as shown in
Appendix II, section ii. This means a single helix occupies the asymmetric unit, and six
copies are related by crystallographic symmetry in the unit cell. However, MR searches
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in P312 failed to produce any solutions because of steric clashed between placed helices.
A further insight into the presence of crystallographic and non-crystallographic
symmetry elements in the ZiCo1 data came from the self rotation function. Calculating
the self rotation function in the various possible space groups showed the presence of
numerous symmetry operators (see Appendix II, section iii). Given that an MR solution
is found in P1, where two crystallographic trimers are related by a non-crystallographic
symmetry axis, it is possible that the apparent P312 symmetry could be explained by
the presence of NCS or twinning that mimics this space group. Therefore the true
symmetry of the crystal is likely to be P3, or possibly even P1 with a high degree of
non-crystallographic symmetry, and the additional possible complication of twinning.
The output of the molecular replacement procedure in space group P3 was used
as a starting point for automated model building, producing a model with 99%
completeness and an R-factor of 0.35. Further refinement gave a final R-factor of 0.23,
which is consistent with a well-refined structure. The slight divergence between the R-
factor and Rfree during the final rounds of refinement may be explained by the
incompleteness of the model. Some residues could not be built using the automated
procedure due to steric clashes, and these may be disordered residues at the ends of the
helix. While the results of molecular replacement are biased towards the initial model
used in the search, the results of ab initio phasing also revealed a trimeric, helical
structure. This supports the conclusion that ZiCo1 has indeed crystallised in its
trimeric form, and that the refined model may be largely correct.
The packing of the final model in the unit cell is shown in Figure 6.23. ZiCo1
trimers are formed by the combination of symmetry operators and the crystalline
lattice, and appear to be stacked in antiparallel layers. An interesting feature that can
be observed in the final structure is that His6 appears to be co-ordinating an atom (see
Figure 6.24). There is a strong blob of density that persists when the maps are
contoured at high sigma, which suggests that an electron is highly likely to be located
in this area. However, this may not be significant, and the solution may not be entirely
correct, given the possible ambiguity of the space group.
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Figure 6.23: Packing of the refined ZiCo1 solution in space group P3. The unit cell is indicated and
the view is along the long cell edge, which corresponds to the coiled coil axis. Helices are
represented as cartoon ribbons, with His6 highlighted.
Figure 6.24: Electron density near His6 in the refined ZiCo1 structure. The map is contoured at 5
σ, and shows a persistent blob of density between three symmetry-related histidines at position 6 in
the ZiCo1 sequence.
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There is scope for the project to be developed further, with possible work including
further manual model building and refinement to improve the structure (for example by
refining in space group P1), or treating the potentially twinned data more eﬀectively by
carrying out twin refinement using SHELX (Sheldrick, 2008). However, the aims set out
for this project have been adequately fulfilled for the coiled coil form of ZiCo1. The
ZiCo1 peptide has been crystallised as a trimeric coiled coil, which is likely to reflect
the structure of the peptide in solution. In terms of validating the design, the ZiCo1
sequence was designed in such a way that it would fold as a coiled-coil type structure,
and therefore this aspect of the design process has been successful. Considering that the
zinc finger form — which is more interesting from a protein design perspective — could
not be crystallised, this project has reached a state of completion which is in
accordance with the aims of the project and the available time and resources.
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Chapter 7
Conclusions
7.1  Conclusions
7.1.1  Complement component C1
A novel purification scheme to isolate native complement component C1 from human
plasma has been developed, using a combination of PEG precipitation, size exclusion
and anion exchange chromatography. All of the C1 subcomponents were shown to be
enriched in the purified sample by SDS-PAGE and mass spectrometry. Dynamic light
scattering studies showed a single population of particles around 40nm in diameter,
which corresponds to the estimated size of the C1 complex. Therefore C1 has been
purified by a new procedure in a form suitable for crystallisation. In addition,
investigations into the eﬀects of relevant metal ions on the structure of the purified
complex under physiologically relevant conditions were pursued. Finally, the
crystallisability of complement component C1 was explored with the hope of achieving
usable crystals. The results suggest that C1 exhibits a diﬀerence in solubility when salts
are used as precipitants compared with polyethylene glycols, which may be useful
information in the search for crystallisation conditions. Several promising conditions
were identified from preliminary screens, and so the objectives set out for this project
can be deemed to have been met successfully.
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7.1.2  Serum amyloid P component
With regards to SAP, the aim of my work was to perform preliminary investigations
into the metal- and ligand-binding properties of this molecule in order to lay the
foundations for further work. SAP was purified from human plasma using established
methods and the quality of the purified product was analysed for its suitability for use
in structural studies. SAP was found to be pure and homogeneous by DLS and could
be crystallised under known conditions. The metal-binding properties of SAP were
examined using the ability of the ligand PE to disrupt the calcium-dependent
aggregation of SAP. This interaction may have functional implications for the role of
SAP in immunity, and the simple assay described here may oﬀer a quick and simple
means of investigating the metal- and ligand-binding properties of SAP. Furthermore, a
possible common functional mechanism between SAP and C1 may have been identified,
since both proteins exhibit copper-dependent aggregation at the low pH characteristic
of sites of infection and inflammation. Further work on this topic might include
studying the interaction of SAP with copper, zinc and physiological ligands such as PE
at acidic and neutral pH, and co-crystallisation of SAP with various divalent metal ions
in order to more fully determine the role of metals in the structure and function of
serum amyloid P component.
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7.1.3  ZiCo
The aims set out for this project have been adequately fulfilled for the coiled coil form
of ZiCo1. The peptide has been crystallised as a trimeric coiled coil, which is likely to
reflect the structure of the peptide in solution. While the apparent space group is P312,
it is likely that the true space group may be a lower-symmetry space group with NCS
and/or twinning. However, both MR and ab initio phasing suggested a coiled-coil type
structure within the crystal, which could be traced by an automated model building
procedure. This helical structure was refined to a final R-factor of 0.23, which is
consistent with a well-refined structure. In terms of validating the design, it the ZiCo1
sequence was designed in such a way that it would fold as a coiled-coil type structure,
and therefore this aspect of the design process has been successful. While neither the
zinc-finger form of ZiCo1, nor the ZiCo95 peptide could be crystallised, the pursuit of
high-resolution structures of ZiCo has reached a state of completion in accordance with
the aims set out for the project.
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7.2  Further work
The C1 crystals obtained were too small to be tested for diﬀraction, so there is
considerable scope for further work on the crystallisation of complement component C1.
In addition, the purified C1 sample may yet contain other complement-related proteins
and high-abundance serum proteins, so further purification or alternative purification
methods could also be explored. Mono Q-purified C1 may also be a more suitable
sample than SEC-purified C1 for electron microscopy. Finally, the interaction of
purified C1 with divalent metal cations — and also C1 inhibitor — merit further
investigation. However, the aims set out for this project have been adequately fulfilled.
Further work on SAP might include studying the interaction with copper, zinc,
and physiological ligands such as PE at acidic and neutral pH. This could be
accomplished either using DLS and the assay method described in this work, or by
other techniques such as CD and FTIR. The co-crystallisation of SAP with various
divalent metal ions and small-molecule ligands may also shed some light on the role of
divalent metal cations in modulating the structural and functional properties of this
interesting immune protein. The aims of this project have been fulfilled, in that further
work has already been carried out by others on the basis of the work outlined herein.
There is also scope for the ZiCo project to be developed further, with possible
avenues including further manual model building and refinement to improve the
structure (for example by attempting refinement in space group P1), or treating the
potentially twinned data more eﬀectively by carrying out twin refinement using
alternative programs. However, the zinc finger form is more interesting in terms of
validating the protein design, and this could not be crystallised. Furthermore,
subsequent NMR studies on the peptide also proved challenging (Dek Woolfson,
personal communication), and so this project has been deemed completed.
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7.3  Concluding remarks
This final section will enclose the present thesis in its wider context. The importance of
high-resolution protein structures has been introduced and the role of metals and
metal-binding proteins in the cause and treatment of disease have been explored —
with specific reference to complement component C1, serum amyloid P component and
the designed peptide ZiCo. Salient structural features of these proteins and our current
understanding of their respective functions have been presented and critically discussed.
The background to my work has also been explored and I believe I have demonstrated
how this thesis complements previous work on the three proteins under study and
opens up new avenues of research. Finally, the aims set out for these investigations into
the structures of the serum proteins complement component C1, serum amyloid P
component, and the designed switch peptide ZiCo have been acceptably met.
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Appendix I
This appendix contains supplementary data for the biochemical experiments described
in the main body of this work, such as calibration data and calculations.
i. C1 charge calculations
Calculations of protein charge were performed using the calculator available at http:/
/www.scripps.edu/~cdputnam/protcalc.html (last accessed 8/3/10). At physiological
pH, the C1 complex appears to be very close to its predicted isoelectric point (pI =
7.2). In this region of the graph (pH5.5–8.5) the charge curve is approximately linear,
and the gradient is shallow, so the predicted net charge of C1 varies little with changes
in pH. We can see that at around pH8.5, the charge curve begins to drop oﬀ sharply, in
other words C1 becomes more negatively charged more rapidly with increasing pH.
Likewise, as the pH drops below approximately pH5.5, there is a sharp increase in the
predicted net charge for a corresponding decrease in pH.
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Figure I.a: Net charge of C1 as a function of pH. The net charge was calculated based on the
predicted number of charged residues present in the assembled C1 complex, and the pKa values of
those residues. Calculated values are shown (filled circles), and the data were interpolated by spline
interpolation (black). The data were fitted using a spline fitting procedure (red), and the derivative
function is also shown (blue). For convenience, pH = 5.5 and pH = 8.5 are also marked with
dashed lines. The plot shows that the net charge of C1 is linear and relatively stable in this region,
which corresponds to the physiological milieu that C1 is likely to encounter.
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ii. Superose 6 calibration
The Superose 6 column was calibrated using a mixture of ribonuclease (14kDa), BSA
(67kDa), ferritin (440kDa) and thyroglobulin (669kDa). The void volume of the
column was determined using 1mg/ml blue dextran. Kav was calculated using the
following formula:
Kav =
Ve − Vo
Vt − Vo
and plotted against the logarithm of the protein molecular weights. Size exclusion
chromatography takes the hydrodynamic radius of molecules into account, so a protein
may elute at an apparently higher or lower molecular weight than its true value, and
molecular weights determined from this calibration were used as a guideline only.
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Figure I.b: Superose 6 calibration curve. A linear regression was performed on the data, and the
corresponding equation is shown. The calibration curve allows molecular weights of unknown
proteins to be estimated within the range of 14–669kDa.
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iii. C1 crystallisation: SEC-purified C1
Fractions containing C1 were pooled and concentrated to 10mg/ml (a 1:10 dilution of
the sample gave 0.971mg/ml by Bradford assay against a BSA standard). The
concentrated sample was yellowish and opalescent. The protein was screened for
precipitation on the addition of small volumes of various common precipitants, and
approximate phase diagrams were constructed from the recorded observations. The
results of these experiments are presented below. The soluble region is clear, while the
region in which the protein precipitates is shaded in red.
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Figure I.c: PEG MME 550 solubility curve.
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Figure I.d: PEG 6000 solubility curve.
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Figure I.e: MPD solubility curve.
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Figure I.f: PEG 3500 solubility curve.
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Appendix II
This appendix contains supplementary data for the crystallographic procedures and
calculations described in the main body of this work. The raw diﬀraction images and
relevant calculation files can be found on the DVDs that are included with this thesis.
i. ZiCo1 and ZiCo95 charge calculations
ZiCo1 net charge v. pH
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Figure II.a: The net charge of ZiCo1 as a function of pH. 
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ZiCo95 net charge v. pH
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Figure II.b: The net charge of ZiCo95 as a function of pH.
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ii. Space groups
Figure II.c: Space group P1.
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Figure II.d: Space group P3.
Figure II.e: Space group P312.
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iii. Self rotation function
The self rotation function was computed in various space groups using MOLREP and
the results are shown in Fig. II.f –Fig. II.k. 
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Figure II.f: Stereographic projection of the self rotation function in space group P1. The resolution
range (25.06–1.92Å) and radius of integration (27.77Å) were determined automatically.
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Self Rotation Function
MOLREP
Rad  :    7.00 Resmax :     1.97RF(theta,phi,chi)_max :    0.7169E+06    rms :     0.1395E+06
 Chi =  180.0
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Figure II.g: Modified stereographic projection of the self rotation function in space group P1.
The radius of integration was set to 7Å, which is close to the diameter of a single α-helix, and the
resolution range 25.06–1.97Å) was determined automatically.
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Self Rotation Function
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Figure II.h: Stereographic projection of the self rotation function in space group P3. The resolution
range (25.06–1.86Å) and radius of integration (19.23Å) were determined automatically.
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Self Rotation Function
MOLREP
Rad  :    7.00 Resmax :     1.86RF(theta,phi,chi)_max :    0.2244E+06    rms :     0.5965E+05
 Chi =  180.0
X
Y
 RFmax =     0.2241E+06
 Chi =   90.0
X
Y
 RFmax =     0.1335E+06
 Chi =  120.0
X
Y
 RFmax =     0.2244E+06
 Chi =   60.0
X
Y
 RFmax =     0.1227E+06
Figure II.i: Modified stereographic projection of the self rotation function in space group P3. The
radius of integration was set to 7Å, which is close to the diameter of a single α-helix, and the
resolution range 25.06–1.86Å) was determined automatically.
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Self Rotation Function
MOLREP
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Figure II.j: Stereographic projection of the self rotation function in space group P312. The
resolution range (25.06–1.84Å) and radius of integration (15.27Å) were determined automatically.
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Self Rotation Function
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Figure II.k: Modified stereographic projection of the self rotation function in space group P312.
The radius of integration was set to 7Å, which is close to the diameter of a single α-helix, and the
resolution range 25.06–1.92Å) was determined automatically.
335
Scio nescio.
